var title_f26_63_27632="Hepatosplenic candidiasis CT";
var content_f26_63_27632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows typical lucencies in the liver of a patient with acute myeloid leukemia who developed chronic disseminated candidiasis following recovery from prolonged neutropenia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27632=[""].join("\n");
var outline_f26_63_27632=null;
var title_f26_63_27633="Preoperative deformities in SSc";
var content_f26_63_27633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe subluxation and contractures in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAYUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxrUbpxcyoJZM7uBn64/8ArfrVT7RcO2FlYL3YnoM85/r6dqL1z9qnbdwrNyfctn6D1qrvBwMc8Yx2xjHfn+XrQA8zyj5TNLnBGBz26Efy9aa91OGOWlUvno2eeen+Paq0ew5IcjgqoGMYx6/Xv2pJo9jjEhIL/d6gHJ6j19qAJBeyEKsk8hA5PJGRx+mccU17m4K7y8it1+VunB6e/wDSqkQYkM2c4yRkc5A7/wBfwp5VEk2HcQeGQcA9cEf4UASx3UkcyYmfd97G4+v8v1zUr3U2wOZXdjyygk44HX37kVRClmGP9YGzknp2/PHWnru2DB+Uj+E8Djjn+VAFsXbkMwlkkbsqMTxz/n3qKSadAUWaZSCOucDJH+P4Uhbc2FGw9Bge55/+v2pkrMjkyMScgYHQ9Pz/AK0ADahIxdnZ9qgbTz6ck89D+vah7u42gpO5BAyd3bnHf8P51XfGSA3VRk9RnBIz7+lRqipzIXwD0PTGf5UATSXUoVX85i3YknPYH60q3zCGYSCdnJAWRZCNvBBBHftx7VFIu6QEl1JOeOe3P41Fko5BfO4YGPx/woAmMt15ZCzOzDglX57469R05pEurgO6eZI3GSASB2z+Ht+NDo0jNgOJFb5cdu/+RUTqAhfdy7YI3ZYcD+fr3oAebyYfMZ5st1Ib2x6U97yZ2X9+4DEjl2AC54yf8mq2FUjBJCnnjIPXHFRyMWyQAOd3IGT60ATNd3J2bppsDnqR6VP9ulcjc7qMANhj754zz/WqT4JJYN04x+H6UFgwG/IPfnj8KALstzOvLTuVzwxJ6dhjOOv5VALqZVH7+TPOQzZA45qMqzDdu+cHJU/h/jSKTvTYMODx9aAJpbqUSFVmkxkYG7H/AOqmi7k4TzpCmeCWwMZz+FQMPlLZJ+velVMsVw3XB9aALa3UwQYlkAJyRuz25/8ArUn22fGBPJ1yPmOfbmq5TCKcYPUEnrjP6cU/Cg7m3BifvevJzx+X5UAWftVwuCZpGcZJXcQQOOP/AK1EF5cfPi5kUP6sTxg5H/16r7CFBVthIyWb0/z+dSptQkAjhdu7HHU9R/TtQBLc3k38E8hVeepyRu4BqEXkzLsMrquOzH06/wCelRyZdgzBgCc9OvPWmMuAOQVPOfw6UAWVvZWzmWUg/L94nPX/AD70q3lwGytxJxkg5ySeM81WXcznIAAONo7jmlMg3P8ALkkcMO3Tt3+lAEi3c5c/vJGwMbckdjkU8Xk4I3zysCck7jwfYUzLHDKDyMAg9Dz39c96j8xN4C7uTyR6ZoAebubcXWdhnACrntjmkF5MCCskh9dzcnr/AJ9qZjbGw+bcMg46Yx1owWlG8ZI9uvWgCyl9N5Un7+TeO+cHAxx/n0o+0TuMLNKDs3Fi3RQOD/n1qIITHuY7kzkk8c5HH8ue1K4yxZm8sgjn8/8A63HegCX7XKpfMrhlGM7jgZPJHH500XcwVMzkkrknJ+U+mOhP+NQABjgkg7sMQcnrx/8ArpExtY7R8y8exx+lAE32uYBw8zZPIG4+pxg/U1Kt3KoRnmn25w7DPbFVnhy0gXDFeTz3z/nNNChwcbUC8/Qcf596AJlvJhGR5sx5/vH39/8A9dPNxcliBI5GcKxODwfr2/SqpUBQcnJBYj064/z2pRF5jyBGztBbJOAQOvX+XegCxHeXGwjznzgncSRxjn6+9Srf3LbVErgnAwCMd+9UogTkEnBGMg+3+fzqfKgFWdWQcKB0OTwfp3x60AStdzA5ErKNuc7+vT9PelFzcRrIu+RcKCQW5Bwcf/q7VXxs/iBDpyc52nFOUqHT5XwOAeoOc4/XpQBsaVcuFkaR5CTjjzCAOv59etFVdNUZlVlBZcAkPt/yaK7qL9xbf18yWWr+ZjeT7XYqu7OPX5uOnXpj0qjJMVDK20xrgErnHbPIHTpmrGpbTezAsmcsCewGT/P9azlcK4wxGMHBHfjJ/nXCUWJ5A5kfeVGARheBhScfX+lBcI3zZOTng44Bz/Pv17VHvYQkiQsGHzb+g68Y645p0snmXLKz4LHrx6j8M0AEUg3nzATkHp6cdR7enbrUhdyynGHwTuJ9m4/z1qvAdqyKqBiyjG44wvHQ9ue/erUhJ+9nOeFxk55B/wA9qAGklm6sHJAGR06cU0oSrKw2pyAc8rkY59/8ikwW/eBiAnc/hn+X45ph+6Q6k5XBO7nocc96AJvmidnyTlsBtuQcHoD+NQlyx5JZFUFWB6A4J/8A19qHZpdwbJB55z644HamKoWQBDkN1BHU4GR/9agCRgqsSHJ7jC9cZ6j+lNcw7lAw0Yx8/Q546fQ5Ge+KFRTNxlQ65yScZyR19O2ah3EEFRu2kbuMYHB4FADlJXcpHy47j8vpzTSSCBhQeyjnnkc8fjTh9wlWLk5BG7LY5ORTUXJKlsjIHI9+KAHxOpkYFNwbHJPuP8+9NZGeQrIxb+Hex246cH0FOBwDmMEk/eI6jjjGeff6cVLIEa3UlVyuVCMRk5Bxx65x9RQBTO4tn5hkkg5ORye/fvUfyHAJwMAZHPenyRHhTsBUkEcDPJ60SbncbjjaMYx+fGKAGs7MmWbhRgA9+2KbgZbAJVDjcB0FJ94ZyM44GM0+RicdhyMAEd/1oAaM5IGM4IJ7duaU9MdwMqB9P/1UBiWXOWBwMZPXilcjG1M+pGeOmKAEkK+YSVIHbPU9eacpKeokHGPc4pjDkkgDafqBQQMtycgZ579OKAJcY2gBWwoJVeSR6f400OAOvXjb/e5oG5Izg8AjI69Qf0qSQD5WQcA88gg9+KAFdWEY3NgqNpGOfXB9/wCVSksJMSbiQCpPX159+D+NRA4XO8OAc46gjHU++fzqRdwuNu4Dd6cHqTj+lADWZQ3U7c9Ac88c/wCelRksyHAUqAO3TinbQYxtwOSVGO2BwfzNKihUVkLc8kjqDg0AKgfau1S3zEe+cnt/So0XaUJ+UMFBI7dPyzV+KIJLlhkEhchSO/X/AD6UgtxHFuDuAVPBHXj/AAHPpQBTkRFYp8wcqQd3Y5IIx/nFIm0bWLBmODjrjkdamuQV3jIPyjJJJ4ySMH/OaaxSNxuOVJ455PQ8/wCeKAIkXdAScBUwPu9c55/pUkI2zMdxOMjJHvyelGFZT5eScHk8Hoc/574qUSsZIwoJMfGQBxk8fU8mgCBCdqgg7OuMc5wOnH04pwbegVPM3queOP73f2Hf8KkmdWiTlQF4C54xj+Xv1obgsJF3bHIAbAzz6fTt6GgCObHmMTwSBlBleOOce/6UisyK4ErKeuM4ycf/AFuvenLtllOGUHAB9ByP/r/Wlcq/yuSgC7UG3r1/T+VAEZU7sLuC5+YdM8+/P0FB2qoDDjbuDAdyBnvSxhvusOgyMqcA5HX/ADzSyjCqURRtXHr29O38qAICoLEA7U7kduvWlU/c4C89cjnp3/HrTnjZWyW+6CehHQ9Pzpq7d4Y7s479c4GfbNACfLuyCASp3D86eqbJCBg4wfr06U4LkMzDC+pz8o5wf/r9+lDRjHHLMBt565IwD/njFACIF2cHnyiSD7DipUl8uQh87skMT3yTnP5/4UxUj3bmPyFTyv8AFx/n60jHCsDiQZy3rnPH/wBagC9pZYecNqscg8DI6cUUabs2yBgWYkMeMDkdRRXZSvyKyJY/UsC8nJc7S7A5JGDn+XX6VRK7lGThByeuOcdv6fjWlqny3cxU/IWKkkAnJPpjn6VSABiDNuK46cZ6Dv6+9cZREy4ZioYf7QfJIwf1p5iJkKkp05wT0yMflSJGEcbg5UjJK/3ee39O1N2kP/EqZ4wc4JIyM+tAChcbnJAU8DeeCcDj8/6U0kpcfMSG64z05P5/1qaN3Ecmzoq7MNycEdajkQb12sd3P1zk5OaAE3eZLtbdyAevHbk/r9KnZ0kUMTjbxu/2ecjHpUe3EZLbipwBxyRxxj+lEhQq24nngj1PqPf3oAVcCUEnbg9SeCOB+f8ASh1wh8sjKgfOO/Bx+HH60u/ywUHzKv3Bjg56f/qpjvJtCgYGOSD1OOfr7/SgBs6Msg3McZ5JHDn6etR4CHJ4Vh37/SpoUd8ruBBxlSelR53hMddw49B6/wCelADBnK8kAnJ98/5/ClfBLsDkdgwIz6/4e9DQk5UnG459u/JpIpdlwJE7EHseaAH+aVJKkFiNufcjHHbp0poMh2ghSqlsAnHHOfw96Gw53Lj1Ixw3v0pZCsm1SwYduBx1z/8AWoAjMagFjywOCp79e/1p0cO5F3MMevGe3v8A/qpuC0ZOVAP3gcDknt7Uxd6AFThiSG9+nFAD5YkjxtO75ep6Hr/nFK6qw+UMcHG49Poff0pdsZj3Zw3dQT71KfLCnygTtyc49D1x6eo/GgCLy2G0OF2gZzjjHHOcc9aQx7IFkOxssSAR1Hv/AJ9alCkR5b7oGBn6eufaojJjqFycexwQeKADactnI+YAKB0z7/1700KxwAC2PlOenIq0rBgm44DMDkYz1HJ/zxSW4MTjcRuxu29jx/UfnQBGYzuXdkKpK8DJ7/5+lR/MqEKxVScYAyT0/wAau3IAVQmWBIAHTue/+cdKrDCqyhshASoxgHkZ4+gNADo4ikZJAcD5uOMrg9fbNSrGzyEgb8nqeT16n8Pzp0UG7eMlccY6twDx/nipYVJKqoMWBg7vukZ7f570AQR2srMxQMcHOQcLyBxWvp9iluczRvKMfdB/3uo+vbtWxpenEW3nS52KOh6scdx+HI7dajuSyXTRxqA5I3bCeDz3/r3oAq30CPsYqUP3iA3T7v6+p71H9kZiiAoyMu0jbntwP8P1rVFnJJejaCo2KOc4zgcf56Vr2vh6ZjvWEhFUvuGdpAznn27+tAHA3tqI5TCmPMYnHPQ55/w9qpeRIcAdM9Tz1AxXatZLJqB2YLFgC2MnqOPrz09KzdQ09XVlyGIO47eFA+vp79qAOXCEsyJGzZP3Rz6jH/16cFLpjK/KOQQeMY5/lx+NWLmE2s8iAlMcDPc5bjHrz0quissyk4OByVPPQd+lADs/ulXdtwueT3wf8Pypo3PKB8vz/MwPQnPGBUmNyAFfvKCSAMBRnI9qjf5yMIcZO09QOe/+P5UAPbEaFt56YXHOeBnJ9vT8qWVohISis0T5CmTqp5z39fzpuQIV+YhSBjqMcYxkdeOn601uJWA3NxwR3HJ/rQAwPklnUYGAQG7cep6dPpTkkZCQF3fIUAIzxg8DPbnp+NO8sqg3eYjseF2nGOD/APXx7UrMwTO1jkEg88nnv/X8KAIyzKyswJJfoSD2/U4NRoI9yjkDjljx0qbYyMWztOCAcHb245+tNKhQu9cKOSvYnH1oAQs4AjwQN3OR356/pT0yznaACwBbPIHT8f8AGnoRI0bc9gW7ZycAfhwKaqCKMYKH5NwIPzD1BPr/ACoAhmcEOCyjbyvv1Bx6eophcsz4BwfvD8etP25zs2mTr14I5zxUeSACo91P5UAaWnO5Dr5jZUAcenPB+lFO0dB+9y2BhQD69aK66T91aEsuapHuu5GVlDBiQTwDz9fTvVF2Rk8zadxY7SR1I9Rn9K0tQBS9lyGO5zz+PT61Ql4YhgwOMYUbgeO3+e1chQ0Auqt5rEIMZ7jrkf561GYj1RwQMMCe+OhA/pTXPlttCltwznPpnn/PSpsEGJyMkZHHHp/n3oAq/d5bI7dPX+nr+lPV0Q/NkN93IH+eaeqho8HOSflHUgYOP5UwKd0iyHf/AHT1B55/CgBJNgjAG7gEg5JGCOce2e/qKkYtwTtbcPlJHU5IPHr7VCkn7vaCzHncMZOMDk0pOSM72/vAdR6f/roAkneRlRZCu3Py4OCRgZ//AF96bJv3Kd53/wAIAxxzjmomkUkH5j7dsf5/KpI1+VWZt+DyCfWgCMvzlkBBwSe5+v6U9W2BDJErkN8ysT83HHTpTVjBUgjPIOcZIPpUUY+U7lz8vHqcdeaAFJwPmAYk5Lc8jPU0KrZyxUovGW7AHgURlfM+RtmV6jk5/wAaWIb1xuQL7jO0D14oADIdi7SwcAnkcL9D61ESCc/dHPHX8KmiO1m25ZCMDcD8w7UmFEmORknkjr1/lQAxW8vbg4kPUgdPTFNyEX5Rg4x8uPanpHwD0AUsDng+lNbGBly2CcHb1/P+VADuqgrg56kfjz0qyEO7cSWVj8hz1PYDA/Xoahmd552kdgJmYbQgCjp2HQfhUSsNwCg8nk7Rn/PtQBYAYE5wMDkc4B9MfXtTgoT5pI+HyNxOctz6fr9OKjdl8vKrhTgYxyeOv+etMUMGUvjAPSgCwF8wh4yu7IAUnA7YB/z9aiiUiRFkA27Tgk8Hg96jUnG/btzzkZ9uPap4Y3L7v4euM9OvH5dqAHuVNuq8j5j9Rz2/U471GjIAzc5zkEnOSMHr6jinbVjchAeD8xz93/63vUYkbay/fABGcYwPpQBcjZmmHlsWY5BHar2jwi8uEyTtVyxZewyO3c1l2cUk0hjij2uSQCDyD612mnWqafp26MKHbaST2HHA+vagDTuisFqkSDZhPXJORx/9b1pmnWQvruM4wwYZKdSQe/8AnishbgNcM8hd2AIQbvr/AJNdf4Vs5xskYgDfuZiPfIAH+c0AdVpvhyE2xurl47e3Q/xYJ2nqMe/61keK9dS4zpGhxSCFjsKJ1Y+ufX/9VT6jD9puJTd3BgSTDZLYVPU59Pf8K5W+8QWWntNBoknn7gUkuWXaPfaP8+tAFPVLmLTkFqoDyDk7R1zj/PrmudkuZZQwlLIhwHAHzHj09cfpSXOpSMZGd2LnO0gDdnAwc+vv6VnFjNudm3MoGAD1GD19s9O9AD78NJIShVYVPUZyeT0Pp71nrKUVyuGPQLg57HP/ANbtWpEWf92Eds9cD7rZ5z/UdutRXdg0BRgNu9dwbkA8fT/9dAFRopDsUgKoGSxP1P4/XvTERsK7OxbHGDggDGD19+KvxQTuU2KWcnkdup9uOvfpVyz8P3dxG2Yyg65bPT5f09u9AGTtLxKZBgEFshiN2e+O3cH36U+SxPLucMx4EnX6Yrpms7bSYmYRLJKWwAx9j+Gf0xWKZZHk2IABnO3BwDnu3pQBnrGNz+af3ZXAIPTIHfH6/hTJrfa/+sbDOBhhhl69v84qw3mK7+YhUgEuMdwPT+nbrSKqSP8AKo2se44Byenr/WgCi5U7wp3ngjI69Mn/AOv3psqAkcbU7Ae3P+NWpSEQDaFZvlIx7DB/z0qOUDeqgxkL8o29D1/yfWgAE54IAkABAOMcHFJJkLsxkkfMSOc47+/86mt0Ak2gnk9AMA9O/r6UrBfLVGKlVUBPpz+OM9/WgCFIyCyhQeNwJON3J6en1/CoxDtc5zxjg9un61cA3GQAkM5KN/s85wP8O1PiQHC7Vbk85xngd/y+tAE2jMimbyS2DjIx3yaKv6NbK3m434wM4G3nJzRW8JJRsKwzUNy3zLyQ7k8joc/5xVOUCTflTHGcsFCYA7celb2o6bOZ5ZERhgnJAzt5+v51kSWrFCm1vRlxjPuP8KwGUTGIpmPRBgFh39gP85pI1bc4lbdhdoCnp/n9Ktz27FMyR/KD8rD/AD+vbpSCBYogRxkCQ4GDuyP8+9AGZtaQRgFdyg5X29fpTFd1AKyOWJIK4weOnNaFxAu0OASTyQo7896oyRLuZFJwOrY6/hQAxXYgMXygGwlfQj+VSBCzoV8wMpO/bzx600ICW3qyhRgEDBJx3pxUxsCh2Eg8evsPUGgBJDNFKWZclQGyfQ9D9aXzA0oDszEnIYDk/UetKylgXwyKpxy3b0P+eKYdgZvk2nP3Tnj0oAdw0QELMrDnk4BH9BnrUJI5OMhz69OKfKpEjrNhmbjHXjHY0OpjhAkCsrcAA9vb2oAiRjjaHCDgNwAMZ4INMLHOBjIJwcYP50nGfujOetKgAYbwApPORxQA5GL/ACgZbntzUiZCMjEKOCcD9D7e1QurYOARgZP07f8A6qcrAYMg6dMGgB4G/opx0UdOabIDyegyApA4OB1qXyzsQ7G2tzjjnBFMlIbfkbgF4K8Hr3HegBzswgCgjazkgken6j3FPhDtIQpzKDzz6Y5HPX+dDkSEAJGSoHTqw/KlWJCdioQ/UOzHI6e3/wCqgBsiiRACUO04BGQT196jG35R0xxkYPT0HpVt0LYRjkdMkdDzxj/JNRPGqbQGzIGw3tx6igBEUJEB1+cDGBgcDkjuaeNrqQzKGxhQOhwTjPt79aVFZU3YYADAA4OPX6U4AFiCQfmyOe/PPHcflQAjyZOG24UYY+35fp2pio7OFO3bgnJPqPX8Pxq0sZTLgjgEBWOcE4/P29a1tD0o3Sh3VPKTAyxAz1/z7UAXfDOmYjE84HHzc8fL2/z2qTV7tGwqtiJckHueBz/jVvUrhY4GtLcBVA5YfXkf561isuWztyz7SMHoccY9KANHRoTcXY+UKMbQD178fX0rt7nUYtNsTIXRQIwBk8Aev/16xvDtoltazXMoUlhgZ4GM81y3im+N9dGGMZhD/Mc9SP60AQa1r11q90UnlZYEJKLyM8dx/T8apuMMyqGzk456D6/1qPy+cEZG3nB5/P8ArW5o+mJqV0sZcRk/dDcZHYD/AA7UAZGzzdrKijgIc9hxjiriae8oCGLc24/d4IIB6/1/SvQbLwU8MS7o3c/eVkGQeOf/AK9df4X+GGqaw6TrA1vbd5ZBtJ9AB368UAeX6L4fnnvEjjjZ3kwVSPkt/nt6167Z/BZ9X0EPcsYrtMbIwcj6Mf69q9j8KeAdM8PQxeVCrSgYZiMk+v8An8q7BY44vuqM47f4UAeGaV8J9P02AvqEkasPvKq7uvr/AId+tUfEPg60iga2snESH+JSGY/T0+vpXsWtWxMxYbgpGQo4ycetcxNoj3W2aaLdLnDqv3SPT6e3agD5w8YeCbmxga7tj9otnPXgEYz29K5i10uRirNGxA46fdxjOeOvrX11beF4lKm7RHQ5xFt4I9T6n1PevOviNpGmaXKEhhjhBIIRXCggnjJ9PSgDwO9sJHdVMeF24yO3HHOPy9az5bRELB8Bgeqk4PPX/PSu31q+0uEMFkRDgggYYE9847eprOuVgurOSfT4S020Bjt4H6f/AK6AOBvikU/l4Y4HzA55yB/h+PWoE+Zt6KGXpnPfmrFzbszDzCBJuztQ/wBf6/hTI0wXLMPK3EMOmTk4FAEYYMvAXegGQT75zj+nrUiSDIDSEhhncQCRgH/JoQ7mA+YEfeOOQfr/AFp4VEXfjKvkIAevXr/SgCQBWJ/hTPUEe3b+vepY9u0MVyQSD8vTjg4/zihEVVYtghiDxyS3Gf8A6/pVn5mtjvOG4GAOTjpQBc0pMLIm/CjkHG7uaKsabj94wfAOOhxk85oraMZNaCue3p4MsLiSRpxswfvxkhvY47n0qnc/DpZsgMLq3Gfn+46/j6f1r02/tjgx+WUdWIxt+UjP/oNJAWikLGNi2fvev/1/6ViM8M1j4c3kDlrVJZQpyFIww/DoT7Vyt14eaNir+ZG46bwV/Dn+dfWcDpKMSxEHA4A4x/hSX/hvStVUrdW6OSOpHP5+v8qAPkGTR5V+YDdkEEE4Hft/SsqXTZ4mCeSVweSeQPXnvX1XdfDe3U5s9sqHJ2yYz+ff+tYlz4F8vIktDGe4AyB/nt6UAfMbWrqXBG8EbR2xj39KgNuzEMwHuP6ivoe+8FW5ykkCAc/MOPz/AK/pXNat4DU58nt/CfXsBQB4qkEiBVxgAksT6/40+RFVmLfeAxjPX6e3vXoN74MmjYqVIDcjPT8/T3rJn8OSJgMpBBI5H+fyoA5AQxCLLHMrAbsn5QO2B9aLh3c4fap3DdwOMemO/rW7JoUsQ/dqVABw3U/5/nWfNp08S5KMHU49Rz3oAxpl/eNxjnacNkN9PanKCq44b5hxgmrDwuCQ+QVBwaVIS6yKcnlTjHIFAFVRuVwMucHPP60jZGFYZYnO/wBR7irH2bAbbjuVOcgfX/PFCxYdSpDEdSBj68Ef/roAiVigUF3X5ewzg/nUuXl2sASVUd/Tt/hTRC+1gQQhP93IPvnt/SpwHjIwcgj76A5X6jHIoAjAJYlFUfxDLcde561NHKz/ALwOnJwNwHH+fShUCscgiM4CjB3fU08oMR4Geec5xigBjKqSfOS78kLnIzzyD/XtQzRyBVIx8u04GMnPOeKmKepGxjwcn/H9KZHEu5dzFtuTk85+nP8A+ugBsIV03SuxYAjcRyP8+tSpHtCAoSp6ZHBHr/gKcqBQzH5t3G3A/wA/4VatLGW7uUhVchuVBHPX+XrQBJpVpNf3CRxghCf4V5HqT/X0rsLm1g06xNvbY8zb1Izj6ep9u9bek6Vb6JYAzAiaRcAFeSfSsg2rXLNLuYqD+X/1vegDDSzaYlgXLHHJPJ6f5z26VpaVoF1e3oUpnOBjsPX8Pb1roNE0Waa48qFQ7N0Vh/P/AA/GvYvCfhGHTU+0yBnuPLCjdyA3cj396APHPFFlcWVmqOphDjaCBzx3x6+9cXHpb3OwGJTjHTofSvaPE2i3viPxG0FlbNLBbgJnoufrXWeF/hFGnlSatIRg/wCqiHX6mgDwTTfDRnn4geWYtgBVyfoR/nFegeHPhDrOpuheP7JARw0vLAf5/OvovRfCmmaWoW2tI4+MFtoz+JrdTy4wAAFUUAcr4F8GQ+HNOjguZjeyr0llHT2HtXZKAAMDgDjFZ13cMV/ddv4jTbS5ZZNjZkHXd1waALc0xD7QO9CRmRt5HBHUmpCF4JAw3XP8qc0iIrEkBV6n0oAbLCsi4YD16Vn3gitImZjhQOT/AJ/yasjUIWk2puZcZ3AcGuX8Y6ki2uNoCMdpL5A/z/KgDj9a8Q3+ryXttpDRWsVsp3XEnRvZR/nFeL+OdLur90uZtVtpd/QgnKjucemev6V7D4kWN/DzQaMIY4i2bh0GSwxyFz09/WvKtfRLVorxo2LBfLAA6t659cfgKAPM47Syt7lxO32mQEDA4y3PTnH9K1bjVGhsXhXbBERgqn3Qp/8Ar96x9YneOSQwoCMYJx8uc+npVEzkgqWYuTnIOTnv9KAKd8UDAvgSY9B/L+lUTIC7DaFTdkZxjn39Perc8RO/HyqOcEkj6+pqkjN8quGbcScMOB2z7/TtQAkAHO5SpIwSvb04/wA4q15W3awOGzng8Hn/ADmoFTeXw7MucDJz2/l7d6sRAPMCJAAVCgEdD60AW4Y127SuZBnLL379KnUh49/3AR93kj61UglDqc/NtHHYkd6lijVjtb5CeRnkg/40AamjzbUlKhSpPXbnP+FFLo8QZZVRCQpHTBx1orpp4PEVY88Kcmu6TYnJLdn2vd6a7sMZPPTOfyNVWsZ1dsBSo9R1Fdbs3M2fwoMKt1H41zDOVgil835sjB79au26MGcAfKelbLWSN2pUslGKAKVsrqgCr07Cp4o8li4GWPINXkgCg4Gc0GEA5xg0AZN1pVvP/rIFb6cGsG+8I28vKjGTnA6CuzKH61GIiTnoaAPMtS8HzBnKxLIOw9fwrkdV8ISdrcIeuPT/AD+te+GI55HtUUlrDIuJEUigD5f1Dw20LOHiZFHcj+f+eKwbjQeG2ooAPpg/5/nX1lPo9pMrBoUO7jkZzWZP4TsSdy2NuznuV5/z/KgD5Mn0APvzGGGeSvU+n/1qz38LvID5CuR6bD/ke9fWb6JYxsy/YIFxnrHgVH/Z1vG237MiYxglec9vxoA+RbnwhqYkLxWU5UdFVG5BHT/PWs6Xw5qUBeOazlhGOAw79uc//qr7PisrYYxEN3THQVBc2MEilZLOFgOPnQE5/wA9qAPjEaNeNG0ZhZWP3sjqf89vxqSTQ51k3OQvQcY4P19ffpX0/rfgu0vY2a2V7aXORtHH/wBb6/hXmGu+Bb+BnBVpQOhUNgfUentQB5abZFYNhZBnltozyaetmHDOBhyxxtx179q6W40G6SYBUfcDyMHP8/1qS10K9Ysi20zZ5yqH9eeBQBxjW7Bm/dgqOnofwxz9e9WrbTJZmACAA9iuPy4//VXdReC78PHLLaTCMnlyBx69/wA/SuwtfAV5hHCQou0ADdkj3P8Ah3oA8pttFjUnehZ3OMMT/L/Oa9U8J+C7TSrU6hqIlW7kAEcadV9ODXY+D/hxBp1ydQ1ZhO4w0MIGFB7E+v17V20mlNdzhjGq4GMkZwP8PagDxO+8J6xqMpnDQlMFsSZXK59B0rW0DwBqa7pHNuXLZHz5z/n0r2VNADvmXPA4NbWmaPb2yR/uwxxz6D04oA4/wv4IMKxzXCxJN/sHOa7SDS4YYQGO4KeQeK11iAXA4pFiVRjG4e9AFG2sIYh+4gVE9hjJ7mrwA+XK4IOKk6ZprJuIzng5FAEVwX2nYdo9e9RKGkPQkepq3j1OailmVeEwT+lAFeSMN8p4HrTDPHb5KqPQZqG9uVhhea5dUjQFmZjgKPevFfGfxQaV5bXw8wVASpuW7/7o/r3oA9T1jxrpukTQwXs4jndvljByT9fSq8l/PqdwX+Uw4BRQflx7+/pXzBPNNc3TTyzvJOxy7sfmY9v/AKw7V7P8J9ee4gFtdOA65Vc9/wDPf1oA9Pt3U5YIBtGOuai1a3gv9NaOeBXRhtZSvP0p7KYn3xrg9wB/Sm+YCzRkEDg5J60AeTyzR+HtWaKZma1YmJogMDaejAn09fwrN8a6LCdEJwn2bfuRiPu5PQex9PxrqfiZponVLtNzhfldQOfrjvj0rktaujL4Pgid380tsU9zj3PfHfv0oA+f/Ep8u7mjRejHDDnnv+OKxIJ1WFYQAUGGBHH4V1niq0IdpFXcMAP8uMc9D/h2rly5j3uNzqDj6frx7/pQBauYYnt5TGMbU+YHr79vz/SsZPLcLvDJ2/D0+v8AOtrSHaaGRZXBfbwD/wDX647frWSysisPvuSRhux9c+nvQAAHYgiJ25zy2GH41IAA+XwpIwMDAPPcdv61EhwfuDAByMA44/zxTosmIKpBxyGxksM9/wDGgCxDjeDllcg5HcHufc1YMqKrYf7o4x/PNQIFVeihQv6+w/p2pVGwBSuUI46cj3oA19GCt5xmlCZI27+Mj/GiotLLsknzMMEAHb1HtntRXdRxGHhBRnRUn35pL8mS0+jP0KJ5ORmlTB6cUzacHGAPanovSuEoftPpSg+tAOKCaAHgCncVED6UuSaAFwM00nB6U5M55p5jzQBXI3dhUboPxq3sxUZQ5oAgSIBef5VMqkjGOPWn7eOV/KngHbgcUAUpYlf7yKQe9ULvS0mHytt9V7GtryvmyTml8oZz0oA5SfTriObhNwB5bH+eaFt22hf4Qvft7f8A166tkJBAIwfXtUb2kbJtxg/3h1oA5hrPfCxCkZ7gZP8An2pslgkg2yRDgdu9dMbJVUeWcYHQ9KrSWkoJPFAHMv4csJx+8tomYdMqMioB4QsQ+5FC+wrqBAwPNSCEnpQBgnw7B5YCqcjvkcVetNGtwgeRAzL3rWEDEKDzVkRkAjjHagDNWyAIGAd3X3/z6VLDbhSAycdSau+Scqc9Oxp3l9R2IoAgVFyvBxU6IAemKcUGAOmKcBigApOnalowM570ANBO88cChmxgAZJ7UrEgcYppyGUDnigCoyTyk7hhC3SiRVhRi5zsBYAdxU083kxlmwGPQetcf4i1JsyNI5BUYA6KKAOQ+K8l5qOksUeRLROTCn8foT/h3rwmVHide6nnPYe3+eley6h4hF27LNIEJUrtP3WHf/65rhPGcdi3lSWwSP5dsiKPvehA9fbvQBy3nrldo3YByO3+f51r+Gdbmsb1GQ7VPIBPfP8AP0PauXadA/zHcfVf8f69qmjlKyiSN0x0OR2+n9KAPrHw/q41XRIbldpk2Zf6j1pt1eqjykg/KFJPcE/1rybwF4lutOubVFUG3mdY5S7bQuR97PevT762Ks6fI6y4O8DG70/D0oAgvXhlR8sAgHHGcg/y+vevO/ilYPZ+Hku4OE8zMgIyQezD/PFd9LFjIbkL3Pp3/wDr1X8WadFqng++tdpUiMsnrnqMH+negD511+0/tDSWvVHGMTBemex6d/1rzW7hlWZlIK7QMAfy/wAPSvSvC2oLaavJYXuGtJxsdScc5+v69q5bxzpI0zV542UPEDlGxwVP8WP6fjQBh6MZIrwICSHyO+0+v1HrUWsRrFcsxch1PAIx+Xv7Ulq3lShsk4fIHcn/ABxWhrtpm5jkADR7dzbeOOOvfH60AYDbkiOTtc4Ay386fDIA4IZgpx165+n+cVIsLeUCw+WTJLHBwB1HSkEEq4HlfKCOc5HPY+/86AJlmRFQgggZyMYOP8/nSu69MlWPU9T9B/Sq4JI+6zv1PPQDtn/OKegTcSGypyOeaANPSpNqOCykYBAOSB16UVJpeXV2Zl5x92igD9EQW3+nPX/GnZOB8tVRLtbBO4YzTkmzyDz6UAWVbPGKOPSoPONL5xoAsDFOFVRMakWagCyKWoVlzTgxI4NAElNY461HvoJJXrQA/dkcUo4NRqSAOeKV/Y0AS5oyKh5FGTQBNTG68UmT603dzQBJk0uRTBnPWl6+xoAVlU9VBpohTsKMPjseaduxx3xmgBcAEClpO4paACijv7UA5oAKKKKACimSvsGcE1mS6hJhj9zB7+lAGmxAyRzTJZUhTLc1ymu6+mnfvLiYqm35e3+favG/EfxSu7m5lS3mdLdDtXBwG9Sf88UAe5a3q1paRNJeTRRDsrtgn/P6VwepeI9PvZZIUCGIKT5gbIUd+a8mfxJZ3haXUzJcyKMorsSB/n071A3iDQ4YcpaIHxhUWYgHPf8ACgDQ8XahpFveeRBfNJdAg5T7o/8Ar1yWr3wljJEhZC2VfPH4e3vVXVJtIu1kCRiJ2XB8snBXNcvfyT2rxrJKZUHKtnnHp9cUAWmucSOHHzA4b3P0/p+NWLS5AmHK4zgjI/Dn+v4VzE90cOw4WToMnAHYD/GgTSux2s2Qw5I49/8A9XagD2DRJBNESSuCAB26f0z+Ve+6DqUGvaLEeY7mJdjBueRwfz9a+S9F1F8DzHYoOh5BHH+frXufwb8RQJdSWFwS5lG6IY6e2f5elAHoa28jqyqrbd3ODke3/wBb9af5Ya1uEmYLFsYEnjj6+nv2puv21xNLEserSWVqc5jRev1Pp7d6rQ2gtbSYvcSynb1fvjpQB8meKmNtrU/lblaKchcKSSc+nr7d+tbWrRprnhNbvrcwccHnHfn+v4Vj/ERBFr2oAEAGQk4PGCfX09/wqLwBfMJZrKQgLKp+UgDPH0/Tt1oA5s7YnBVV3M4DBh27d+la+txZs45hy23J6Z9+fWq2r2ItdTlVsgKSdnQjnrnHJ/nV1QLjQw20kp8h56DjjH+cd6AOdDIFC8qWXnP8IPbH8qrbiP3e4BgexGMZ9TUpPltviKsMfIDnnn+VQz/6wFUbBOdzDkk+38qAJVjT5i7hOygD7xx1+nt3qOMIrD5gE3YDZ/P/APXUaMnMgG3CkHcc/TFT7gNpAGD94Dt/+v0oA1dIICy+U42kgjPTHt7UVHpiLGHychgpAPOKKAPvbdJnO8kjg1Ik0g6HNQNgnAH06inx8HHQ+9AFuK4Y/e4qcPnoaqovrVmPb0oAdyakTNAx61IooAemfWpU6dajxxTS2PagCcDGaAQeMkGq/mk980b+OR+NAFlVwPvU4jng1QeYoO59hVdtTSI4Y8nt3oA2M46ilG01kw6tHIcZ/A8VaWZX5VufSgC2yDqKaVAGabFMM4Y1KRnp39aAIyQRnOKehGOuaQr0zTgAOlADgMDilA9eabuA6mnAg9DQAY5zRRRQAd6KKTI9aAFprcYPNR3M4hiZjn5Rnp2qoL8TxFo+FHB9QaAK2p3ZSTCSDpnGemP8/jXOzzSTPI8sm2BOXOeauXrmQjy2GQOWbgBe/wDntXCeL/EMSRPaWkm2FBmWYfxj2Hp/OgDjvij4ie4lYRyEiRSoz/dH+ea8hu3dZgpJwTkZ6557f071t+KdZa9vpJZAU3YVF64wO3vXKXtwAcFvnxgDPbP8qALd3cLDCreYMkYwp+n+c1kXd3ISVYHYQDnpx6f/AFqhllfK7myyttwep6VEWkLFHyowct+fT/GgBJJiWDZIOSeDjBzjGf61JqEwlgtn2bAuO2QDx+lUVyYwrLmRVJ/DP+eO1TvlrBGwwGSrFskqcf5zQBDJlGkAAywJI4wDz/k02Ibp9kYCFiBx+H+femSMSFG0lshBjsMn/I/Wm7jFIHLMSATnPfPQ8/n6UAdfahLVkMbxsqDOPf64/wD1V1vhfxCmnaxbzMyKFbB+UnGTyB7e3euASfbbqUOd4GQR0ODx/wDW71LBNJ5gUryG4+Yevr/X8KAPsi8v0uNNhmRSWbGB6fj0z71y/wDa/wDaV7cWhlPlRJlQOhI6n6frmo/DOoG/8HQTblJWANgj09R9e3brXIeGbr/ia3BLEyFmBbOSfX6n37igDzH4oR7fEMwBP7wZzjnj+vrXG6RK9tqcEqEvnA3D+vp7etdp8WHzq+YsHcv4EZH+RXAK5W6QANuVgD2PTr/jQB03i3y21KF3YM7Ju3Hv7D/PFM0grLpc6qwzj5sgE8jrj/OasazCt7p8Bd2DpwhbPPIxk/071S8PyZMsJ5Z05UEjGPf/ADjpQBztzEY5ZsN86joeQDk4/rURXK7l3e4xj0/StHUDF9ol3l1GCF29TlvT09vxqlLLlFAXzJUzg9ew/PH5UARrIcsxUMgBBzgnHPbtSqDHNjoCMlg2Q3oM0NGfM4AOck9MADP502Fixb5RgAn7vTpnigDV04lfMDRtkY6t1/H/ADiil0pWXzMkuSF+4A2Ov5UUAfdizb2I3bufz/z+tSpKATjHGOPSsJbgCXDdyRxx/n+lW4ZUIO0ls5JH+f1HegDXSbIFSpNxzWVHKBnB569ef/109bgAgc5oA1VlGeDVhJ8dTWUso9KkE4HrQBqC4Ge9Esu4Zzisv7Qp9cU17tMEZ4oAuvOBwT+VRPegAhST9KzJLlcnB/Wod4Y53D8aAJ9Qu5iq7C2Accd6xJr0o7Ag9zz/AJ/Sr9y26M5bp/n/ACKz7lI9u4sSD3zyeP8APP4UAO+2q7j5jnqRnvU1rrckLKVdXj6ncccfWszap3beeOBjjr/L2qFogVJRiTk8DrnHegDv7HUo72EgnkHse/8Aj7VqwzbQnOQeASev4/1rya2nurRxJbyE5P3egx2/D0rsdH8SwS+ULxfKc9iflz3/AB9fSgDsiCY1YE4pNxKkc5qvbTxvFuiyyn0P6j/PNWVZGX5W/OgCrJKQcGkWYjoafMgZveoNuDQBcS4yOTSG4OTVXtlW/SpFZVjJLfpQBLNMBGAW5PPNVhdYdv3mQD/F+FRTSlwNpI2nseT/AJ/WsbULj7PnG4tgY9D9P88UAbdxfIxWPcDvO32FeY6j4obSr+6jSb5lYgqTgcH/ADzXQR3zXDh2z5Y65GMYzz9PWvGfiPdpb6jPLlvMm+YA/ePB5+tAHQ638RZQ3liOAgja3Pzf59u9eca74ilvwWkcBMZwhx+v9fwrk76fc2SxBH+17+vp71jXErseHYFQM54yMDt/T8aAL+pXShpCW46E+2D/AJxWS8w8wh3O4gnPXp/Wq8sjmXcgwR03HI6n8zjvUbPvk4yFJyQVx6f40AWipK5R1xgDOeoqGRm+XJJAzkg9Rz/n2pgfezfxcYVsf5x6mplR/MYEY3AkfWgCu5GPLV2B6cL93nrn+verdth7OSMli2AQc9cCqrRbImCehO4nr/n9DVjST+/KMT8y5O4ex7f070AZ8sjrcvt27cHA7AZ7/nTFJPlAgLtPzkHLFj0JGMZxU90rJcsAQOfudzz1B7H/APVVY7XDbRg7QSw5GPp1x7UAa2msJ7WUCXHlsTnPHUj9anjYq+Odn0Oeoxx/T8apaWwW7AYZDkgk45YcfnirmxWmkAXa5IHB65xj/wCtQB794I1GQfDksr4ljXyzn6+vc+/esbTZY4NdZ3Vogjdv73+eg7d6TwlMbTwa0bKAkr7WyOQAM5x29/SqhZU1BvMDq8xC4P4HP5fnQBxfxRcNqYLEktuIwR6DJH9fXtXDlQpJVgV4HbIxnFdt8SlJuE2Fw+DwDnsO/wCH4Vw0yr5xcZYHpgHAPOfcc0AdS8+/Qo1wrRqAww2AORk9P8moNC3zyPJv3M2QxCjJ69vXjkVQtJyulx79zKcFAD82RjnH9OmKsaNfLZ3ZkiACDKY7E85755oAo6qHW9uBt+ZgMEn3+n61mOJVChQkeB8uOmSP88dq1/EzpPevMdsSOQWAPBJI4/DP4ViyoqwqGJELDjncM9CR/nmgAj3FnkUH5T90HHc/5NPj5JDuW837rDjnioXQNI+9+UO3JOOnv/KhAhVCz4yuORxjHpQBtaIwja43BMEjA5A79Pain6Ctw0lyUIJwueR74orohhK9SPNCDa7pMXMl1Pr551LYDgZz15I/D+nemrcksq7xknhgen4+vv8AhXHvrdp5vFwvI4PI/I/1/Cp7fVrIlCLhdvXkfnx/T8a5xnXxTyJgCTIHX5eMcfp7evNSvqDgkEksDg88/wD665W31a22nbcqQSD9/tjnn+vfpSvqMDjMc8fl8AHPUdv/AK3p3oA6iLVG4ORjoOff/OKtf2uq8HHT1rhZdT2/vPOUZBwAwOee/wDX9Kqy6lM7EpICAf1/x9PWgDu5NcUE/N+HSoP7ciIOW9utcKb2RwWGwk8nB/r/AF7VG17Ichgp9WHHH0/p+NAHcNrMRHDADGTz2oTWImYgSBWBxj/PeuFWcgjGS2f4Tn/J96ha4ZSVQEL0PPBXt+FAHoB1VCp+ZDjqd2Bj1+nvUNxqMbR9e5H+R/MdutcN57norAn3HOOtV7i6cJsDHnuDyfx/r3oA7CDWxzzwepzz+B/r3p66vFyG9BggYGP89u1cMtw+9yWAI9uv1H9O1OS4lL4HB6YzkH/P60AdyupROw4wxJOMfn+Pr+lTx3CuvHzA4wcdfTj+Xr3riY7qUJzkHAO0c/T/AOt6d6speHAXeM88YIz6/h6/pQB3+m63cafIrwMGX+KMt8p/w/pXeWuqRzwpPCxKucYx909wf8PxrxCK8BxtlIBxkYyc4/zx3FdF4Z1fyC0e5mVsMOcA8+vp7/hQB6v9sSXG0kEfr/n1pFukOd3Y1ylvfBJN6ksuOVx0/D+nbrViXUUjQGTcFJJB7defx/nQBuTXoAyq8HuSKpSz+YfvhgRjr35x/wDW9azjcQzKxiwflx+7bP8A46f8jvTAQoVEDk5+7z055x/OgDSafy4trMAc9Rz3/wA/Sqd7G8lu5Zsqo4HcH/Pbv1oaSKBlkuJFjHQmR8E9DjHrXHeLPHCRI9toq+a4GPNzhF7df/ZqAJtZ1WDRYWUOj3EgKoN2GJ559uOh/CvBvGupm812V53GRtUgfdA57dh/Wt/V9UlV3vLifzrqQnzJD/CAOuP6fjXm99cm4upHJx85OS3uf8570AV7lizsCRlmySTyOn61QmZdp/iJA6H7owcE1PdyuhUiL5CvQdD04/wrHklO1sq3O4YJx6/40APbG8O3qOe/Uj/PpUYn/e/PgMRlVXnI4Of0x701nLTTMQU2sDn06YAH0/Oo4yfKyq7WHAOec4+8Py/CgCyxYZ5ULuxsHrzg/Tj9amiyAuPmAz93qMnv7Z61SYtHA/HJJIYdDyc8elWbQsJQxChJOg754/lQA6feRGA2ASMEjJyFyeKltQgdCRn+IjPuR1/rUT7pIso4BCZ4HB/H0GAKdb4WUuVPmg4wvOeemPXmgCbVYyZiwAMb8kDJxyP/ANWKzpEHlrkyZ6q3sBgcjqeldLdWS3GmLOgzNjkBuMcHH/1+9c+8IDhd+DkKACBjr/n2oAl0yINeodxPI4yQByen9K6Owt1+0JIOYwRuDcdAMj9Of0rnoxtlD7W+UkbAQe4z+GOvrXT6JE95NBuD8fKGC/dGOMep449O9AHb7p7CxtpdshgkBKoB0JyB+PoO461Wku97L5pRcHO9Tgr04z6e/bpXaeMbFbe2sYLcjYkKlMjGUIz+WT19favPp7VgFQcqT8wIye2cj19vxoAxviGUma3lVdygHcRjgkdcfh0/GuSeHLxAKNhYDcG3EMeM49cV1vi2IS2SkMTHvBQ/gwP/AOv8Kw2gEE0UsQVkGOB0BGOozn8O1AFFIdpVFLj2PAAxx2/L9aiMbRxvJExX5snnJ7/h65/SuklsBfj7Vp5Se2kGeGG9HxhgRn1HXvWJcWBt7j5wyoisFPGScnHHr6UAVBJPOJoyXc4DqCMkYxj69fxz7VTZj8pZWMe0kn14OD9f5Vetw8UrrlWkILbScDGAcj1H9elVXUsGKgszfMxAGeh6D29O9AFdyzzOh3bVyM5zxkf5xUUbpvCgMBgk4Oc8cY/KpcYyxydhzuz1XI6H86Ryo5WNVTBK59f8549aANjQQJRMBEGK4PPOAScDn6frRTNIYIj7FkU8A4Oc4J5PuaK+wyqFB4WDna+vV92c8782hvz6jKl2+JSdxPpnAwScevtVZ9cuUB2SkjqM9x6+2agv41EzNghC3TPOM9jVJpIzuyWJGACDjc2c8+vH5Yr486DZi8Q3JYASqrEg4xwRn9Pp2qdfEt6UyXK5B+XHTj+dc85VWdpHBxghgeME5/x+vFKkiESbWdsgDg9/X/PSgDoRr1zs2lymMDI7HnBqQ+I50O1pWbIPQnHaufYqqqd5+bjnsO4PtTEZtyAuDGfbDdsfj/SgDpE8VTuxQmQ4H8Rxjg8//Wp6eJXiZlEjjJx948HPr347/hXKM4YBZSRuwuB0HX/Cn+eSMlVwvJORwe3+FAHRr4onDuY3lVdvfPHTHH9PxqFvFdxvXMsxYZ+bd9c/j/OueaXEQbfulOMDrzjrn6UJtLEMF2lSSV9yeR647elAG6PFFwcAPKOhUZODz/L0o/4SS+ZsidixJUjP3en8+/pisBm8sE7skH19SP8ADmk3ZdFK7dvHycZ9+nX370Ab3/CR30aM5myucEgZ3HnHP+cinw+K7xJDmVGz1PTHPTr1/lXONtEjqyu3IO3OB1OT71MhjZv3uSueC3Y8cH/PNAG/J4vugM+cgXGcr/dPXP8AX1qT/hMZmTmecZbIwR74/wDrVyk0Wza6nceTzyT7n29KiHO9iw2nOR2Gep69M0AdzZeKZGGIrxlxxgvjPTnp0z+Ofauj0vxjPb3KO13IdpwTjrwc8Y6+3415MZdqrhipHIPAboDnr1HH4U4XCrKcMMKvBP1Pb60AfQ1r46zHtkcjIwjKSAR6g/5z0rYsfHNlcIttdlhuOVkK4Ck92Hpn0+7Xzfa6jPEcq5fOTtAB9O3r7dq1LXXId7eZE5k6Ao3DHB49B9O9AHt+ra/dQXalIURUGRIpLBvcEcfX1qjJ4s1W4wpvrgHIACNyfQf4V57Y+N5rDCwW+QCRiVywHI7Y/XtVq48dm+VjdW8MHb/R4tqk+hA5xQB1L6hJK8aTSGSNwSSxJ7n8hn9abdXq2KkOFdGwcdAOnX/D8a4G58X3TxyJblo+cliOSQf5/wBKwZtSmndjJOzBwM5Y47d/SgDb8R6yLiSRImRUzlip6jnA+nv3rnLmQ4YKiDLAnj3/AP1YHanOw8xVYheNxU8DvjP4flVRzuuWQkZB6EZx0PB/zmgCViHDDIUBSu5myQdozx296pnDeYEP+zhhyeTj8aUOGIYSjGDtBHXg/wCR6U2MAyMXZWkycluh5/lQA2QK5Jyi8cZPA+7+dMwzRxrIyjarHA54Gc/j7d6c+xg5GFDYIGOQRjkU0rudFwu1t3HYcHv/AFoAcwQhhG208nce3fP/ANeiOOTMeCoUnIbPVeOfp04pg2rLsR/LUHBU85HHA9R04qODmRWIGNueD146UAXseU525AHQg55wefrwKuR2suyOUKwdWBVumAWHPHr2qnCoeRF+ULgKQeRgE4H+fSuy0+ImzxGyn5Tk4wOozn+p7dqAItPwdOw6/LzuHuRyf89K5y+sws8u0BkJ5XGMfMcH8P1rp0ii0yBHubmLEq7dmd3GDjj19PWsC5u457svCv7snauTgON3+ee1AEmkac9/I4BAKLuJH8QyOB7/AMq9L+HukSS3gkiEYYrujicY3r3XHv6dzXnVrfPZTBlwrgZwRkZ4/h9OOn413nhjXreQD7SjRTITJEytna5J596AO617VbOKO10rXJHtrqLc1pcSrw8ZxhD6MOnpiuR1d9Kt4BMl7b3bhQQsHG4e/oPfv0rV1TxBPLCTffY7u2YZaKaMOmOMAZ5X/GvKPFgt4NQ32SLaGRSfJEm4DIPTmgDR1a8N9eyMqqig/LEvIUc+3X1HbrXPTnyJ98ZbIA5XJ+bjvj3z71HJdLHblIsKd3LscZwf19vWs5Zdq7y3LZzIzd+M/wCe1AG20sdwfNWMJLjDtESA5wfmx2P8qzZ5XhczIWC7iQAvAGefw9f0pkc7vCEDhS64wR2+bPb3/HFMuJ2YlA+5ThFLHB4Ix0Hv1oAiJfzizvuKc7SfukDp9cfhimpKCrOsmxNuM9OOePof50xPMK4MqqEGFQ5xkj+R5p7siztuBXa2Bn3zwf8APpQBGSfNcHLErtY9QSMfoBTQhS2Y7sK3BH5/r6evNTKAH3IgIOGwG4xwcD17UjxPIyptOASSg6E7m/L+lAF3SkAWQKWTbgEfnRRp3zeduz97pj9aK7aM5KCSZLLuqlnmlyxPzH5emazmiXjZyyqSSemM9/8APNaeoDbNMGTczMdoHU9ec1ShkCuj8E8HBGR1Oa4ihuduUO719u3+P4U1UI+WNGUNgMv932AqRpS8XynfgDJAzjPt/SpNvzlcHKjBCkYHHGD6+/4UARlVDvxtYtglj155A9//ANVNkmI3oVw2z5scD1Oae4yu5ducYG4c4yKZOhIOQFRup7g44P1oAYJWLFTmVdwOG9BntRJI+GO1cYxn06UzDF8nIPGGHU4P8ueKbgEhT8zcli5xngZ5/wA4oAhiyCpU4AzgnjJ7D/PSrvnshZmQgD+EdB15H6/Wo4hvR96gfNuG3kFf/rDn3qQspAUbnGOBj1/z+FADCQ5A4zgZDdAeMfnRIy7VXBUnIwOeOcn3HFORAmV8seUABg9jj/8AXTp4RuQkc+qdWODj8TQBFgKoif7pzv4+Zjzz9faiElZ0+QA4zk9Dgjp/j60xnKs+Vycfe5I9cfT39aljkYLsOXDfMysuccDp+H+NACSDfGTsJJbaE6EcHj8+1MfcoVg5Uu2AM8Z9B6daUyYGJCHO0lACOOvH/wBf8KIXHmBtvlEFjtXHQ8DGe2cUAV3eNYn8xVZzxGMdOMfj/Oq+JHKqnY/3seue/wCJqxGZBEjtIVBB4HQHBzxTRGqnhsgtt3qOmR04Ge/TpxQAyOSRIXC5EZ43HjnI79cfT8aEkckjOGbqd3GcHHf8PapJo9u0KWIUlc5J9CcUhkZ35CsSfurn3zx+fHegCS3uHyGctuLbQQv3R17fj9etSfbJGRVyVdcqTkHPGBg1XSV0ZUMW9jnoxyx4AwKGYO7H7rnAIx8q9eMf07UAOEjBot7YxwB1GM8E+2e1ELkBvMI3ADKDp/njmnL85Ql13K5JbGdvPIJ71FsWKMq7ujY2lR1Oen9KALcjzGTyptgBIcAA85JH/wBb3xVUyMrko3LAj2HTn61JJJ867xhFYhsn1NNCkyph8rjnjbgHB6fXtQA+3YufJwSJDgDbjntz2B70m8OWDyBs/Mu1fvYb/IpZRtjeMgg4+ZM9Dk8inwtyd65LAE56AAgcH0PpQAw7HL7fmjxkbj8vQZ/DPSmPgRQlWk3kEOD688j8ulSO6hAkcbbkyv8AvZ7fXApkYAlUlOdzJgc568A/iKAI0CsN3BVc7TnaQeP6/nUkagIv7wBiAxPbvxTZI2SNfMUAqShDdumMURgfaA+FPlr8wbgH/I/OgDRsGR5sAlYCdpK/xDPXHpXTwTpFKI4yRJtwAT8nAGP/AK361zEUyRNA+1mCj5m79c8fTNKbvbMixlsAHA6ZGBn8KANi9Ebb5bryVOw7mPUHBwPYE96522mjF2JDlgp3Ln178f0qxq9w67Ih/rCQ5B5LnJ/ziqShQZFiBZnLBlXogGOQSenvQBIt7GYyJRH5mTg7jyMev9a1dFvzPcgYIIwM7cdz1/nWFbW8ly0YQF8DaVB+71PTPtmr99cQ2brZ2wD4J8592Cx6YB/zmgDW1HXVErx2km+RAGy2cE8dOP8A9dYb3Ek0m5237so2Wxu69Pb0FVg58t1+9HxheOnH+fbvUtugkwFG7a+GHQYyckfTuaAHXbsrMfuxoMr1z17/AOeKh3blQuQIzweOjYHvjn+lWpsS3BKx7iHPGeOAuD9apqVUK7ICo+9k5DZ/D9fwoAkt1BVg0gVjzt38EAnjP9abG7SSNu2MgAVm28AHHUDtntSHImLhBgNnaAcsPf8APpS7WWOJmIGTjcG4LDHX8+vegCSOIshiBDdVXnnIU8j8DUrK48tRtZVAwwHXJ4x7896YrL9xPmHAORznngD2qUkCZQeCw3Dnls4yD7e9AFcRmJCEAcldx3jpxyf8fSpFV5JsgsX45IwG5OP/ANXepyS6Iy7Gfbkg/jjj1/nSw+Wkjnk54CccYPXP49e1ADtOt5UWQOyqcjhzggY9e9FXdNBUzB/LZsjIZckcfpRXVTm1FJEsbqIAuJCCShY88jv/AJ+tCsu5QTlVbPPPfpTtRyzNkHG5j+v0qtGSSQ2Sc9//ANVcpRKu0EbSCuMDHAz/APWpHjRUx9+Q5zleAO5+v6VEMAq+exJ47gVMpLn5XUDoNxx36UARIf3bLuGCcgDr/n371FOAxILHLEDB4Ax6f54qwTGiOvlbi4x16Y/z+FNlwq8pnjuCTjnOB70AU3UbpfJYjcOSTz/n1NOQI20YU/KAUIznpyT/AJ461LLBIgIz8rY2MvJI4x+NEY2iQMvykZzg8cdaAGxfeV8dyuM/dPP6e9RmPMiZDyK2RkdR04x/SrwALRg7uvUDk+5Hr7UpYeQTkl156dPx9/WgCiXHD7s5G0c9f/r+9NQrIEjLMrAEkAYz7ew9KnlZTLH8pCE4BXrk9cCoZsyTOxJLDAVjkEYP86AIWD5ZSQMMMj09sdzSqSzZSQmKMc4JyBjHJ9KJSCJA+H+YMM+p/l9KXcuzeVJVhtAbB9zn60AOE5MbFnG3jC45YjPT0+lBDIy4UhiCQf73Y5oYIJQTHwvJGA3XqaiSNZZUDgpDj728fL09uM/pQAbQYcHOCM5KnI9hzj6UyMkKGO1Yw5OMDGe9PXYqHzd+5QQR9c4/z361JIqnDPIVUkkMCRgj2xQBXkiPlrIjHcTt3MeTnHHpxTCAkojbB2HJIPBA7/T8KsqkRhZZSygjI2npntx/KllhW3bL5UH+EfN075/p6UAVpJVUINweQ55HGM4I4/p2xUjO+XkcLIzcHAJzjoen696Yvlea21WySNpB9v8AOKPNzJmXnJwvzY/XPUfpQBKqyeYwjMZ2txg9Tx+XWokjKYd2LNzzg49x7+5py/IDsTIxg7SCW/z39aRApB5LNjjOBjrz7mgCwkbXFyka7ychVU4wOc9fXrRgyojIB+7+8M/KR25/CoJceUqlCc9OOBz/AFpCGizhsADLoORnHegCyXV5d4HzA5znOTz+X/1qfaygy7SocH+L34/Wq8G5s7Y9yhd2AeoGckewpkTjbhchjhvl5B6UAT3UYLBB8oyT0wFOP8/SiSIxK7sQVY8bTkZ/x9aRnHmNySnLBScliQQaUmNY1Ikfgbiuc856fWgCqSWjHAVPu5PPpgf560o2h5JNsZ2AYPY9e3+cUMFkCMkm1Mbio6fQU/yVeLzM5y2Mnt14x3NAEseZQoRTlVGAcbTyD/kUmnAtdx7uA5GTn2/nUlhG7ShIy2SvynOe4/zn8K6jw9Z28hkunVWWHKkn1xzxQBzAga/1RwdqIzffHAUAnH0qtfeXFcvHCVKI2EI4OeOvr79qdeXbPOSm4BpGI/2Tk/5zUUOQGkkY+WvBAGef8KANOMiw08OjM0swwevHXk/0Pes4sGVM5VhkA4O48g5x/nGKJLhnkM7uo3rgBT0BJ6j0/lUAxhlO1n7OOCOn5n2/OgCcghkVgwx/eX2zxzwfbvV6xSKSSRxiMqwKdiT9Cfy7VSgEq24VXcQ/eZQOCRnv6+/akJzMWIfJfBDAsAP89qAJEiWSRt+NuQeDx1GT9M/5xSTADKjKy/MmNgHGD3z19qkUYhOEYuxxhj8xwBk+n/1qriOQoMuVAHvjAzxjt2oAISgKDIfBJHHJ5/WlVgAXADcZwVz0Hp+X0pUkTerHcRg9c5IGOfc0gdPIjAKp0VeOW92/zzQBPbnLAqBjBz/dPXI/z1p1ou7dgAhiGAJII6Y/XpTWDxvNHtXIOw4GMc59e4P4VLEFARSwAxu6ZOMDj2HtQA3y28zavyoo+XHfrz9KsKoMsReJs56AZIORwffviowpR1CgpKD97qe/f1xUiyYRkGB6sMgFSRQBcsCN8gUHAVeCeR1796Kk0wgGV0UMGCj5vbP+NFaxlZbCsQXYyx4/TP8AT/P86sYwW4xj2/8Arf5/WrN2VEpEhwMnnGfXpVcoU8wHAZVz/nj6VkMdFEFhU5AJXrjpxUiqEhXaqndlQgIbnpn609eUSM9MZA9TS3DMWZ2UGQgbnXjgYx0oArPvEJ+fJBACj/PXH51PH5xjYPtC5GH96WICQled+Mg+o7gD1p0jLhSAfNVuVI6Ad/8A61AEUuBOUG1h3YHj3/OkB3qPL3E9ck8g/Xue1TSMJncJhFHKgnAxx0qFg3kRhVKqB82Dg57celAETzJuwhj3lgQ2T+WPT+tMVnaMOXXkgg45yOD/APqppi3tnp8xOc9PWnmMK6DPO0dBke3+fzoAY6EAL1G057nHPb+tMmEolYeYdpQZ2nt7j1/lTgQoLMSGP3m75+lJIysHLEbsY3DqM+o6fh3oAh+ZYQWB5xkbj+tKcGBwmeDgYyD04yP5UuNjKd2DjHTcucdMf5AohVSw2hUHJBY4Ge4oAUpvgXaDuz90ggA+vNRoHR9x2yADcUc5B9M/4VbcDeq5HmuQDg9AO3SkmXaIhMqgsMsOeSO5FAFdsM5ywZ24GDnb7df17UuFLAP95QcjGCBxg4p7QMFcgE7Ru+UEcZ4BPr7UyR5BKFd3DnmUtkDtQBAoVWYhiWDcgY4P19fen3DSn5WVGK4UH8eOR3pwyVVJEZ1HQd/p1/8A1UNKozldxXcTnIK++c880AVps7AyAgnO4nkFu5H+NGAMhVEi8HIPT2/z1qVvJLYKsA4yAjZz/wDXpqLGQDtBJbaOM96ABD8xPPzDcQO3TFSCIFVRgEBwqFmzlu5+ntQm/JJQ7O/Q4PpjtTW+fJYZBI284IH5UASsWR4UMjNuflc9vU+lV5d24bigYD5tp5Oc4qaUhSBtOCepI4OOv6fhQQBvfHyDsD8p9aAGxqA259ilgQADyfUf40iL5qE/LGwwQijg/SntgGQKA2QG4+bk+n9DSRFJMK+9sqRuPRf/AK3vQArCJZc5cDPBHJJPv/Wo5kVAQSmQSxDdwfWpmj3RwhAfLLFd2cHPXB/z0pm0sHZjxjHzDuP89aAGKqiVHicpIcLhlzn3qZGVYCCvAJXaOOc/eHtUW0EdMhVyMgjHtT/mbb8pD5ypI6jv+PvQBZhaWCY7FI+XGCQSTgc//W7V02kzBfDc8cTqsrKQxPGDz0P+c1ybzOsO0cCMZU4wB7e596sRXT/Z5ogT5bpjbjgH1z6/yoAzpFBcqCNxzkH69fpnt2p/JRFdnAAYB8Hk45GP6d6WNAvAKnI5XbjPqv8AnrTRHhcKQpHTPXA7Z/lQA0kLL5UPys6jLEct+BpTFIoVSojXnj0BxyMH9asRxBn8zbuAGQx+vOadcRmGWP5HDj35H14xQBC7CMEf8tAvbGCeeoJ/SkUb5/n3DnICcZ6dTnp796kiVmeRfnKc5BJCnH6/lzTnLrIPmwWOWzkgf4/TtQAyWYMyB1G1eMhBjpxgdf8ACl8tmAxuZA20Efjx0/P9KRCzAptBPO1WJ5z6HPT69aGjLjKztjI+6MDrwOv/AOqgCGcl5PnOOMseoT/P/wCunIjhRuQMqrnj05xViONWjXevl44IPPHf/wDVSh4vMRXQvgcru5frge3FADYwGJk2sMYGT/Hjt/8AWqYYdgQ52MuGIOM8DgHpn3qFFRgsauVbPXGQi57fj3qxBuLFYuY0OApUD8cdj7UAPy/lsp2g7zhWHJHPX9OO3WmpGzICxcFD8pHcYGf8+lNGWICElVPyjv8A5/nUi7niQEkOMABf5+xHb0oAuaawZpRCo3DGeOMc4x7daKdpsJPmYOE4xvHfnPHailoBFcgPIoPfjB781CVDyDA2lsDj6/5/KiimBrx28gQMCgV1xnuB7ccfWop9NmYBg8e3dnHr9eKKKAG/2dMLd2EigJg8df5U77BKfLBZOp5yc/yoooAY2nykrlkI+6RnhvQ9KWTT5jgl4y3cknn9KKKAIW0+VZXyyMSOhPAx+H5Un9nyRoFJR1cDqTkZ/CiigAl01thJ2EqP7x5xR/ZbpGShQE4Y/MetFFADBp8wO3zEORgt9fanpp0ot1dGj35J3EHIGaKKACTSnwfmTY4+7k8e2fSmjS5G2s7owfnPcAdulFFAEb6U8TkIyDPAwcY5zjp0pBpruJAWQ7uOTn+lFFACw6ZJtUReTu6AsTj8sf8A66Y+ksVaTcA2cn5ifT2oooAkOmOse1zHkr1BPTvUa6awJdPLwTnvk+/1oooAdHo7iVnDIOgwCfTmmLYsV3gINrFSMnnNFFABFp7jecR7vvLliR078enFNTTpGWMxiEKCSFJPb8PyoooAWPSpczorRgMoUgE9OuOlOh0+VlRlkX7nft29OlFFAEh0qRYgMxljyeTgnP0pBpkj7lDIGGeSeO3t0oooAd/ZsrSKyyII0HzA8k54Hanf2XL5H31Me4pgsc8c+nSiigBo0lyxCsoLDg5PU+vHekSwdVAJT5chcHpj8KKKAEOmygszMm4uCTk0NpbPINzJ8xx36Y/zxRRQAktiYyApViRuBYnpn+dL9gZ5VUlBE3BXk42jIA9qKKABNPdjvVl6AgEn3po095J1UiLc3JOfxPaiigBp0xjFKzmPCHaAB2A57f8A6qkXTHJEisoBAUjJ5z+H/wCuiigBqabKsazblJHA+Y9PyqddKlMuwPGoHHGeh5xRRQAqae4IcmPJ4H49/rSzabITsJT5c4+Y849aKKAIhZydSyEcZ7cf5/KpxpjHG1wuSDnJ70UUAXbfT2WSRgRzgZ3HJxnrxRRRWE5NMD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preoperative radiograph showing metacarpophalangeal hyperextension deformities combined with fixed proximal interphalangeal joint flexion contractures. This patient with scleroderma subsequently underwent resection arthroplasty and proximal interphalangeal joint fusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27633=[""].join("\n");
var outline_f26_63_27633=null;
var title_f26_63_27634="Pink colonies Rhodococcus";
var content_f26_63_27634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salmon-pink colonies visible 4 days after incubation of the aspirated pus obtained from the patient's cavitary lung mass at 37&deg;C on chocolate agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mackowiak, PA. A 40-year-old man with cough and fever. Clin Infect Dis 2007; 44:1461. Copyright &copy;2007 The University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27634=[""].join("\n");
var outline_f26_63_27634=null;
var title_f26_63_27635="Patient information: Vertebral compression fracture (The Basics)";
var content_f26_63_27635=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82825\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"         Anatomy of the back",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/6/23650\">",
"         Patient information: Bone density testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/29/1491\">",
"         Patient information: Bone density testing (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vertebral compression fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vertebral-compression-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28191456\">",
"      <span class=\"h1\">",
"       What is a vertebral compression fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The word &ldquo;vertebral&rdquo; has to do with the back bones, which doctors call the &ldquo;vertebrae&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"UTD.htm?4/51/4917\">",
"       figure 1",
"      </a>",
"      ). A &ldquo;fracture&rdquo; is another word for a broken bone. A vertebral compression fracture is when a back bone breaks by collapsing.",
"     </p>",
"     <p>",
"      Vertebral compression fractures happen most often in people who have osteoporosis. Osteoporosis is a disease that makes the bones weak.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191488\">",
"      <span class=\"h1\">",
"       What are the symptoms of a vertebral compression fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with a vertebral compression fracture have no symptoms. They find out they have it after their doctor does an X-ray of their chest or belly for another reason.",
"     </p>",
"     <p>",
"      When a vertebral compression fracture causes symptoms, it causes back pain. The pain usually starts suddenly after a fall or after bending, coughing, or lifting. But sometimes the pain starts slowly. The pain can be dull or sharp, and often spreads to the belly.",
"     </p>",
"     <p>",
"      Over time, people with vertebral compression fractures can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get shorter (lose height)",
"       </li>",
"       <li>",
"        Get a bent posture with a hunched back",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191503\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check if you have a vertebral compression fracture, your doctor will order an X-ray.",
"     </p>",
"     <p>",
"      He or she will also do other tests to see if another condition caused your fracture. These can include blood tests, urine tests, or imaging tests. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      If you have a vertebral compression fracture, your doctor will probably order bone density testing. Bone density testing is a way for your doctor to measure how strong your bones are. The test used most often to measure bone density is a special kind of X-ray called a &ldquo;DXA test.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191518\">",
"      <span class=\"h1\">",
"       How are vertebral compression fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for a vertebral compression fracture involves different parts.",
"     </p>",
"     <p>",
"      Your doctor will treat your pain. Depending on how severe your pain is, your doctor can treat it with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Strong pain medicines",
"       </li>",
"       <li>",
"        Over-the-counter pain medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;)",
"       </li>",
"       <li>",
"        Other medicines that are used to treat osteoporosis, but can also relieve pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also treat your osteoporosis. Long-term osteoporosis treatment includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Doctors usually treat osteoporosis with medicines called bisphosphonates.",
"       </li>",
"       <li>",
"        Lifestyle changes &ndash; Your doctor or nurse will talk with you about ways to keep your bones as healthy as possible. He or she will probably recommend that you stop smoking (if you smoke) and that you not drink too much alcohol. You should also eat a healthy diet with enough calcium and vitamin D (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Exercise &ndash; It&rsquo;s important to be active for at least 30 minutes a day, on most days of the week. &ldquo;Weight-bearing&rdquo; exercise, such as walking, is best. Weight-bearing exercise means that your feet and legs support your weight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might have heard or read about other treatments that are sometimes used for vertebral compression fractures. For example, some people might wear a back brace. Back braces sometimes help people who have a fracture from a serious car accident. They do not usually help people who have a fracture from osteoporosis.",
"     </p>",
"     <p>",
"      Other treatments that are sometimes used for vertebral compression fractures are procedures called \"vertebroplasty\" and \"kyphoplasty.\" These involve putting a cement material or device into the collapsed back bone. Doctors do not always agree whether these treatments help. Many doctors do not recommend that people with a vertebral compression fracture from osteoporosis have these treatments. That's because doctors don't know how much they help with pain, and they can have serious downsides.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191556\">",
"      <span class=\"h1\">",
"       When will the pain from my fracture get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For most people, the pain will get better in 4 to 6 weeks. But people can have pain that lasts up to 3 months.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191571\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help with healing, you can follow all of your doctor&rsquo;s instructions. This will probably include doing gentle back stretches while your fracture is healing, and other back exercises when your pain gets better. To learn which stretches and exercises to do, your doctor might have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p>",
"      It&rsquo;s important to be active as soon as possible after your pain gets better. Being active will help keep your back and bones as strong as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191586\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call him or her if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe pain, or pain that gets worse",
"       </li>",
"       <li>",
"        Have numbness or weakness in your legs or feet",
"       </li>",
"       <li>",
"        Cannot control your bladder or bowels",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28191601\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23650?source=see_link\">",
"       Patient information: Bone density testing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"       Patient information: Bone density testing (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/63/27635?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82825 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-E64BEA0BEF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27635=[""].join("\n");
var outline_f26_63_27635=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191456\">",
"      What is a vertebral compression fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191488\">",
"      What are the symptoms of a vertebral compression fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191503\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191518\">",
"      How are vertebral compression fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191556\">",
"      When will the pain from my fracture get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191571\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191586\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28191601\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"      Anatomy of the back",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=related_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23650?source=related_link\">",
"      Patient information: Bone density testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27636="Scurvy - perifollicular hemorrhage";
var content_f26_63_27636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scurvy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perifollicular purpuric macules are present in this patient with scurvy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27636=[""].join("\n");
var outline_f26_63_27636=null;
var title_f26_63_27637="Milnacipran: Patient drug information";
var content_f26_63_27637=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Milnacipran: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     see \"Milnacipran: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6858966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Savella&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ideas of harming yourself. If you are planning on harming yourself, call the ER (emergency department) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat fibromyalgia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to milnacipran or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12186 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-6DA085BC69-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27637=[""].join("\n");
var outline_f26_63_27637=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6858966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018094\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018096\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018095\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018100\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018101\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018103\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018098\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018099\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018104\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018105\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=related_link\">",
"      Milnacipran: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27638="Doxazosin: Pediatric drug information";
var content_f26_63_27638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxazosin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"    see \"Doxazosin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/2/44?source=see_link\">",
"    see \"Doxazosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardura&reg;;",
"     </li>",
"     <li>",
"      Cardura&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Doxazosin;",
"     </li>",
"     <li>",
"      Apo-Doxazosin&reg;;",
"     </li>",
"     <li>",
"      Cardura-1&trade;;",
"     </li>",
"     <li>",
"      Cardura-2&trade;;",
"     </li>",
"     <li>",
"      Cardura-4&trade;;",
"     </li>",
"     <li>",
"      Gen-Doxazosin;",
"     </li>",
"     <li>",
"      Mylan-Doxazosin;",
"     </li>",
"     <li>",
"      Novo-Doxazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1009916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1009946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"      see \"Doxazosin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If drug is discontinued for greater than several days, consider beginning with initial dose and retitrate as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dysfunctional voiding:",
"     </b>",
"     Limited data available, efficacy results variable: Children &ge;3 years and Adolescents: Oral: Immediate release: Initial: 0.5 mg once daily at bedtime; some trials maintained a fixed dose; others titrated at weekly or biweekly intervals to effect as tolerated (maximum daily dose: 2 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (Austin, 1999; Cain, 2003; El-Hefnawy, 2012; Yucel, 2005). In some trials, a larger initial dose (1 mg/",
"     <b>",
"      day",
"     </b>",
"     ) was used in patients weighing &gt;40-50 kg (Austin, 1999; Yucel, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: Immediate release: Initial: 1 mg/",
"     <b>",
"      day",
"     </b>",
"     ; maximum daily dose: 4 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hypertrophy (BPH):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: 1 mg once daily in morning or evening; may be increased to 2 mg once daily. Thereafter titrate upwards, if needed, over several weeks, balancing therapeutic benefit with doxazosin-induced postural hypotension. Usual range: 4-8 mg/day; maximum dose: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: 4 mg once daily with breakfast; titrate based on response and tolerability every 3-4 weeks to maximum recommended dose of 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 4 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Conversion to extended release from immediate release: Omit final evening dose of immediate release prior to starting morning dosing with extended release product; initiate extended release product using 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Immediate release: 1 mg once daily in morning or evening; may be increased to 2 mg once daily. Thereafter titrate upwards, if needed, over several weeks, balancing therapeutic benefit with doxazosin-induced postural hypotension. Maximum dose: 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate as before",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: Use with caution in mild-to-moderate hepatic dysfunction. Do not use with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer's labeling; however, limited data suggest renal impairment does not significantly alter pharmacokinetic parameters.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg, 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardura&reg;: 1 mg, 2 mg, 4 mg, 8 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardura&reg; XL: 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1009949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Administer without regard to meals at the same time each day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release (Cardura&reg; XL): Tablets should be swallowed whole; do not crush, chew, or divide. Administer with morning meal.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14787801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1009917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets: Treatment of hypertension alone or in combination with diuretics, beta-blockers, calcium channel blockers, or ACE inhibitors (FDA approved in adults); treatment of urinary outflow obstruction and/or obstructive and irritative symptoms associated with benign prostatic hyperplasia (BPH) (FDA approved in adults); has also been used for treatment of dysfunctional voiding and primary bladder neck dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablets: Treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxazosin may be confused with doxapram, doxepin, DOXOrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardura&reg; may be confused with Cardene&reg;, Cordarone&reg;, Cordran&reg;, Coumadin&reg;, K-Dur&reg;, Ridaura&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F162950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, edema, facial edema, flushing, hypotension, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, dizziness, fatigue, headache, hypertonia, insomnia, malaise, movement disorder, pain, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, incontinence, polyuria, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis,muscle cramps, muscle weakness, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, respiratory disorder, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal lacrimation, abnormal thinking, agitation, allergic reaction, alopecia, amnesia, angina, anorexia, appetite increased, arthralgia, back pain, blurred vision, bradycardia, breast pain, bronchospasm, cerebrovascular accident, chest pain, cholestasis, confusion, cough, depersonalization, diaphoresis increased, diarrhea, dry skin, dysuria, earache, eczema, emotional lability, fecal incontinence, fever, gastroenteritis, gout, gynecomastia, hematuria, hepatitis, hot flashes, hypoesthesia, hypokalemia, impaired concentration, impotence, infection, influenza-like syndrome, intraoperative floppy iris syndrome (cataract surgery), jaundice, leukopenia, liver function tests increased, libido decreased, lymphadenopathy, micturition abnormality, migraine, MI, neutropenia, nocturia, pallor, palpitation, paranoia, paresis, parosmia, peripheral ischemia, pharyngitis, photophobia, priapism, pruritus, purpura, renal calculus, rigors, sinusitis, skin rash, syncope, taste perversion, thirst, thrombocytopenia, tremor, twitching, urticaria, vomiting, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1009920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxazosin, quinazolines (prazosin, terazosin), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14787800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild to moderate hepatic impairment or receiving medications known to affect hepatic function; use is not recommended if severe hepatic impairment. Use with caution with concomitant use of strong CYP3A4 inhibitor, such as atanazavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole;",
"     <i>",
"      in vitro",
"     </i>",
"     data suggests doxazosin is a CYP3A4 substrate. Use with caution in patients with cataracts or undergoing corrective cataract surgery; intraoperative floppy iris syndrome (IFIS) has been observed in cataract surgery patients receiving or previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; there appears to be no benefit in discontinuing alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers prior to surgery. Use with caution in patients with coronary insufficiency; discontinue drug if angina occurs or worsens.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The extended release tablet consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Use with caution in patients with increased GI retention (eg, chronic constipation) as doxazosin exposure may be increased.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1009921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Marked orthostatic hypotension, syncope, and loss of consciousness may occur with first dose or within first few days of therapy; syncope usually occurs 30-90 minutes after initial dose; occasionally preceded with severe tachycardia (120-160 bpm in adults); anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, if large initial dose (&ge;2 mg in adults), or if another antihypertensive drug (eg, beta-blockers, diuretics, and particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward. May cause priapism (rarely).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1009934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases the maximum serum concentration and AUC (by 32% and 18%, respectively) of extended release tablets (Cardura&reg; XL); administration with food does not significantly affect exposure of immediate release tablet.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2931842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Delayed postnatal development was also noted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1009951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Standing and sitting/supine blood pressure, especially 2-6 hours after the initial dose, then prior to doses (to ensure adequate control throughout the dosing interval); urinary symptoms if used for dysfunctional voiding or BPH treatment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1009937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure; ~50% as potent on a weight by weight basis as prazosin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BPH: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors in prostatic stromal and bladder neck tissues. This reduces the sympathetic tone-induced urethral stricture causing BPH symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14787808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Urinary outflow effects (immediate release): 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Antihypertensive effect (immediate release): 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Antihypertensive effect (immediate release):  &gt;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1009939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to active metabolites; primarily via CYP3A4; secondary pathways involve CYP2D6 and 2C19; may undergo enterohepatic recycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: ~65%; Extended release relative to immediate release: 54% to 59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Immediate release: ~22 hours; Extended release: 15-19 hours; prolonged in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release: 2-3 hours; Extended release: 8-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (63%, primarily as metabolites); urine (9%, primarily as metabolites; trace amounts as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1009955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/2/44?source=see_link\">",
"      see \"Doxazosin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush or chew extended release forms, swallow whole; extended release tablet shell may be visible in the stool; take with breakfast. Immediate release tablets should be taken consistently at the same time each day. Avoid alcohol; rise slowly from sitting or lying position; may cause dizziness or drowsiness, headache, or nausea; ability to perform activities requiring mental alertness or physical coordination may be impaired; may cause dry mouth. Report increased nervousness or depression, sudden weight gain, palpitations or rapid heartbeat, muscle weakness, fatigue, vision changes, rash, or changes in urinary pattern.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Austin PF, Homsy YL, Masel JL, et al, \"Alpha-Adrenergic Blockade in Children With Neuropathic and Nonneuropathic Voiding Dysfunction,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 1999, 162(3 Pt 2):1064-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/10458432/pubmed\" id=\"10458432\" target=\"_blank\">",
"        10458432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cain MP, Wu SD, Austin PF, et al, \"Alpha Blocker Therapy for Children With Dysfunctional Voiding and Urinary Retention,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2003, 170(4 Pt 2):1514-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/14501648/pubmed\" id=\"14501648\" target=\"_blank\">",
"        14501648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase J, Austin P, Hoebeke P, et al, \"The Management of Dysfunctional Voiding in Children: A Report From the Standardisation Committee of the International Children's Continence Society,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2010, 183(4):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/20171678/pubmed\" id=\"20171678\" target=\"_blank\">",
"        20171678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      El-Hefnawy AS, Helmy T, El-Assmy MM, et al, \"Doxazosin Versus Tizanidine for Treatment of Dysfunctional Voiding in Children: A Prospective Randomized Open-Labeled Trial,\"",
"      <i>",
"       Urology",
"      </i>",
"      , 2012, 79(2):428-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/22196407/pubmed\" id=\"22196407\" target=\"_blank\">",
"        22196407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yucel S, Akkaya E, Guntekin E, et al, \"Can Alpha-Blocker Therapy be an Alternative to Biofeedback for Dysfunctional Voiding and Urinary Retention? A prospective Study,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2005, 174(4 Pt 2):1612-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27638/abstract-text/16148665/pubmed\" id=\"16148665\" target=\"_blank\">",
"        16148665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86242 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27638=[""].join("\n");
var outline_f26_63_27638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162904\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162905\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009916\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009946\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162884\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162869\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009949\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787801\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009917\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162953\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162950\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787800\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009921\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299231\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162878\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009934\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162880\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2931842\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009951\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009937\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787808\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009939\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009955\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=related_link\">",
"      Doxazosin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/2/44?source=related_link\">",
"      Doxazosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27639="Prasugrel: Drug information";
var content_f26_63_27639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prasugrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/50/5925?source=see_link\">",
"    see \"Prasugrel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11238845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7901908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effient&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14464693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Effient&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7910294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Antiplatelet Agent, Thienopyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7912224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Acute coronary syndrome (ACS):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Percutaneous coronary intervention (PCI) for ACS:",
"     </i>",
"     Loading dose: 60 mg administered promptly (as soon as coronary anatomy is known or before if risk for bleeding is low and need for CABG considered unlikely) and no later than 1 hour after PCI; Maintenance dose: 10 mg once daily (in combination with aspirin 81-325 mg/day day; 81 mg/day recommended [Levine, 2011]). For patients with STEMI, a loading dose may also be administered if PCI is performed &gt;24 hours after treatment with a fibrin-specific thrombolytic (ie, alteplase, reteplase, tenecteplase) (O&rsquo;Gara, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Duration of prasugrel (in combination with aspirin) after stent placement:",
"     </i>",
"     <b>",
"      Premature interruption of therapy may result in stent thrombosis with subsequent fatal or nonfatal MI.",
"     </b>",
"     Those with ACS receiving either stent type (bare metal [BMS] or drug-eluting stent [DES]) or those receiving a DES for a non-ACS indication, prasugrel for at least 12 months is recommended. Those receiving a BMS for a non-ACS indication should be given at least 1 month and ideally up to 12 months; if patient is at increased risk of bleeding, give for a minimum of 2 weeks.  A duration &gt;12 months, regardless of indication, may be considered in patients with DES placement (Jneid, 2012; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Maintenance dosing in low body weight (ie, &lt;60 kg) individuals:",
"     </i>",
"     Due to a higher incidence of bleeding in patients weighing &lt;60 kg, a maintenance dose of 5 mg once daily may be considered. In aspirin-treated patients weighing &lt;60 kg (mean: 56.4 &plusmn; 3.7 kg) with stable coronary artery disease, the use of prasugrel 5 mg once daily was shown to reduce platelet reactivity to a similar extent as prasugrel 10 mg administered once daily to patients &gt;60 kg (mean: 84.7 &plusmn; 14.9 kg); clinical events were not evaluated (Erlinge, 2012). In patients with ACS (medically managed) treated with aspirin, a 5 mg daily maintenance dose (after a 30 mg loading dose) in patients &lt;60 kg did not demonstrate a significant difference in the composite primary end point of death from cardiovascular causes, MI, or stroke compared to patients &gt;60 kg treated with a 10 mg maintenance dose; bleeding risk was not increased (Roe, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7910728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Patients &ge;75 years: Use not recommended; may be considered in high-risk situations (eg, patients with diabetes or history of MI).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7910729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7910730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary for mild-to-moderate hepatic impairment; use in severe hepatic impairment has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7910736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effient&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7910292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7984963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM238428.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM238428.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7910732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals. Tablets may be chewed and swallowed (bitter to taste) or crushed and mixed in food or liquid (eg, applesauce, juice, or water) and immediately administered by mouth or gastric tube.",
"     <b>",
"      Note:",
"     </b>",
"     Administration via an enteral tube that bypasses the acidic environment of the stomach may result in reduced bioavailability of prasugrel (data on file, Daiichi Sankyo-Lilly, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7910296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces rate of thrombotic cardiovascular events (including stent thrombosis) in patients who are to be managed with percutaneous coronary intervention (PCI) for unstable angina (UA), non-ST-segment elevation MI (NSTEMI), or ST-elevation MI (STEMI)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14941519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial treatment of UA/NSTEMI in patients undergoing PCI with allergy or major gastrointestinal intolerance to aspirin (",
"     <b>",
"      Note:",
"     </b>",
"     Dual antiplatelet therapy with another P2Y12 receptor inhibitor is not recommended in this situation [Jneid, 2012].)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10227670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prasugrel may be confused with pravastatin, propranolol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - weak).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7910606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is associated with prasugrel. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including patient susceptibility and concurrent use of multiple agents which alter hemostasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (8%), hypotension (4%), atrial fibrillation (3%), bradycardia (3%), noncardiac chest pain (3%), peripheral edema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (6%), dizziness (4%), fatigue (4%), fever (3%), extremity pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia/hyperlipidemia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (5%), diarrhea (2%), gastrointestinal hemorrhage (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (3%), anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (6%), dyspnea (5%), cough (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Allergic reaction, anaphylaxis, angioedema, hematoma, hemoptysis, hemorrhage (postprocedural, retinal, retroperitoneal), liver function (abnormal), thrombocytopenia, thrombotic thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7910301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, anaphylaxis) to prasugrel or any component of the formulation; active pathological bleeding such as peptic ulcer  or intracranial hemorrhage; history of transient ischemic attack (TIA) or stroke",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7910302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding:",
"     <b>",
"      [U.S. Boxed Warning]: May cause significant or fatal bleeding.",
"     </b>",
"     Use is contraindicated in patients with active pathological bleeding or history of TIA or stroke. Additional risk factors for bleeding include age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent GI bleeding, active PUD, severe hepatic impairment, moderate-to-severe renal impairment), body weight &lt;60 kg, CABG or other surgical procedure, concomitant use of medications that increase risk of bleeding (eg, warfarin, NSAIDs). Bleeding should be suspected if patient becomes hypotensive after undergoing recent coronary angiography, PCI, CABG, or other surgical procedure even if overt signs of bleeding do not exist; if possible, do not discontinue prasugrel. Management of bleeding episodes includes the use of PRBCs and platelet transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous thienopyridine hypersensitivity. Use of prasugrel is contraindicated in patients with hypersensitivity (eg, anaphylaxis) to prasugrel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported with prasugrel; urgent plasmapheresis is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: No dosage adjustment is necessary in patients with mild-to-moderate hepatic impairment (Child-Pugh class A and B); use with caution in patients with severe hepatic impairment (patients not studied and generally are at higher risk of bleeding).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: No dosage adjustment is necessary; use with caution in patients with end-stage renal disease (experience is limited and generally are at higher risk of bleeding).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants (eg, warfarin); bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; NSAIDs: Use with caution in patients chronically receiving NSAIDs; bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fibrinolytics: Use with caution in patients receiving fibrinolytics; bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly:",
"     <b>",
"      [U.S. Boxed Warning]: In patients &ge;75 years of age, use is not recommended due to increased risk of fatal and intracranial bleeding and uncertain benefit;",
"     </b>",
"     use may be considered in high-risk situations (eg, patients with diabetes or history of MI). Risk of bleeding is increased in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Low-weight patients: In patients weighing &lt;60 kg, risk of bleeding increased; consider lower maintenance dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Surgical patients:",
"     <b>",
"      [U.S. Boxed Warning]: Do not initiate therapy in patients likely to undergo urgent CABG surgery; when possible, discontinue &ge;7 days prior to any surgery; increased risk of bleeding.",
"     </b>",
"     The American College of Chest Physicians (ACCP) recommends discontinuing prasugrel 5 days before surgery (Guyatt, 2012). When urgent CABG is necessary, the ACCF/AHA CABG guidelines suggest that it may be reasonable to perform surgery within 7 days of discontinuing prasugrel (Hillis, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug discontinuation: Discontinue therapy  for active bleeding, elective surgery, stroke, or TIA; reinitiate therapy as soon as possible unless patient suffers stroke or TIA where subsequent use is contraindicated; if possible, manage bleeding without discontinuing therapy since premature discontinuation of treatment may cause increased risk for cardiac adverse events; lapses in treatment should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May diminish the antiplatelet effect of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7910297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7910298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7910300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/consider risk:benefit",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7910731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Effient Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (24): $200.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $250.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7910734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin and hematocrit periodically; may consider platelet function testing to determine platelet inhibitory response if results of testing may alter management (Jneid, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apagrel (IN);",
"     </li>",
"     <li>",
"      Effient (AR, AU, CO, HK, IL, IN, KP, MY, NZ, PH, SG);",
"     </li>",
"     <li>",
"      Efient (AT, BE, CH, CZ, DE, DK, EE, FR, GB, IE, NL, NO, PL, PT, SE);",
"     </li>",
"     <li>",
"      Nefagrel (AR);",
"     </li>",
"     <li>",
"      Prasudoc (IN);",
"     </li>",
"     <li>",
"      Trocal (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7910614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prasugrel is a prodrug that is metabolized to both active (R-138727) and inactive metabolites. The active metabolite irreversibly blocks the P2Y",
"     <sub>",
"      12",
"     </sub>",
"     component of ADP receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation. Platelet aggregation returns to baseline within 5-9 days of discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7910616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Inhibition of platelet aggregation (IPA): Dose dependent: 60 mg loading dose: &lt;30 minutes; median time to reach 20% IPA: 30 minutes (Brandt, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: Time to maximal IPA: Dose-dependent:",
"     <b>",
"      Note:",
"     </b>",
"     Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry: 60 mg loading dose: Occurs 4 hours post administration; mean IPA (ADP 5 &mu;mol/L): 78.8%: mean IPA (ADP 20 micromole/L): 84.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of effect: &gt;3 days; platelet aggregation gradually returns to baseline values over 5-9 days after discontinuation; reflective of new platelet production",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid; &ge;79%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 44-68 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Active metabolite: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Rapid intestinal and serum metabolism via esterase-mediated hydrolysis to a thiolactone (inactive), which is then converted, via CYP450-mediated (primarily CYP3A4 and CYP2B6) oxidation, to an active metabolite (R-138727)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Active metabolite: ~7 hours (range 2-15 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Active metabolite: ~30 minutes (peak plasma levels begin to decrease at ~24 hours); with high-fat/high-calorie meal: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~68% inactive metabolites); feces (27% inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brandt JT, Payne CD, Wiviott SD, et al, &ldquo;A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition is Related to Active Metabolite Formation,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2007, 153(1):66.e9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/17174640 /pubmed\" id=\"17174640 \" target=\"_blank\">",
"        17174640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erlinge D, Ten Berg J, Foley D, et al, \"Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER Trial,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 60(20):2032-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/23083774/pubmed\" id=\"23083774\" target=\"_blank\">",
"        23083774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JS and Serebruany VL, &ldquo;Prasugrel as a Potential Cancer Promoter: Review of the Unpublished Data,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2010, 170(12):1078-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/20585076/pubmed\" id=\"20585076\" target=\"_blank\">",
"        20585076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall R and Mazer CD, \"Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2011, 12(2):292-318.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/21212258/pubmed\" id=\"21212258\" target=\"_blank\">",
"        21212258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerneis M, Silvain J, Abtan J, et al, &ldquo;Switching Acute Coronary Syndrome Patients from Prasugrel to Clopidogrel,&rdquo;",
"      <i>",
"       JACC Cardiovasc Interv",
"      </i>",
"      , 2013, 6(2):158-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/23428007/pubmed\" id=\"23428007\" target=\"_blank\">",
"        23428007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mega JL, Close SL, Wiviott SD, et al, &ldquo;Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(19):2553-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/19414633/pubmed\" id=\"19414633\" target=\"_blank\">",
"        19414633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Donoghue ML, Braunwald E, Antman EM, et al, &ldquo;Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton Pump Inhibitor: an Analysis of Two Randomised Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9694):989-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/19726078/pubmed\" id=\"19726078\" target=\"_blank\">",
"        19726078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Payne CD, Li YG, Brandt JT, et al, &ldquo;Switching Directly to Prasugrel from Clopidogrel Results in Greater Inhibition of Platelet Aggregation in Aggregation in Aspirin-treated Subjects,&rdquo;",
"      <i>",
"       Platelets",
"      </i>",
"      , 2008, 19(4):275-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/18569863/pubmed\" id=\"18569863\" target=\"_blank\">",
"        18569863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riesmeyer JS, Salazar DE, Weerakkody GJ, et al, \"Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2012, 52(6):789-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/21628601/pubmed\" id=\"21628601\" target=\"_blank\">",
"        21628601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roe MT, Armstrong PW, Fox KA, et al, &ldquo;Prasugrel versus Clopidogrel for Acute Coronary Syndromes Without Revascularization,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(14):1297-309.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22920930/pubmed\" id=\"22920930\" target=\"_blank\">",
"        22920930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serebruany VL, &ldquo;Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package,&rdquo;",
"      <i>",
"       Am J Cardio",
"      </i>",
"      l, 2010, 105(9):1356-7",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al, &ldquo;Intensive Oral Antiplatelet Therapy for Reduction of Ischaemic Events Including Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Stenting in the TRITON-TIMI 38 Trial: A Subanalysis of a Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9621):1353-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/18377975/pubmed\" id=\"18377975\" target=\"_blank\">",
"        18377975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al, &ldquo;Prasugrel versus Clopidogrel in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(20):2001-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/63/27639/abstract-text/17982182/pubmed\" id=\"17982182\" target=\"_blank\">",
"        17982182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9533 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27639=[""].join("\n");
var outline_f26_63_27639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238845\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901908\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464693\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910294\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912224\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910728\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910729\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910730\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910736\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910292\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7984963\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910732\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910296\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941519\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10227670\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910606\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910301\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910302\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299935\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018470\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910297\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910300\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910731\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322568\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910734\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962010\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910614\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7910616\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9533|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/50/5925?source=related_link\">",
"      Prasugrel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27640="Initial evaluation and stabilization of children with thoracic trauma";
var content_f26_63_27640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and stabilization of children with thoracic trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27640/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27640/contributors\">",
"     Donna Reyes Mendez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27640/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27640/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27640/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/63/27640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is the leading cause of death in children. Thoracic injury typically occurs as the result of forceful mechanisms that also cause serious associated injuries. For children who have sustained thoracic trauma, most deaths are caused by associated injuries. Immediate or potentially life-threatening thoracic injuries are uncommon, but must be quickly identified and treated.",
"   </p>",
"   <p>",
"    The initial evaluation and stabilization of children with thoracic trauma will be reviewed here. Thoracic trauma in adults and specific thoracic injuries in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link\">",
"     \"Intrathoracic injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link\">",
"     \"Chest wall injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=see_link\">",
"     \"Pulmonary contusion in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among injured children, thoracic trauma occurs infrequently. In several observational series describing pediatric trauma victims, between 4 and 8 percent of children sustained thoracic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blunt mechanisms are involved in 85 percent or more of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Most patients are injured as passengers or pedestrians in motor vehicle crashes. Other mechanisms include falls (8 to 10 percent) and abuse (7 to 8 percent). Children with inflicted injuries usually have rib fractures and are young (typically less than three years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H19#H19\">",
"     \"Orthopedic aspects of child abuse\", section on 'Rib fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Penetrating thoracic trauma may be caused by a gunshot wound or from",
"    <span class=\"nowrap\">",
"     stabbing/impalement:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, gunshot wounds are the major cause of penetrating thoracic injury among children. A retrospective study describing reports to the National Pediatric Trauma Registry noted that 60 percent of penetrating thoracic injuries were the result of gunshot wounds, while 33 percent were from stab wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Australia describing the management and outcome of penetrating trauma in children, 21 percent of injuries were caused by gunshot wounds, while 70 percent were the result of knife wounds or impalement [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall mortality rate for children with thoracic trauma is between 15 and 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-3,8\">",
"     1-3,8",
"    </a>",
"    ]. Most children who have sustained blunt mechanisms die of associated injuries, whereas thoracic injuries are the cause of death for the majority of those with penetrating trauma. This is demonstrated in the following observational reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children with chest injuries alone, 5 percent or less died [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Mortality rates for those with chest and head injuries ranged from 28 to 37 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among children with blunt thoracic trauma and associated injuries who died, the cause of death was thoracic injuries in about 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mortality rate for children injured from penetrating mechanisms was 14 percent, with thoracic injuries as the cause of death in over 97 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thorax is composed of the following anatomic structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Anatomy and mechanism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chest wall is formed by ribs, costal cartilage, sternum, clavicles, and intercostal muscles, with additional support from the pectoralis muscles anteriorly and the scapula posteriorly. Functionally, the chest wall is an essential part of the mechanics of respiration and provides protection for intrathoracic organs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link&amp;anchor=H3#H3\">",
"       \"Chest wall injuries in children\", section on 'Anatomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mediastinum is a division of the thorax that contains the heart, aorta, trachea, and esophagus.",
"     </li>",
"     <li>",
"      The diaphragm forms the floor of the thoracic cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Injury patterns as the result of thoracic trauma in children are different from those seen in adults. This is because of the following anatomic and physiologic characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chest wall of a child is more compliant than that of an adult. This is because the bones are less ossified and contain more cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/9\">",
"       9",
"      </a>",
"      ]. As a result, the following injury patterns are noted in children:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant force is required to cause rib fractures in children, as compared with adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children may have serious intrathoracic trauma without obvious injuries to the chest wall [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Traumatic asphyxia and commotio cordis are more common in children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H4#H4\">",
"       \"Intrathoracic injuries in children\", section on 'Traumatic asphyxia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H10#H10\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Commotio cordis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mediastinum is more freely mobile in children than in adults. As a result, the heart and trachea may become displaced by pneumothorax, hemothorax, or diaphragmatic rupture, causing decreased venous return to the heart, decreased cardiac output, and hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although children have significant cardiac and pulmonary reserves, they also have higher metabolic demands than adults. Consequently, once children become hypoxic, their conditions may deteriorate rapidly [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF THORACIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries that occur as the result of thoracic trauma include direct injuries to anatomic structures (such as rib fractures or pulmonary contusions) and those that develop as the consequence of direct injuries (such as pneumothorax, hemothorax, or cardiac tamponade). Many children have more than one injury. In a retrospective report describing children who had sustained thoracic trauma, 44 percent had two or more chest injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The types of injuries that occur as the result of thoracic trauma vary depending upon the mechanism of injury. In a series describing children with thoracic injuries reported to the National Pediatric Trauma Registry, the following patterns were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injuries that occurred commonly among children with blunt trauma included pulmonary contusions (49 percent),",
"      <span class=\"nowrap\">",
"       pneumothorax/hemothorax",
"      </span>",
"      (38 percent), and rib fracture (35 percent).",
"     </li>",
"     <li>",
"      Among children with penetrating mechanisms, frequent injuries included",
"      <span class=\"nowrap\">",
"       pneumothorax/hemothorax",
"      </span>",
"      (64 percent), pulmonary contusion (14 percent), pulmonary laceration (10 percent), and blood vessel injury (10 percent).",
"     </li>",
"     <li>",
"      Regardless of mechanism, mortality was highest for children with injuries to the heart or intrathoracic blood vessels and for those with associated head injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Life-threatening thoracic injuries are uncommon among children (",
"    <a class=\"graphic graphic_table graphicRef79921 \" href=\"UTD.htm?31/3/31803\">",
"     table 1",
"    </a>",
"    ). Those that can be immediately life-threatening include tension pneumothorax, massive hemothorax, cardiac tamponade, and commotio cordis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H10#H10\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Commotio cordis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of injuries that are potentially life-threatening, pulmonary contusion occurs in nearly half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=see_link\">",
"     \"Pulmonary contusion in children\"",
"    </a>",
"    .) Other potentially life-threatening injuries occur less frequently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link\">",
"     \"Intrathoracic injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link&amp;anchor=H8#H8\">",
"     \"Chest wall injuries in children\", section on 'Flail chest'",
"    </a>",
"    .) These include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flail chest (1 percent)",
"     </li>",
"     <li>",
"      Bronchial disruption (&lt;1 percent)",
"     </li>",
"     <li>",
"      Intrathoracic vessel injury (3 percent)",
"     </li>",
"     <li>",
"      Myocardial contusion (3 percent)",
"     </li>",
"     <li>",
"      Diaphragmatic injury (4 percent)",
"     </li>",
"     <li>",
"      Esophageal rupture (&lt;1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traumatic asphyxia is a rare consequence of thoracic trauma that occurs in children because of greater flexibility of the chest wall. Direct compression of the chest from crushing injury, in conjunction with a deep inspiration and closed glottis, results in a marked increase in intrathoracic pressure that is transmitted directly through the superior and inferior vena cava. A rapid increase in intracranial pressure may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H4#H4\">",
"     \"Intrathoracic injuries in children\", section on 'Traumatic asphyxia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSOCIATED INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with thoracic trauma frequently have associated injuries. In one retrospective series describing children with thoracic trauma treated at a pediatric trauma center, 82 percent of patients had multisystem injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1\">",
"     1",
"    </a>",
"    ]. Head injuries were reported in 82 percent of children, extremity injuries in 40 percent, and abdominal injuries in 38 percent.",
"   </p>",
"   <p>",
"    Extrathoracic injuries are more often life-threatening, as compared with intrathoracic injuries. Because initial evaluation and stabilization may be focused on associated injuries, the diagnosis of potentially significant thoracic injuries is sometimes delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of children with thoracic trauma is to identify those with significant injuries. Life-threatening conditions (such as airway compromise, impaired respiratory mechanics,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhagic shock) must be rapidly identified and stabilized (primary survey). The full extent of the child's injuries can then be determined with a detailed history, careful physical examination, and diagnostic testing (secondary survey).",
"   </p>",
"   <p>",
"    An initial approach to the injured child that includes a description of the primary and secondary surveys, as well as prehospital preparation, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of airway, ventilatory, and circulatory function in children is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this discussion will focus on the evaluation specific to children with blunt (",
"    <a class=\"graphic graphic_algorithm graphicRef59720 \" href=\"UTD.htm?27/7/27761\">",
"     algorithm 1",
"    </a>",
"    ) and penetrating thoracic trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial rapid assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with significant thoracic trauma who have respiratory or circulatory compromise at the time of initial presentation may have immediately life-threatening injuries such as tension pneumothorax, cardiac tamponade, or injury to the great vessels. Procedures (such as endotracheal intubation or needle thoracostomy) may be required to stabilize these injuries, sometimes before imaging studies have been obtained. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway obstruction from secretions or blood can occur as the result of direct injury to the upper airway or in association with altered mental status, as with traumatic brain injury (TBI).",
"   </p>",
"   <p>",
"    Immediate interventions may include suctioning of blood and secretions, repositioning with the jaw thrust maneuver,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    assisted ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H23#H23\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Upper airway patency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link&amp;anchor=H5#H5\">",
"     \"Basic airway management in children\", section on 'Jaw thrust'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory failure that develops immediately following a traumatic event is typically caused by tension pneumothorax, open pneumothorax, or hemothorax or is related to associated injuries (such as TBI). Children with pulmonary contusion or flail chest often have some evidence of respiratory distress (such as tachypnea), but respiratory failure usually develops later.",
"   </p>",
"   <p>",
"    Stabilization may include assisted ventilation, needle chest decompression (to rapidly remove air)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tube thoracostomy (to remove air or blood). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link&amp;anchor=H20#H20\">",
"     \"Prehospital care of the adult trauma patient\", section on 'Needle chest decompression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a patient with an open chest wound, placement of an occlusive dressing (taped on three sides) may prevent development of an open pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with major thoracic trauma with circulatory collapse may have tension pneumothorax, massive hemorrhage as the result of vascular injury, or cardiac injury. Indicated interventions may include needle chest decompression, rapid infusion of isotonic fluid or blood, pericardiocentesis, or (rarely) emergency thoracotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Emergency department thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency department thoracotomy may be performed for patients in extremis (cardiac arrest or decompensated shock) to release pericardial tamponade, control hemorrhage, control massive air embolism, or perform open cardiac massage.",
"   </p>",
"   <p>",
"    Emergency department thoracotomy should only be performed by experienced clinicians when a thoracic or trauma surgeon is available in a timely manner. Following the procedure, the patient must be taken immediately to the operating room for definitive surgery. Emergency department thoracotomy entails risk. Transmission of communicable diseases, such as HIV and hepatitis, can occur; multiple sharp instruments, suture needles, and open rib fractures can cause iatrogenic injury. In addition, patients receiving emergency department thoracotomy require many resources, diverting care from other patients in frequently over-burdened trauma centers. Given the resources required and risks entailed in emergency department thoracotomy, we strongly encourage hospitals to develop policies to determine the circumstances under which the procedure is to be performed.",
"   </p>",
"   <p>",
"    Potential indications for emergency department thoracotomy in children are similar to adults. Patients in whom it is performed should meet the following conditions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H9256840#H9256840\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Guidelines and indications'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient manifests signs of life in the field or the hospital, AND",
"     </li>",
"     <li>",
"      Patient has penetrating thoracic trauma and is hemodynamically unstable despite appropriate fluid resuscitation OR has not been pulseless for longer than 15 minutes, AND",
"     </li>",
"     <li>",
"      A thoracic or trauma surgeon is available within approximately 45 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency department thoracotomy is futile in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient has no pulse or blood pressure in the field",
"     </li>",
"     <li>",
"      Asystole is the presenting rhythm and there is no pericardial tamponade",
"     </li>",
"     <li>",
"      Prolonged pulselessness (over 15 minutes) occurs at any time",
"     </li>",
"     <li>",
"      Massive, nonsurvivable injuries have occurred",
"     </li>",
"     <li>",
"      No thoracic or trauma surgeon is available within approximately 45 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survival rates after emergency department thoracotomy have generally been poor. Survival rates are best among patients with isolated stab wounds to the heart. Survival is rare among blunt trauma victims without signs of life or patients with multiple gunshot wounds to the chest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H9256832#H9256832\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Overview and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features that may identify children with significant injuries include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of injury &ndash; Mechanisms that may result in serious injury include high impact acceleration-deceleration mechanisms (such as motor vehicle crashes) and penetrating injuries.",
"     </li>",
"     <li>",
"      Vital signs at the scene &ndash; Changes in respiratory rate, heart rate, or blood pressure may indicate deterioration in the child's clinical condition as the result of a significant injury.",
"     </li>",
"     <li>",
"      Chest pain &ndash; Children with thoracic, cardiac, or esophageal injury may have chest pain. In a small observational series describing adults with blunt trauma, chest pain was a predictor of thoracic injury as diagnosed by chest radiograph [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination, including vital signs with pulse oximetry, should be performed. The presence of certain physical findings may indicate specific thoracic, cardiac, or intrathoracic vessel injuries.",
"   </p>",
"   <p>",
"    The following findings are suggestive of chest injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal respiratory rate - In two observational reports describing children with blunt trauma, abnormal respiratory rate correlated with thoracic injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/4,14\">",
"       4,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Signs of respiratory distress - Signs of respiratory distress (including nasal flaring or retractions) suggest a significant chest injury such as pneumothorax, hemothorax, or pulmonary contusion.",
"     </li>",
"     <li>",
"      Distended neck veins - A patient with distended neck veins may have a tension pneumothorax or cardiac tamponade.",
"     </li>",
"     <li>",
"      Chest wall findings - Abnormalities to palpation over the chest wall have been correlated with thoracic injuries, as diagnosed by chest radiograph [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/4,13,14\">",
"       4,13,14",
"      </a>",
"      ]. Findings to note include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Crepitance may indicate rib fractures or subcutaneous air. Subcutaneous air can develop as the result of a pneumothorax or pneumomediastinum.",
"     </li>",
"     <li>",
"      Focal tenderness over the sternum, ribs, or scapula may indicate fracture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link\">",
"       \"Chest wall injuries in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abrasions, ecchymoses, or lacerations over the chest wall may correlate with more significant chest wall or intrathoracic injuries.",
"     </li>",
"     <li>",
"      Open wounds may represent the track of a penetrating wound. An open pneumothorax (sucking chest wound) can develop as air is drawn into the chest through the wound during inspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paradoxical chest wall movement - A flail segment bulges during expiration (",
"      <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link&amp;anchor=H8#H8\">",
"       \"Chest wall injuries in children\", section on 'Flail chest'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal lungs sounds on auscultation - Decreased or absent breath sounds may indicate pneumothorax, hemothorax, or pulmonary contusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs of cardiac injury include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distant or muffled heart tones suggest hemopericardium.",
"     </li>",
"     <li>",
"      An irregular rhythm may develop as the result of a cardiac contusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Injury to the great vessels should be suspected with the following signs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Asymmetric, diminished, or absent peripheral pulses",
"     </li>",
"     <li>",
"      Paraplegia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with bronchial, esophageal, or diaphragmatic injuries may have respiratory distress or decreased breath sounds. A scaphoid abdomen suggests traumatic diaphragmatic hernia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic studies that are important in the evaluation of children with thoracic trauma include imaging and electrocardiography. Laboratory evaluation depends upon the extent and severity of associated injuries. Children with multiple injuries should usually receive at least a hematocrit, type and screen, and urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H22#H22\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated cardiac troponin levels appear to be sensitive indicators of myocardial injury among patients with blunt thoracic trauma. The definition of clinically significant myocardial contusion remains elusive. In observational reports describing adults and children with myocardial contusions, the majority of patients had elevated troponin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, troponin levels may be elevated in patients with minor cardiac injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with normal troponin levels who are hemodynamically stable and have normal EKGs are unlikely to have significant myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 12-lead electrocardiogram (EKG) should be performed for the child who has sustained anterior chest trauma, a sternal fracture, or has any arrhythmia (including unexplained sinus tachycardia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EKG findings that can be seen in patients with cardiac contusion include ST-T wave changes (injury pattern) and arrhythmia. In a retrospective report from the National Pediatric Trauma Registry describing children with blunt cardiac injury, EKG was abnormal in 57 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EKG for patients with cardiac tamponade can show sinus tachycardia, low voltage, and, less commonly, electrical alternans (caused by swinging of the heart in the pericardial fluid) (",
"    <a class=\"graphic graphic_waveform graphicRef72525 \" href=\"UTD.htm?42/27/43450\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging modalities that can be used to evaluate children with thoracic trauma include plain chest radiography and computed tomography. Ultrasonography (Focused Assessment with Sonography in Trauma, or FAST, exam) is being used more extensively for adult patients to identify pericardial fluid. Experience with this modality for children is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain chest radiography is a routine part of the evaluation of children with major thoracic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/21\">",
"     21",
"    </a>",
"    ]. Chest radiographs (CXRs) are widely available, inexpensive, and identify many life-threatening injuries, including clinically significant pneumo or hemothorax. For patients with penetrating trauma, entry and exit wounds (identified with opaque markers on the CXR) may suggest the course of the missile.",
"   </p>",
"   <p>",
"    Computed tomography (CT) has been used extensively to evaluate trauma patients. Although adult patients in some trauma centers receive CT of the chest as an initial imaging study, limited evidence suggests that this approach may not be as advantageous for children because the incidence of cardiac and great vessel injury is much lower, while the risk of radiation exposure is higher, than for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children, CT is used primarily to identify vascular injury and should be performed for the following indications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected aortic injuries, as suggested by mechanism of injury, physical examination, or findings on CXR (wide mediastinum, obscured aortic knob, left apical cap, or large left hemothorax)(",
"      <a class=\"graphic graphic_algorithm graphicRef73037 \" href=\"UTD.htm?39/59/40894\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H6#H6\">",
"       \"Intrathoracic injuries in children\", section on 'Traumatic aortic injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs of great vessel injury (such as asymmetric, diminished, or absent peripheral pulses or paraplegia).",
"     </li>",
"     <li>",
"      Suspicion for tracheobronchial injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiography should be performed for children with physical findings concerning for cardiac injury (such as muffled heart tones or arrhythmias), elevated troponin levels, or abnormal EKGs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H5#H5\">",
"     \"Intrathoracic injuries in children\", section on 'Blunt cardiac injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who have sustained isolated minor thoracic trauma may not require imaging. Those who have normal blood pressures, Glasgow coma scale (GCS) scores of 15, and no localizing findings on chest examination are unlikely to have abnormal CXRs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/4\">",
"     4",
"    </a>",
"    ]. This was demonstrated in several observational series in which thoracic injuries identified on chest radiography correlated with the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal respiratory rate",
"     </li>",
"     <li>",
"      Palpation tenderness over the chest wall",
"     </li>",
"     <li>",
"      Abnormal auscultatory findings such as decreased or absent breath sounds or crackles",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial rapid assessment and stabilization (primary survey), potentially life-threatening injuries that have been identified by physical examination or diagnostic studies may require immediate treatment in the emergency department (ED) or the operating room. Children with significant thoracic injuries are typically hospitalized for medical management (as with pulmonary contusion) or observation, while those with mild or moderate injuries can often be discharged from the ED.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5360117\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;General management considerations for children with thoracic trauma who are symptomatic (such as with chest pain or abnormal physical examination), those with multiple injuries, or those with high-impact mechanisms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supplemental oxygen",
"     </li>",
"     <li>",
"      Monitoring of vital signs, including pulse oximetry",
"     </li>",
"     <li>",
"      Prompt surgical consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advanced airway management, including endotracheal intubation, should be considered for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe respiratory distress",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Glasgow coma scale (GCS) score &lt;9",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cervical spine immobilization should be maintained for patients with thoracic trauma who have multiple injuries, particularly those with head trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link&amp;anchor=H9#H9\">",
"     \"Pediatric cervical spine immobilization\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluids should be provided as needed to support blood pressure and improve end-organ perfusion. Although patients with pulmonary contusions may develop pulmonary edema with excessive fluid administration, this is rarely a consideration during initial management and never takes precedent over supporting circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5360124\">",
"    <span class=\"h2\">",
"     Chest decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions that may be required in the emergency department for children who have serious thoracic injuries include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Needle decompression to relieve tension pneumothorax is typically performed for patients who are unstable while preparations are made for tube thoracostomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link&amp;anchor=H20#H20\">",
"       \"Prehospital care of the adult trauma patient\", section on 'Needle chest decompression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergent tube thoracostomy is indicated for patients with traumatic pneumo- or hemothoraces. The technique for performing the procedure is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The appropriate size tube may be determined by the child's age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight (",
"      <a class=\"graphic graphic_table graphicRef81970 \" href=\"UTD.htm?21/2/21547\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5360138\">",
"    <span class=\"h2\">",
"     Emergency thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency department thoracotomy may be indicated during the initial rapid assessment. Specific criteria for performing this procedure are discussed separately. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Emergency department thoracotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children who present to the emergency department in decompensated shock caused by penetrating chest trauma should be taken immediately to the operating room for resuscitative thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/2,24\">",
"     2,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with serious thoracic injuries may be transferred from the ED to the operating room; however, most thoracic injuries in children do not require surgical intervention. In one retrospective report describing children with thoracic trauma, 7 percent had surgical procedures to treat their thoracic injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients require surgery for associated injuries. Many children are hospitalized for observation, while some may be discharged from the ED.",
"   </p>",
"   <p>",
"    Indications for urgent surgical intervention include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27640/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Massive hemorrhage identified at thoracostomy placement (20 to 30 percent of blood volume for a child or 1000 to 1500 cc for an adolescent)",
"     </li>",
"     <li>",
"      Persistent hemorrhage (2 to 3",
"      <span class=\"nowrap\">",
"       cc/kg",
"      </span>",
"      per hour over four hours)",
"     </li>",
"     <li>",
"      Tracheobronchial rupture",
"     </li>",
"     <li>",
"      Esophageal disruption",
"     </li>",
"     <li>",
"      Diaphragmatic rupture",
"     </li>",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Great vessel injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Admission to the hospital for further evaluation and observation is generally indicated for children with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal vital signs, respiratory symptoms, or severe pain",
"     </li>",
"     <li>",
"      Abnormal chest radiograph (other than rib fracture)",
"     </li>",
"     <li>",
"      Associated injuries",
"     </li>",
"     <li>",
"      High-impact mechanism",
"     </li>",
"     <li>",
"      Suspicion of inflicted injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who can typically be managed as outpatients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with isolated thoracic injuries who are asymptomatic, have normal vital signs (with GCS score 15), and no abnormalities on physical examination.",
"     </li>",
"     <li>",
"      Those with chest wall injuries such as rib fracture or contusions who have normal vital signs, good pain control, and no other injuries noted on examination or imaging studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic injury in children typically occurs as the result of forceful mechanisms such as motor vehicle crashes. For blunt mechanisms, death usually occurs as the result of associated injuries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic and physiologic characteristics of children influence injury patterns caused by thoracic trauma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary contusion, pneumothorax, and rib fracture occur most frequently (",
"      <a class=\"graphic graphic_table graphicRef79921 \" href=\"UTD.htm?31/3/31803\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of thoracic injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head injury is the associated injury seen most commonly in children with thoracic trauma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Associated injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediately life-threatening injuries (such as tension pneumothorax, cardiac tamponade, or injury to the great vessels) must be identified and treated during the initial rapid assessment. Interventions may include assisted ventilation, needle or tube thoracostomy, or (rarely) emergency thoracotomy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial rapid assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergency department thoracotomy may be performed for patients in extremis (cardiac arrest or decompensated shock) to release pericardial tamponade, control hemorrhage, control massive air embolism, or perform open cardiac massage. Specific indications are discussed in detail in the text but include an experienced clinician performing the procedure and timely availability of a thoracic or trauma surgeon. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Emergency department thoracotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic studies that may be useful for the evaluation of children with thoracic trauma include plain chest radiography, computed tomography, and electrocardiography. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with thoracic trauma should receive oxygen and surgical consultation. Cervical spine immobilization should be considered for those with multiple injuries, particularly head injuries. Some patients require specific interventions such as assisted ventilation, fluid resuscitation, or tube thoracostomy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, thoracic injuries require urgent surgical intervention. Hospitalization for medical treatment or observation is indicated for most children. Some children with mild thoracic injuries can be safely discharged from the emergency department. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/1\">",
"      Peclet MH, Newman KD, Eichelberger MR, et al. Thoracic trauma in children: an indicator of increased mortality. J Pediatr Surg 1990; 25:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/2\">",
"      Black TL, Snyder CL, Miller JP, et al. Significance of chest trauma in children. South Med J 1996; 89:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/3\">",
"      Cooper A, Barlow B, DiScala C, String D. Mortality and truncal injury: the pediatric perspective. J Pediatr Surg 1994; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/4\">",
"      Holmes JF, Sokolove PE, Brant WE, Kuppermann N. A clinical decision rule for identifying children with thoracic injuries after blunt torso trauma. Ann Emerg Med 2002; 39:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/5\">",
"      Bulloch B, Schubert CJ, Brophy PD, et al. Cause and clinical characteristics of rib fractures in infants. Pediatrics 2000; 105:E48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/6\">",
"      Barsness KA, Cha ES, Bensard DD, et al. The positive predictive value of rib fractures as an indicator of nonaccidental trauma in children. J Trauma 2003; 54:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/7\">",
"      Holland AJ, Kirby R, Browne GJ, et al. Penetrating injuries in children: is there a message? J Paediatr Child Health 2002; 38:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/8\">",
"      Cooper A. Thoracic injuries. Semin Pediatr Surg 1995; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/9\">",
"      Sarihan H, Abes M, Akyazici R, et al. Blunt thoracic trauma in children. J Cardiovasc Surg (Torino) 1996; 37:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/10\">",
"      Sartorelli KH, Vane DW. The diagnosis and management of children with blunt injury of the chest. Semin Pediatr Surg 2004; 13:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/11\">",
"      Kissoon N, Dreyer J, Walia M. Pediatric trauma: differences in pathophysiology, injury patterns and treatment compared with adult trauma. CMAJ 1990; 142:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/12\">",
"      Ayling J. An open question. Emerg Med Serv 2004; 33:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/13\">",
"      Rodriguez RM, Hendey GW, Marek G, et al. A pilot study to derive clinical variables for selective chest radiography in blunt trauma patients. Ann Emerg Med 2006; 47:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/14\">",
"      Gittelman MA, Gonzalez-del-Rey J, Brody AS, DiGiulio GA. Clinical predictors for the selective use of chest radiographs in pediatric blunt trauma evaluations. J Trauma 2003; 55:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/15\">",
"      Rajan GP, Zellweger R. Cardiac troponin I as a predictor of arrhythmia and ventricular dysfunction in trauma patients with myocardial contusion. J Trauma 2004; 57:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/16\">",
"      Hirsch R, Landt Y, Porter S, et al. Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury. J Pediatr 1997; 130:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/17\">",
"      Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of clinically significant blunt cardiac injury. J Trauma 2003; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/18\">",
"      Beaver BL, Laschinger JC. Pediatric thoracic trauma. Semin Thorac Cardiovasc Surg 1992; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/19\">",
"      Dowd MD, Krug S. Pediatric blunt cardiac injury: epidemiology, clinical features, and diagnosis. Pediatric Emergency Medicine Collaborative Research Committee: Working Group on Blunt Cardiac Injury. J Trauma 1996; 40:61.",
"     </a>",
"    </li>",
"    <li>",
"     Chou TC. Electrocardiography in Clinical Practice: Adults and Pediatrics, 4th ed, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/21\">",
"      Moore MA, Wallace EC, Westra SJ. The imaging of paediatric thoracic trauma. Pediatr Radiol 2009; 39:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/22\">",
"      Renton J, Kincaid S, Ehrlich PF. Should helical CT scanning of the thoracic cavity replace the conventional chest x-ray as a primary assessment tool in pediatric trauma? An efficacy and cost analysis. J Pediatr Surg 2003; 38:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/23\">",
"      Patel RP, Hernanz-Schulman M, Hilmes MA, et al. Pediatric chest CT after trauma: impact on surgical and clinical management. Pediatr Radiol 2010; 40:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27640/abstract/24\">",
"      Working Group, Ad Hoc Subcommittee on Outcomes, American College of Surgeons. Committee on Trauma. Practice management guidelines for emergency department thoracotomy. Working Group, Ad Hoc Subcommittee on Outcomes, American College of Surgeons-Committee on Trauma. J Am Coll Surg 2001; 193:303.",
"     </a>",
"    </li>",
"    <li>",
"     Kadish, H. Thoracic trauma. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1433.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6568 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27640=[""].join("\n");
var outline_f26_63_27640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF THORACIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSOCIATED INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial rapid assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Emergency department thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5360117\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5360124\">",
"      Chest decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5360138\">",
"      Emergency thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6568|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/7/27761\" title=\"algorithm 1\">",
"      Blunt chest trauma algo ped",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/59/40894\" title=\"algorithm 2\">",
"      Algorithm for management of blunt aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6568|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 1\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/3/31803\" title=\"table 1\">",
"      Pediatric thoracic injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/2/21547\" title=\"table 2\">",
"      Chest tube size in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6568|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/27/43450\" title=\"waveform 1\">",
"      ECG in electrical alternans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=related_link\">",
"      Chest wall injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=related_link\">",
"      Intrathoracic injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=related_link\">",
"      Pulmonary contusion in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27641="Management of hypoglycemia during treatment of diabetes mellitus";
var content_f26_63_27641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hypoglycemia during treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Philip E Cryer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27641/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/63/27641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is an important problem in type 1 diabetes, especially in patients receiving intensive therapy in whom the risk of severe hypoglycemia is increased more than threefold (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Less commonly, hypoglycemia may also affect patients with type 2 diabetes who take a sulfonylurea or a meglitinide or who use insulin.",
"   </p>",
"   <p>",
"    Identification of patients at risk for hypoglycemia and the prevention and management of hypoglycemia are reviewed here. The clinical manifestations of hypoglycemia and the physiologic response to hypoglycemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL AND CLINICAL CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2005, The American Diabetes Association (ADA) published criteria for the definition and clinical classification of hypoglycemia in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with diabetes, hypoglycemia is defined as all episodes of an abnormally low plasma glucose concentration (with or without symptoms) that expose the individual to harm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/1\">",
"     1",
"    </a>",
"    ]. The workgroup recommended that people with diabetes become concerned about the possibility of hypoglycemia at a self-monitored blood glucose (SMBG) level &le;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    While that value is higher than the value used to diagnose hypoglycemia in people without diabetes, it approximates the lower limit of the physiological fasting nondiabetic range, the normal glycemic threshold for glucose counterregulatory hormone secretion, and the highest antecedent low glucose level reported to reduce sympathoadrenal responses to subsequent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This cut-off value has been debated, with some favoring a value of &lt;63",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to avoid overclassification of hypoglycemia in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. However, when an SMBG value is &le;70",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    it does not mean that patients should always self-treat. Defensive options include repeating the measurement in the near term, avoiding critical tasks, such as driving, adjusting the subsequent treatment regimen, or ingesting carbohydrates. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment of hypoglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Diabetes Association Workgroup on Hypoglycemia recommends the following classification of hypoglycemia in diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe hypoglycemia &ndash; An event requiring the assistance of another person to actively administer carbohydrate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      or other resuscitative actions is classified as a severe hypoglycemic event. Plasma glucose measurements may not be available during such an event, but neurological recovery attributable to restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.",
"     </li>",
"     <li>",
"      Documented symptomatic hypoglycemia &ndash; An event during which typical symptoms of hypoglycemia are accompanied by a measured (typically with a monitor or with a validated glucose sensor) plasma glucose concentration &le;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is classified as a documented symptomatic hypoglycemic event.",
"     </li>",
"     <li>",
"      Asymptomatic hypoglycemia &ndash; Asymptomatic hypoglycemia is classified as an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration of &le;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Probable symptomatic hypoglycemia &ndash; Probable symptomatic hypoglycemia is classified as an event during which typical symptoms of hypoglycemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration &le;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.9",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      Relative hypoglycemia &ndash; Relative hypoglycemia is classified as an event during which the person with diabetes reports typical symptoms of hypoglycemia, and interprets those as indicative of hypoglycemia, but with a measured plasma glucose concentration &gt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      This category reflects the fact that patients with chronically poor glycemic control can experience symptoms of hypoglycemia at plasma glucose levels &gt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      as glucose levels decline into the physiological range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MAGNITUDE OF THE PROBLEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Frequency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia occurs frequently in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ]. The average patient suffers countless numbers of episodes of asymptomatic hypoglycemia (which are not benign because they impair defenses against subsequent falling plasma glucose concentrations), two episodes of symptomatic hypoglycemia per week, and one episode of temporarily disabling hypoglycemia per year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Severe hypoglycemia events, the most reliable values albeit representing only a small fraction of the total hypoglycemic experience, have been reported to range from 62 to 170 episodes per 100 patient years in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the Diabetes Control and Complications Trial (DCCT), a greater proportion of patients in the intensively treated group had at least one episode of severe hypoglycemia (65 versus 35 percent of patients in the control group), with overall rates of 61 and 19 per 100 patient-years, respectively (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is less common in type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4,9,11\">",
"     2-4,9,11",
"    </a>",
"    ]. Population-based data indicate that the overall event rate for severe hypoglycemia (requiring the assistance of another individual) in insulin-treated type 2 diabetes is approximately 30 percent of that in type 1 diabetes (35 versus 115 episodes per 100 patient-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/11\">",
"     11",
"    </a>",
"    ] and that event rates for hypoglycemia requiring professional emergency medical treatment range from 40 to 100 percent of those in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, because there are a greater number of individuals with type 2 than type 1 diabetes, and because most people with type 2 diabetes ultimately require treatment with insulin, most episodes of iatrogenic hypoglycemia occur in people with type 2 diabetes.",
"   </p>",
"   <p>",
"    Among the commonly used insulin secretagogues (sulfonylureas, meglitinides), hypoglycemia is most often reported in patients taking long-acting drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    (glibenclamide) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/14\">",
"     14",
"    </a>",
"    ]. Hypoglycemia is relatively uncommon during treatment with insulin early in the course of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ]. However, its frequency increases, approaching type 1 diabetes, as patients approach the insulin deficient end of the spectrum of type 2 diabetes. The prevalence of mild hypoglycemic symptoms has been reported as 16 to 20 percent in patients using sulfonylurea agents, and 30 to 50 percent in patients treated with insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H14#H14\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Type 1 versus type 2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to insulin and insulin secretagogues, agents that do not cause unregulated hyperinsulinemia, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , alpha glucosidase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    , voglibose), thiazolidinediones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ), GLP-1 receptor agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    ), and DPP-IV inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    , vildagliptin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    ) probably do not cause hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/16\">",
"     16",
"    </a>",
"    ]. However, they increase the risk if used with insulin or an insulin secretagogue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Better glycemic control is associated with an increased incidence of symptomatic hypoglycemia in patients with type 2 diabetes. In three large randomized trials (ACCORD, ADVANCE, VADT) of intensive glucose control in patients with type 2 diabetes, hypoglycemia occurred more frequently in the intensively treatment groups (A1C 6.4 to 6.9 percent), and in one trial (ACCORD), there were more deaths in the intensive treatment arm. Although the cause of excess mortality could not be ascribed to recognized hypoglycemia, unrecognized iatrogenic hypoglycemia may have resulted in arrhythmias and been a possible contributor. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H9#H9\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nocturnal hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A particular problem is nocturnal hypoglycemia, which can lead to disruption of sleep and delays in correction of the hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4,10\">",
"     3,4,10",
"    </a>",
"    ]. Nighttime is typically the longest period between self-monitoring of plasma glucose, between food ingestion, and the time of maximum sensitivity to insulin. Nocturnal hypoglycemia is less common in individuals using rapid acting insulin analogs (lispro, aspart, glulisine) rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    before meals and in individuals using long-acting insulin analogs (glargine, detemir) rather than NPH as the basal insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report of patients undergoing continuous glucose monitoring, patients with type 1 diabetes had hypoglycemic values (glucose &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;3.9",
"    <span class=\"nowrap\">",
"     mmol/liter])",
"    </span>",
"    an average of 2.3",
"    <span class=\"nowrap\">",
"     hours/day",
"    </span>",
"    and type 2 patients 1",
"    <span class=\"nowrap\">",
"     hour/day;",
"    </span>",
"    most of the hypoglycemic values occurred at night [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/17\">",
"     17",
"    </a>",
"    ]. In another study with continuous glucose monitoring at night in type 1 patients, nocturnal hypoglycemia occurred on more than half the nights studied, with an average duration over 2.5 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is an important problem in type 1 diabetes and in many with advanced (absolutely endogenous insulin deficient) type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4,19,20\">",
"     2-4,19,20",
"    </a>",
"    ]. It can cause a vicious cycle of recurrent hypoglycemia, resulting in morbidity and preventing the maintenance of euglycemia over a lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition, hypoglycemia can be fatal, with hypoglycemia mortality estimates in patients with type 1 diabetes ranging from 6 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Hypoglycemia mortality rates in type 2 diabetes are currently unknown, but fatal hypoglycemia has been documented in type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4,24\">",
"     3,4,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent to which recurrent hypoglycemia causes cognitive impairment is uncertain. The results from the DCCT are reassuring. Although the frequency of severe hypoglycemia in the DCCT was over three times higher in the intensive treatment group as compared with the conventional treatment group, there were no differences between the two groups in multiple psychosocial and neurobehavioral parameters measured at two, five, seven, and eighteen years; furthermore, patients with repeated episodes of hypoglycemia did not perform differently from those who rarely had hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. However, those data did not include young children or elderly persons with diabetes; recurrent severe hypoglycemia has been associated with cognitive impairment in both groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of type 2 diabetes mellitus in the elderly patient\", section on 'Avoiding hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hypoglycemia is related to the duration of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] and appears to be increased in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/15\">",
"     15",
"    </a>",
"    ]. Older adults may have more neuroglycopenic manifestations of hypoglycemia (dizziness, weakness, delirium, confusion) compared with adrenergic manifestations (tremors, sweating).",
"   </p>",
"   <p>",
"    Severe hypoglycemia requiring hospitalization has been associated with an increased risk of dementia. In addition, even mild episodes of hypoglycemia may lead to adverse outcomes in frail elderly; episodes of dizziness or weakness increase the risk of falls and fracture leading to nursing home placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of type 2 diabetes mellitus in the elderly patient\", section on 'Avoiding hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is typically the result of the interplay of absolute or relative therapeutic insulin excess and compromised physiological and behavioral defenses against falling plasma glucose concentrations (defective glucose counterregulation and hypoglycemia unawareness). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical practice, insulin excess alone explains only a minority of episodes of hypoglycemia. Impaired counterregulatory defenses resulting in hypoglycemia is the primary risk factor for subsequent hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Impaired counterregulatory responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first and second physiological defenses against hypoglycemia, decrements in insulin and increments in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    as glucose levels fall in response to therapeutic hyperglycemia, are lost in parallel with beta-cell failure in diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This occurs rapidly in type 1 diabetes and more gradually in type 2 diabetes.",
"   </p>",
"   <p>",
"    The third physiological defense, an increment in epinephrine, is typically attenuated in such patients. In the setting of absent insulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    responses, the attenuated epinephrine response causes defective glucose counterregulation. In addition, an attenuated epinephrine response is a marker of an attenuated sympathoadrenal, including sympathetic neural, response that causes hypoglycemia unawareness. These are the components of hypoglycemia-associated autonomic failure (HAAF) in diabetes. [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. HAAF can be caused by recent antecedent hypoglycemia, prior exercise, or sleep, but the precise mechanisms are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H12#H12\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Hypoglycemia-associated autonomic failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for HAAF include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute endogenous insulin deficiency",
"     </li>",
"     <li>",
"      A past history of severe hypoglycemia, hypoglycemia unawareness, recent antecedent hypoglycemia, prior exercise, or sleep",
"     </li>",
"     <li>",
"      Intensive glycemic therapy, ie, lower A1C level levels, stricter glycemic goals, or both",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Insulin excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute or relative insulin excess occurs in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin (or insulin secretagogue) doses are excessive, ill-timed or of the wrong type",
"     </li>",
"     <li>",
"      Exogenous glucose influx is reduced (eg, during an overnight fast or following missed meals)",
"     </li>",
"     <li>",
"      Insulin-independent glucose utilization is increased (eg, during and shortly after exercise)",
"     </li>",
"     <li>",
"      Sensitivity to insulin is increased (eg, hours after exercise, in the middle of the night, following improved glycemic control or weight loss)",
"     </li>",
"     <li>",
"      Endogenous glucose production is reduced (eg, following alcohol ingestion)",
"     </li>",
"     <li>",
"      Insulin clearance is reduced (eg, with renal failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is the most common adverse effect of intensive insulin therapy in both the outpatient and inpatient setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link&amp;anchor=H14#H14\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\", section on 'Hypoglycemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H25#H25\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H10#H10\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Intensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although insulin secretagogues and insulin are the most common drugs associated with hypoglycemia, other drugs that are often prescribed for people with diabetes and that possibly increase the risk of hypoglycemia are angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, and non-selective beta2-adrenergic antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .) Alcohol is an additional drug that can potentially cause hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prediction of risk from blood glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring symptomatic and counterregulatory hormone response to hypoglycemia, although accurate in determining the risk of severe hypoglycemia, is too cumbersome for routine use. A simpler and more practical approach during intensive insulin therapy is to evaluate the frequency and severity of low blood glucose readings from blood glucose monitoring records kept by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STRATEGIES TO PREVENT HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, The Endocrine Society published evidence-based guidelines for the evaluation and management of hypoglycemic disorders in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2\">",
"     2",
"    </a>",
"    ]. Our approach to the management of hypoglycemia outlined here is consistent with the guidelines.",
"   </p>",
"   <p>",
"    The prevention of hypoglycemia involves assessing for risk factors and tailoring treatment regimens to reduce risk. Reducing the risk of hypoglycemia while maintaining or improving glycemic control involves application of the principles of aggressive glycemic therapy in people with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4,28\">",
"     2-4,28",
"    </a>",
"    ]. These principles include patient education and empowerment, frequent self-monitoring of blood glucose (SMBG), flexible and rational insulin (and other drug) regimens, individualized glycemic goals, and ongoing professional guidance and support.",
"   </p>",
"   <p>",
"    Regular SMBG is critical to the glycemic management of intensively treated",
"    <span class=\"nowrap\">",
"     (basal/bolus",
"    </span>",
"    insulin) type 2 diabetes as well as that of type 1 diabetes. Continuous glucose monitoring may further facilitate glycemic control as accurate and reliable continuous sensors become available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glycemic targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycemic control can minimize risks for retinopathy, nephropathy, and neuropathy in both type 1 and type 2 diabetes and may decrease the risk for cardiovascular disease. Target A1C levels in patients with type 1 and 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Less stringent treatment goals may be appropriate for patients with a history of severe hypoglycemia, patients with limited life expectancies, very young children or older adults, and individuals with comorbid conditions.",
"   </p>",
"   <p>",
"    Glycemic goals are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link&amp;anchor=H13#H13\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Insulin regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with type 1 or type 2 diabetes, the use of long-acting insulin analogs (eg, glargine, detemir) as the basal insulin and rapid-acting insulin analogs (eg, lispro, aspart, glulisine) as the pre-meal bolus insulin reduces the risk of hypoglycemia, particularly nocturnal hypoglycemia. Although many clinicians believe continuous subcutaneous insulin infusion (CSII) is better, at comparable A1C levels CSII has not been found to consistently result in less hypoglycemia than a basal-bolus regimen with insulin analogs. However, sensor-augmented CSII has been reported to achieve lower A1C levels without an increase in hypoglycemia. Continuous glucose monitoring is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H13#H13\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Continuous glucose monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Continuous glucose monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Behavioral approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of severe hypoglycemia requires the recognition of early symptoms and signs by the patient (and by those around them). Autonomic symptoms include sweating, tremor, hunger, and anxiety, while neuroglycopenic symptoms include difficulty concentrating, incoordination, weakness, lethargy, blurred vision, and confusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H3#H3\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Response to hypoglycemia in normal subjects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the exact set of symptoms perceived varies between patients, and also within the same patient on different occasions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/32\">",
"     32",
"    </a>",
"    ]. Factors such as alcohol, fatigue, and beta-blockers can affect which symptoms occur and how well they are recognized. Beta-blockers, for example, can mask the early warning symptoms of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/33\">",
"     33",
"    </a>",
"    ]; detection of symptoms is also less likely if the person is asleep, tired, or distracted by other events.",
"   </p>",
"   <p>",
"    Using a variety of well-validated behavioral approaches, people can be trained to improve their ability to recognize hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, this increase in recognition may be associated with long-term improvement in A1C values and a reduction in the number of severe hypoglycemic events. Blood glucose awareness training involves techniques in which patients are asked to guess their blood glucose concentration, record their symptoms, and then verify the blood glucose values with a glucose meter. Patients also can be taken through hypoglycemic thresholds in a controlled hospital setting, while recording the symptoms they notice at different times. Using these techniques, the most frequently helpful symptoms were, in rank order, difficulty concentrating, trembling, feeling uncoordinated, pounding heart, slowed thinking, feeling nervous and tense, and sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hypoglycemia unawareness",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a history of hypoglycemia unawareness, a two- to three-week period of scrupulous avoidance of hypoglycemia is advisable since that often restores awareness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. That can be accomplished by more intensive professional involvement (eg, by telephone); in practice, it may require higher glycemic goals in the short-term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prevention of nocturnal hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bedtime snacks are the traditional strategy for preventing nocturnal hypoglycemia. Snacks containing protein have not been shown to be more effective than carbohydrate alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/42\">",
"     42",
"    </a>",
"    ]. A study of 21 patients with type 1 diabetes managed with intensive insulin regimens found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    5 mg, a beta2-adrenergic agonist, decreased nocturnal hypoglycemic episodes but caused morning hyperglycemia; a usual bedtime snack, snack plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , or cornstarch snack were not more effective than no intervention in preventing nocturnal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/18\">",
"     18",
"    </a>",
"    ]. A lower dose of terbutaline produced intermediate nocturnal plasma glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other experimental approaches include overnight infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    and reduction of insulin doses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/31\">",
"     31",
"    </a>",
"    ]. None of these approaches have been shown to be safe and effective in suitably powered randomized clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prevention of exercise-induced hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise increases glucose utilization by muscle and, therefore, can cause hypoglycemia in patients with insulin deficient diabetes who have near normal or moderately elevated plasma glucose levels at the start of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/2-4,28\">",
"     2-4,28",
"    </a>",
"    ]. In addition, exercise, like hypoglycemia, can shift the glycemic threshold for the sympathoadrenal response to subsequent hypoglycemia to a lower plasma glucose concentration hours later. This shift causes defective glucose counterregulation by reducing epinephrine responses in the setting of absent insulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    responses. It also causes hypoglycemia unawareness by reducing autonomic symptom responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H16#H16\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoglycemia during or shortly after exercise can be prevented by frequent SMBG and, when indicated, reduced insulin doses, carbohydrate ingestion, or both prior to exercise. Because post exercise hypoglycemia can occur many hours after exercise, patients should remain vigilant for its occurrence and consider action (eg, bedtime snack) to prevent nocturnal hypoglycemia (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Prevention of nocturnal hypoglycemia'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Fear of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia can be a frightening, unpleasant, and potentially lethal complication of diabetes and, therefore, fear of hypoglycemia is understandable. At its best, this concern should prompt diabetic patients to be aware of early symptoms and to ingest carbohydrate before symptoms progress. In some cases, however, fear of hypoglycemia can become a major barrier to lowering blood glucose concentrations substantially. In one survey, patients who had a frightening episode of severe hypoglycemia in the previous year often became so fearful that they kept their blood glucose excessively high for several months afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/44\">",
"     44",
"    </a>",
"    ]. As a result, it is important to explore the patient's past experience with hypoglycemia before embarking on an intensified insulin regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT OF HYPOGLYCEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Asymptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;When SMBG reveals a blood glucose of &le;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    it is reasonable for a person with drug-treated diabetes to consider defensive actions. The options include repeating the measurement in the near term, avoiding critical tasks such as driving, ingesting carbohydrates, and adjusting the treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to treat early symptoms of hypoglycemia, patients should be certain that fast-acting carbohydrate (such as glucose tablets, hard candy, or sweetened fruit juice) is available at all times. Fifteen to 20 grams is usually sufficient to raise the blood glucose into a safe range without inducing hyperglycemia. This can be followed by long-acting carbohydrate to prevent recurrent symptoms.",
"   </p>",
"   <p>",
"    In patients taking insulin or an insulin secretagogue in combination with an alpha-glucosidase inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    , voglibose), only pure glucose (dextrose) should be used to treat symptomatic hypoglycemia. Other forms of carbohydrates, such as table sugar (sucrose), will be less effective in raising blood sugar as alpha-glucosidase inhibitors slow digestion of other carbohydrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of severe hypoglycemia, when the patient is unconscious or unable to ingest carbohydrate, requires that close friends or relatives be trained to recognize and treat this complication. Dealing with a loved one who is pale, sweaty, acting in a bizarre fashion, or unconscious and convulsing is often a terrifying situation, yet one that can be reversed with an injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    . Successful glucagon therapy requires that the glucagon kit can be located and that the relative or friend is able to remain calm, mix the glucagon powder with the diluent, draw it up, and give the injection. The glucagon kit should be checked regularly and replaced when it is beyond its expiration date.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subcutaneous or intramuscular injection of 0.5 to 1.0 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      will usually lead to recovery of consciousness within 10 to 15 minutes, although it may be followed by marked nausea or even vomiting.",
"     </li>",
"     <li>",
"      Patients brought to the hospital can be treated more quickly by giving 25 g of 50 percent glucose (dextrose) intravenously. A subsequent glucose infusion (or food, if patient is able to eat) is often needed, depending upon the cause of the hypoglycemia.",
"     </li>",
"     <li>",
"      There are no efficacy or safety data to guide the management of severe hypoglycemia (while awaiting emergency personnel) in patients with impaired consciousness and no immediate access to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      or intravenous dextrose. In a study of normoglycemic volunteers, the buccal absorption of&nbsp;glucose&nbsp;was minimal [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/45\">",
"       45",
"      </a>",
"      ]. However, in the absence of other options for such patients, some experts, including some UpToDate authors and editors, suggest that while awaiting emergency personnel, family members squeeze a glucose gel (eg, InstaGlucose) or cake frosting in the space between the teeth and buccal mucosa, keeping the patient's head tilted slightly to the side. If a glucose gel or cake frosting is unavailable, some advocate sprinkling table sugar under the tongue, as table sugar has been reported to raise plasma glucose concentrations to some extent in ill children with malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27641/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, other experts, including the author of this topic review, would not administer buccal or sublingual preparations or foods, given the lack of supporting evidence and concerns about aspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a comatose diabetic patient may have marked hyperglycemia (with or without ketoacidosis) rather than hypoglycemia, these disorders can be distinguished by estimating blood glucose with a glucose stick. If this is not available, then glucose should be given empirically. This will correct hypoglycemia and will not be particularly deleterious if the blood glucose concentration is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"       \"Patient information: Low blood sugar in people with diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"       \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to the management of insulin secretagogue or insulin-treated patients is as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Risk factor assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask about hypoglycemia at every patient contact, particularly details about previous major episodes of hypoglycemia, accompanying symptoms, the frequency of minor episodes, the timing of meals, exercise, and diabetes medications preceding hypoglycemia, and how hypoglycemic episodes are usually treated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk factors for hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Review the self-monitoring of blood glucose record to estimate the frequency of hypoglycemia and the adequacy of counterregulation, particularly before starting intensive insulin therapy or if there is a previous history of hypoglycemic episodes. Review any continuous glucose sensing data obtained. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prediction of risk from blood glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia can occur at any level of glycemia, but the risk increases with more intensive therapy. The goal is to achieve the best degree of mean glycemia (A1C) that can be accomplished safely. We consider more modest goals for A1C values in patients with one or more previous episodes of severe hypoglycemia, with significant impairment in recovery from hypoglycemia, or in those with little expected benefit from glycemic control. We continually reevaluate with the patient whether the benefits of improved blood glucose control are worth the number of hypoglycemic episodes that are occurring. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Glycemic targets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provide education for the patient on the recognition and treatment of hypoglycemia. Patients should be told to be especially vigilant following an episode of hypoglycemia, since both recognition of hypoglycemia and the counterregulatory response to it will be impaired during this time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H12#H12\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Hypoglycemia-associated autonomic failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have hypoglycemia unawareness, avoidance of hypoglycemia for two to three weeks may restore awareness. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hypoglycemia unawareness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a person with drug-treated diabetes, we suggest defensive actions when self-monitoring reveals a glucose level &le;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.) Defensive actions include repeating the measurement in the near term, avoiding critical tasks such as driving, ingesting carbohydrates, and adjusting the treatment regimen.",
"     </li>",
"     <li>",
"      Patients with asymptomatic or symptomatic hypoglycemia should ingest carbohydrates. Fifteen to 20 grams of oral glucose is typically sufficient. Glucose may be ingested in the form of tablets, juice, milk, other snacks, or a meal. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Symptomatic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of hypoglycemia in a person with impaired consciousness and no established intravenous (IV) access, we suggest the immediate administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      , rather than waiting to establish IV access (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The usual dose is 0.5 to 1.0 mg given as a subcutaneous or intramuscular injection. Education and training for clinicians, friends, and family on the recognition and treatment of severe hypoglycemia, including the use of glucagon kits, is necessary. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous dextrose (25 g of 50 percent glucose [dextrose]) can be administered to treat hypoglycemia in patients with impaired consciousness and established IV access (typically in a hospital). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the latter settings, a subsequent glucose infusion (or food, if patient is able to eat) is often needed, depending upon the cause of the hypoglycemia, to prevent recurrence of symptoms.",
"     </li>",
"     <li>",
"      We routinely check that the patient's blood glucose monitoring equipment is accurately calibrated, that fast-acting carbohydrate is being kept available, that the patient is staying vigilant, and that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      kits are not out of date.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/1\">",
"      Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/2\">",
"      Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709.",
"     </a>",
"    </li>",
"    <li>",
"     Cryer PE. Hypoglycemia in Diabetes. Pathophysiology, Prevalence and Prevention. American Diabetes Association, Alexandria, VA, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/4\">",
"      Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/5\">",
"      Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia 2009; 52:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/6\">",
"      Swinnen SG, Mullins P, Miller M, et al. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 2009; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/7\">",
"      Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/8\">",
"      Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 2009; 52:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/9\">",
"      UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/10\">",
"      Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/11\">",
"      Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/12\">",
"      Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia--a prospective population-based study. Exp Clin Endocrinol Diabetes 2003; 111:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/13\">",
"      Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/14\">",
"      Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/15\">",
"      Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/16\">",
"      Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/17\">",
"      Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005; 28:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/18\">",
"      Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab 2006; 91:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/19\">",
"      Amiel SA. Hypoglycemia: from the laboratory to the clinic. Diabetes Care 2009; 32:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/20\">",
"      McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes 2010; 59:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/21\">",
"      Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/22\">",
"      Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care 2008; 31:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/23\">",
"      Skrivarhaug T, Bangstad HJ, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006; 49:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/24\">",
"      Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/25\">",
"      Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/26\">",
"      Murad MH, Coto-Yglesias F, Wang AT, et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/27\">",
"      Cox DJ, Gonder-Frederick L, Ritterband L, et al. Prediction of severe hypoglycemia. Diabetes Care 2007; 30:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/28\">",
"      Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/29\">",
"      Pogach L, Aron D. Balancing hypoglycemia and glycemic control: a public health approach for insulin safety. JAMA 2010; 303:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/30\">",
"      Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/31\">",
"      Cryer PE. Elimination of hypoglycemia from the lives of people affected by diabetes. Diabetes 2011; 60:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/32\">",
"      Cox DJ, Gonder-Frederick L, Antoun B, et al. Perceived symptoms in the recognition of hypoglycemia. Diabetes Care 1993; 16:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/33\">",
"      Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 1991; 40:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/34\">",
"      Cox DJ, Kovatchev B, Koev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med 2004; 11:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/35\">",
"      Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/36\">",
"      Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/37\">",
"      Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/38\">",
"      Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/39\">",
"      Lingenfelser T, Buettner U, Martin J, et al. Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Diabetes Care 1995; 18:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/40\">",
"      Fritsche A, Stefan N, H&auml;ring H, et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/41\">",
"      Fanelli C, Pampanelli S, Lalli C, et al. Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation. Diabetes 1997; 46:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/42\">",
"      Gray RO, Butler PC, Beers TR, et al. Comparison of the ability of bread versus bread plus meat to treat and prevent subsequent hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/43\">",
"      Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE. Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 2008; 31:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/44\">",
"      Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 1992; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/45\">",
"      Gunning RR, Garber AJ. Bioactivity of instant glucose. Failure of absorption through oral mucosa. JAMA 1978; 240:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/46\">",
"      Barennes H, Valea I, Nagot N, et al. Sublingual sugar administration as an alternative to intravenous dextrose administration to correct hypoglycemia among children in the tropics. Pediatrics 2005; 116:e648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27641/abstract/47\">",
"      Graz B, Dicko M, Willcox ML, et al. Sublingual sugar for hypoglycaemia in children with severe malaria: a pilot clinical study. Malar J 2008; 7:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1805 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27641=[""].join("\n");
var outline_f26_63_27641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOCHEMICAL AND CLINICAL CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MAGNITUDE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nocturnal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Consequences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RISK FACTORS FOR HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Impaired counterregulatory responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Insulin excess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prediction of risk from blood glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STRATEGIES TO PREVENT HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glycemic targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Insulin regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Behavioral approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hypoglycemia unawareness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prevention of nocturnal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prevention of exercise-induced hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Fear of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT OF HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Severe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Risk factor assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1805|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5789\" title=\"figure 1\">",
"      Hypoglycemia and HbA1c",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27642="Basic principles of wound management";
var content_f26_63_27642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles of wound management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     David G. Armstrong, DPM, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Andrew J Meyr, DPM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/63/27642/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/63/27642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H55268705\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wound is a disruption of the normal structure and function of the skin and skin architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/1\">",
"     1",
"    </a>",
"    ]. An acute wound has normal wound physiology and healing is anticipated to progress through the normal stages of wound healing, whereas a chronic wound is defined as one that is physiologically impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To ensure proper healing, the wound bed needs to be well vascularized, free of devitalized tissue, clear of infection and moist. Wound dressings should eliminate dead space, control exudate, prevent bacterial overgrowth, ensure proper fluid balance, be cost-efficient, and be manageable for the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nursing staff. Wounds that demonstrate progressive healing as evidenced by granulation tissue and epithelialization can undergo closure or coverage.",
"   </p>",
"   <p>",
"    Many topical agents and alternative therapies are available that are meant to improve the wound healing environment and, although data are lacking to support any definitive recommendations, some may be useful under specific circumstances.",
"   </p>",
"   <p>",
"    The basic principles and available options for the management of various wounds will be reviewed. The efficacy of wound management strategies for the treatment of specific wounds is discussed in individual topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"       \"Management of diabetic foot lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of pressure ulcers\", section on 'Ulcer treatment by stage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"       \"Treatment of chronic lower extremity critical limb ischemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32070?source=see_link\">",
"       \"Overview and management strategies for the combined burn trauma patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20794882\">",
"    <span class=\"h1\">",
"     MEDICAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20794890\">",
"    <span class=\"h2\">",
"     Role of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is not indicated for all wounds, and should only be reserved for wounds that appear clinically infected. There is no published evidence to support antibiotic therapy as &ldquo;prophylaxis&rdquo; in non-infected chronic wounds, or to improve the healing potential of wounds without clinical evidence of infection. Clinical signs of infection that warrant antibiotic therapy include local (cellulitis, lymphangitic streaking, purulence, malodor, gangrene, exposed bone, etc) and systemic (fever, chills, nausea, hypotension, hyperglycemia, leukocytosis, confusion) symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20794898\">",
"    <span class=\"h2\">",
"     Control of blood sugar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no overwhelming clinical evidence in support of short-term glycemic control as directly affecting wound healing potential or preventing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], we make glycemic control a priority in our practice when treating wounds and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=see_link\">",
"     \"Susceptibility to infections in persons with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at risk for the development of chronic wounds often have comorbid conditions associated with immunocompromised states (eg diabetes), and may not have classic systemic signs of infection such as fever and leukocytosis on initial presentation. In these patients, hyperglycemia may be a more sensitive measure of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268712\">",
"    <span class=\"h1\">",
"     WOUND DEBRIDEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds that have devitalized tissue, contamination or residual suture material require debridement prior to further wound management. Acute traumatic wounds may have irregular devitalized edges or foreign material within the wound, and surgical wounds that have dehisced may have an infected exudate, bowel contamination or necrotic muscle or fascia. These materials impede the body&rsquo;s attempt to heal by stimulating the production of abnormal metalloproteases and consuming the local resources necessary for healing.",
"   </p>",
"   <p>",
"    Characteristics of chronic wounds that prevent an adequate cellular response to wound-healing stimuli include accumulation of devitalized tissue, decreased angiogenesis, hyperkeratotic tissue, exudate, and biofilm formation (ie, bacterial overgrowth on the surface of the wound) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/6\">",
"     6",
"    </a>",
"    ]. These wounds need repeated debridement to restore an optimal wound healing environment.",
"   </p>",
"   <p>",
"    Wound bed preparation facilitates ordered restoration and regeneration of damaged tissue and may enhance the function of specialized wound care products and advanced biologic tissue substitutes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456665404\">",
"    <span class=\"h2\">",
"     Irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrigation with warm, isotonic (normal) saline should be a routine part of wound management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/1\">",
"     1",
"    </a>",
"    ]. Irrigation is important for decreasing bacterial load and removing loose material [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The addition of dilute iodine or other antiseptic solutions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    ) is generally unnecessary. These solutions have minimal action against bacteria and could potentially impede wound healing through toxic effects on normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H369372661\">",
"     'Antiseptics and antimicrobials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Low pressure irrigation (eg, &lt;15 pounds per square inch [psi]) is usually adequate to remove material from the surface of most wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/13\">",
"     13",
"    </a>",
"    ]. Decreased bacterial load has been documented clinically with the use of pulsed irrigation in lower extremity chronic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/14\">",
"     14",
"    </a>",
"    ]. Higher pressure irrigators may cause local tissue damage by dissecting loose connective tissue and increasing tissue edema.",
"   </p>",
"   <p>",
"    Bacteria do not appear to accompany the irrigation fluid into adjacent tissues in animal studies even at higher pressure levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/15\">",
"     15",
"    </a>",
"    ]. In an experimental model, high-pressure irrigation decreased bacterial levels more than bulb irrigation (average reduction, 70 versus 44 percent) with no increase in the rate of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/16\">",
"     16",
"    </a>",
"    ]. For highly contaminated wounds, the benefits of reducing bacterial load may outweigh the risk of adjacent tissue damage associated with the use of higher irrigating pressures. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456663268\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sharp excisional debridement uses a scalpel or other sharp instruments (eg, scissors, or curette) to remove devitalized tissue (",
"    <a class=\"graphic graphic_picture graphicRef69031 \" href=\"UTD.htm?9/32/9732\">",
"     picture 1",
"    </a>",
"    ) and accumulated debris (biofilm). Sharp excisional debridement of chronic wounds decreases bacterial load and stimulates contraction and wound epithelialization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/17\">",
"     17",
"    </a>",
"    ]. Surgical debridement is the most appropriate choice for removing large areas of necrotic tissue and is indicated whenever there is any evidence of infection (cellulitis, sepsis). Surgical debridement is also indicated in the management of chronic non-healing wounds to remove infection, handle undermined wound edges, or obtain deep tissue for culture and pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with active infection, antibiotic therapy should be targeted and determined by wound culture and sensitivity to decrease the development of bacterial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H8#H8\">",
"     \"Cellulitis and erysipelas\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with chronic critical limb ischemia, surgical debridement must be coupled with revascularization in order to be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268733\">",
"    <span class=\"h2\">",
"     Enzymatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzymatic debridement involves applying exogenous enzymatic agents to the wound. Many products are commercially available (",
"    <a class=\"graphic graphic_table graphicRef85776 \" href=\"UTD.htm?39/62/40940\">",
"     table 1",
"    </a>",
"    ), but results of clinical studies are mixed and their use remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/24\">",
"     24",
"    </a>",
"    ]. Ulcer healing rates are not improved with the use of most topical agents, including debriding enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/25\">",
"     25",
"    </a>",
"    ]. However, collagenase may promote endothelial cell and keratinocyte migration, thereby stimulating angiogenesis and epithelialization as its mechanism of action, rather than functioning as a strict debridement agent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/26\">",
"     26",
"    </a>",
"    ]. It also remains a good option in patients who require debridement but are not surgical candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361001514\">",
"    <span class=\"h2\">",
"     Biologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative method of wound debridement uses the larvae of the Australian sheep blow fly (",
"    <em>",
"     Lucilia (Phaenicia) cuprina",
"    </em>",
"    ) or green bottle fly (",
"    <em>",
"     Lucilia (Phaenicia) sericata",
"    </em>",
"    , Medical Maggots&trade;, Monarch Labs, Irvine, CA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Larval therapy can be used as a bridge between debridement procedures, or for debridement of chronic wounds when surgical debridement is not available or cannot be performed.",
"   </p>",
"   <p>",
"    Maggot therapy has been used in the treatment of pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], chronic venous ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], diabetic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/27\">",
"     27",
"    </a>",
"    ], and other acute and chronic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/33\">",
"     33",
"    </a>",
"    ]. The larvae secrete proteolytic enzymes that liquefy necrotic tissue which is subsequently ingested while leaving healthy tissue intact. Basic and clinical research suggests that larval therapy has additional benefits, including antimicrobial action and stimulation of wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/28,31,34\">",
"     28,31,34",
"    </a>",
"    ]. However, randomized trials have not found consistent reductions in the time to wound healing compared with standard wound therapy (eg, debridement, hydrogel, moist dressings) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Larval therapy appears to be at least equivalent to hydrogel in terms of cost [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dressing changes include the application of a perimeter dressing and a cover dressing of mesh (chiffon) that helps direct the larvae into the wound and limits their migration (",
"    <a class=\"graphic graphic_movie graphicRef70202 \" href=\"UTD.htm?35/26/36256\">",
"     movie 1",
"    </a>",
"    ). Larvae are generally changed every 48 to 72 hours. One study that evaluated larval therapy in chronic venous wounds found no advantage to continuing larval therapy beyond one week [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients were randomly assigned to larval therapy (n = 58) or conventional treatment (n = 61). The difference in the slough percentage was significantly increased in the larval therapy group compared with the control groups at day 8 (67 versus 55 percent), but not at 15 or 30 days.",
"   </p>",
"   <p>",
"    The larvae can also be applied within a prefabricated &ldquo;biobag,&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef67885 \" href=\"UTD.htm?16/2/16423\">",
"     picture 2",
"    </a>",
"    ), commercially available outside the United States, that facilitates application and dressing change [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Randomized trials comparing &ldquo;free range&rdquo; with &ldquo;biobag&rdquo; contained larvae in the debridement of wounds have not been performed.",
"   </p>",
"   <p>",
"    A main disadvantage of larval therapy relates to negative perceptions about its use by patients and staff. One concern among patients is the possibility that the larvae can escape the dressing, although this rarely occurs. Although one study identified that about 50 percent of patients indicated they would prefer conventional wound therapy over maggot therapy, 89 percent of the patients randomly assigned to larval therapy said they would undergo larval treatment again [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/42\">",
"     42",
"    </a>",
"    ]. Pain associated with larval therapy may limit its use in about 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268740\">",
"    <span class=\"h1\">",
"     TOPICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268755\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors important for wound healing include platelet derived growth factor (PDGF), fibroblast growth factor (FGF) and granulocyte-macrophage colony stimulating factor (GM-CSF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link\">",
"     \"Wound healing and risk factors for non-healing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recombinant human growth factors have been developed and are being actively investigated for the treatment of chronic ulcers, mostly those affecting the lower extremity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet-derived growth factor &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/61/30675?source=see_link\">",
"       Becaplermin",
"      </a>",
"      is a platelet-derived growth factor (PDGF) gel preparation that promotes cellular proliferation and angiogenesis, and thereby improves wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/44\">",
"       44",
"      </a>",
"      ]. It is approved for use in the United States as an adjuvant therapy for the treatment of diabetic foot ulcers and is the only pharmacological agent approved for treatment of chronic wounds. The growth factor is delivered in a topical aqueous-based sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"       carboxymethylcellulose",
"      </a>",
"      gel. It is indicated for non-infected diabetic foot ulcers that extend into the subcutaneous tissue and have an adequate vascular supply [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/45\">",
"       45",
"      </a>",
"      ]. A black box warning mentions a concern for malignancy; however, the overall malignancy risk is believed to be low. Malignancy complications of this therapy may reflect usage of the agent in multiple courses of treatment, and possible selective transformation of wounds already at risk [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/46\">",
"       46",
"      </a>",
"      ]. A post-marketing study found an increased rate of mortality secondary to malignancy in patients treated with three or more tubes of becaplermin (3.9 versus 0.9 per 1000 person years) compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of diabetic foot lesions\", section on 'Growth factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidermal growth factor &ndash; In a study of chronic venous ulcers, topical application of human recombinant epidermal growth factor was associated with a greater reduction in ulcer size (7 versus 3 percent reduction) and higher ulcer healing rate (35 versus 11 percent) compared with placebo, but these differences were not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/49\">",
"       49",
"      </a>",
"      ]. Epithelialization was not significantly affected.",
"     </li>",
"     <li>",
"      Granulocyte-macrophage colony stimulating factor &ndash; Intradermal injections of granulocyte-macrophage colony stimulating factor (GM-CSF) promote healing of chronic leg ulcers, including venous ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. A trial that randomly assigned 60 patients with venous ulcers to four weekly injections with GM-CSF 200 mcg, 400 mcg, or placebo found significantly higher rates of healing at 13 weeks in the GM-CSF group (57, 61, and 19 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/51\">",
"       51",
"      </a>",
"      ]. GM-CSF has been used in various types of chronic wounds to promote healing [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369372661\">",
"    <span class=\"h2\">",
"     Antiseptics and antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most topically-applied antiseptic and antimicrobial products are irritating, partially cytotoxic leading to delayed healing and can cause contact sensitization. However, two of these agents may be associated with potential benefits in select populations:",
"   </p>",
"   <p>",
"    Cadexomer iodine (eg, Iodosorb) is an antimicrobial that reduces bacterial load within the wound and stimulates healing by providing a moist wound environment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/53\">",
"     53",
"    </a>",
"    ]. Cadexomer iodine is bacteriocidal to all gram-positive and gram-negative bacteria. For topical preparations, there is some evidence to suggest that Cadexomer iodine generates higher healing rates than standard care.",
"   </p>",
"   <p>",
"    Silver is toxic to bacteria.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     Silver sulfadiazine",
"    </a>",
"    (eg, Silvadene) is a topical antiseptic cream shown to decrease the incidence of sepsis in the treatment of cutaneous wounds, including partial thickness wounds, chronic wounds, skin graft donor sites, and burns. Silver impregnated dressings have not demonstrated significant benefits. A systematic review identified three trials that treated 847 participants with various silver-containing dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/54\">",
"     54",
"    </a>",
"    ]. One trial compared silver-containing foam (Contreet) with hydrocellular foam (Allevyn&trade;) in patients with leg ulcers. The second compared a silver-containing alginate (Silvercel&reg;) with an alginate alone (Algosteril&reg;). The third trial compared a silver-containing foam dressing (Contreet) with best local practice in patients with chronic wounds. Silver-containing foam dressings were not found to significantly improve ulcer healing at four weeks compared with non-silver-containing dressings for best local practices. Nevertheless, silver dressings are used by many clinicians to decrease the heavy bacterial surface contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268776\">",
"    <span class=\"h1\">",
"     WOUND DRESSINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a suitable dressing is applied to a wound and changed appropriately, the dressing can have a significant impact on the speed of wound healing, wound strength and function of the repaired skin, and cosmetic appearance of the resulting scar. No single dressing is perfect for all wounds; rather, a clinician should evaluate individual wounds and choose the best dressing on a case by case basis. In addition, wounds must be continually monitored, as their characteristics and dressing requirements change over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little clinical evidence to aid in the choice between the different types of wound dressings. Consensus opinion supports the following general principles for chronic wound management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrogels for the debridement stage",
"     </li>",
"     <li>",
"      Foam and low-adherence dressings for the granulation stage",
"     </li>",
"     <li>",
"      Hydrocolloid and low-adherence dressings for the epithelialization stage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all intents and purposes, dressings are best suited to manage the moisture level in and around the wound. Although some may have additional benefits in terms of local antimicrobial effects, odor control, or mild debridement ability, these are secondary benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dressings are typically changed once a day or every other day to avoid disturbing the wound healing environment. Because some dressings may impede some aspects of wound healing, they should be used with caution. As examples, alginate dressings with high calcium content may impede epithelialization by triggering premature terminal differentiation of keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/57\">",
"     57",
"    </a>",
"    ], and silver-impregnated dressings are cytotoxic and should not be used in the absence of significant infection. (See",
"    <a class=\"local\" href=\"#H369372661\">",
"     'Antiseptics and antimicrobials'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H456664393\">",
"     'Alginates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The advantages and disadvantages of the various dressing types are discussed below. (See",
"    <a class=\"local\" href=\"#H456665430\">",
"     'Common dressings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664428\">",
"    <span class=\"h2\">",
"     Importance of moisture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For much of the history of medicine, it was believed that wounds should not be occluded but left exposed to the air. However, an important study in a pig model showed that moist wounds healed more rapidly compared with wounds that dried out [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/59\">",
"     59",
"    </a>",
"    ]. Similar results have been obtained in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occluded wounds heal up to 40 percent more rapidly than non-occluded wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/60\">",
"     60",
"    </a>",
"    ]. This is thought to be due, in part, to easier migration of epidermal cells in the moist environment created by the dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/61\">",
"     61",
"    </a>",
"    ]. Another mechanism for improved wound healing may be the exposure of the wound to its own fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/63\">",
"     63",
"    </a>",
"    ]. Acute wound fluid is rich in metalloproteinases, platelet-derived growth factor, and basic fibroblast growth factor, which interact with one another and with other cytokines to stimulate healing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/64\">",
"     64",
"    </a>",
"    ]. On the other hand, the effect of chronic wound fluid on healing may not be beneficial. Chronic wound fluid is very different from acute wound fluid and contains persistently elevated levels of inflammatory cytokines which may inhibit proliferation of fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Excessive peri-wound edema and induration contributes to the development of chronic wound fluid and should be managed to minimize this effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link&amp;anchor=H1070222546#H1070222546\">",
"     \"Wound healing and risk factors for non-healing\", section on 'Phases of wound healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to faster wound healing, wounds treated with occlusive dressings are associated with less prominent scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/68\">",
"     68",
"    </a>",
"    ]. One study of porcine skin found an acceleration in the inflammatory and proliferative phases of healing when wounds were covered with an occlusive dressing as opposed to dry gauze [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/69\">",
"     69",
"    </a>",
"    ]. This &ldquo;acceleration&rdquo; through the wound phases may prevent the development of a chronic wound state which is typically arrested in the inflammatory phase of healing. Wounds that have a greater amount of inflammation tend to result in more significant scars, and thus the decreased inflammation and proliferation seen with wound occlusion may also decrease the appearance of the scar.",
"   </p>",
"   <p>",
"    An ideal dressing is one that has the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absorbs excessive wound fluid while maintaining a moist environment",
"     </li>",
"     <li>",
"      Protects the wound from further mechanical or caustic damage",
"     </li>",
"     <li>",
"      Prevents bacterial invasion or proliferation",
"     </li>",
"     <li>",
"      Conforms to the wound shape and eliminates dead space",
"     </li>",
"     <li>",
"      Debrides necrotic tissue",
"     </li>",
"     <li>",
"      Does not macerate the surrounding viable tissue",
"     </li>",
"     <li>",
"      Achieves hemostasis and minimizes edema through compression",
"     </li>",
"     <li>",
"      Does not shed fibers or compounds that could cause a foreign body or hypersensitivity reaction",
"     </li>",
"     <li>",
"      Eliminates pain during and between dressing changes",
"     </li>",
"     <li>",
"      Minimizes dressing changes",
"     </li>",
"     <li>",
"      Is inexpensive, readily available, and has a long shelf life",
"     </li>",
"     <li>",
"      Is transparent in order to monitor wound appearance without disrupting dressing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, a dressing with all of these characteristics is not available, and a clinician must decide which of these is most important in the case of a particular wound. The moisture content of a wound bed must be kept in balance for both acute and chronic wounds. The area should be moist enough to promote healing, but excess exudate must be absorbed away from the wound to prevent maceration of the healthy tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456665430\">",
"    <span class=\"h2\">",
"     Common dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dressings can be categorized based upon many characteristics, it is most useful to classify dressings by their water-retaining abilities because the primary goal of a dressing is the maintenance of moisture in the wound environment. As such, dressings are classified as open, semi-open or semi-occlusive.",
"   </p>",
"   <p>",
"    Open dressings include, primarily, gauze which is typically moistened with saline before placing it into the wound. Gauze bandages are available in multiple sizes including 2 x 2 inch and 4 x 4 inch square dressings and in 3 or 4 inch rolls (eg, Kerlix&trade;). Thicker absorbent pads (eg, ABD pads) are used to cover the gauze dressings. For managing large wounds, self adhesive straps (Montgomery straps) can be used to hold a bulky dressing in place. As discussed above, dried gauze dressings are discouraged. Wet-to-moist gauze dressings are useful for packing large soft-tissue defects until wound closure or coverage can be performed. Gauze dressings are inexpensive but often require frequent dressing changes.",
"   </p>",
"   <p>",
"    Semi-open dressings typically consist of fine mesh gauze impregnated with petroleum, paraffin wax, or other ointment and have product names such as Xeroform&trade;, Adaptic, Jelonet&trade;, and Sofra Tulle. This initial layer is covered by a secondary dressing of absorbent gauze and padding, then finally a third layer of tape or other method of adhesive. Benefits of semi-open dressings include their minimum expense and their ease of application. The main disadvantage of this type of dressing is that it",
"    <strong>",
"    </strong>",
"    does not maintain a moisture-rich environment or provide good exudate control. Fluid is permitted to seep through the first layer and is collected in the second layer, allowing for both desiccation of the wound bed and maceration of the surrounding tissue in contact with the secondary layer. Other disadvantages include the bulk of the dressing, its awkwardness when applied to certain areas, and the need for frequent changing.",
"   </p>",
"   <p>",
"    Semi-occlusive dressings come in a wide variety of occlusive properties, absorptive capacities, conformability and bacteriostatic activity. Semi-occlusive dressings include films, foams, alginates, hydrocolloids and hydrogels and are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664407\">",
"    <span class=\"h3\">",
"     Films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymer films are transparent sheets of synthetic self-adhesive dressing that are permeable to gases such as water vapor and oxygen but impermeable to larger molecules including proteins and bacteria. This property enables insensible water loss to evaporate, traps wound fluid enzymes within the dressing, and prevents bacterial invasion. These dressings are sometimes known as synthetic adhesive moisture-vapor-permeable dressings, and include Tegaderm&trade;, Cutifilm&reg;, Blisterfilm&trade;, and Bioclusive. Transparent film dressings were found to provide the fastest healing rates, lowest infection rates, and to be the most cost-effective method for dressing split-thickness skin graft donor sites in a review of 33 published studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/70\">",
"     70",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Advantages of these dressings include their ability to maintain moisture, encourage rapid re-epithelization, and their transparency and self-adhesive properties. Disadvantages of film dressings include limited absorptive capacity and they are not appropriate for moderately to heavily exudative wounds. If they are allowed to remain in place over a wound with heavy exudates, the surrounding skin is likely to become macerated. In addition, if the wound dries out, film dressings may adhere to the wound and be painful and damaging to remove.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664400\">",
"    <span class=\"h3\">",
"     Foams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foam dressings can be thought of as film dressings with the addition of absorbency. They consist of two layers, a hydrophilic silicone or polyurethane-based foam that lies against the wound surface, and a hydrophobic, gas permeable backing to prevent leakage and bacterial contamination. Some foams require a secondary adhesive dressing. Foams are marketed under names such as Allevyn&trade;, Adhesive, Lyofoam, and Spyrosorb.",
"   </p>",
"   <p>",
"    Advantages of foams include their high absorptive capacity and the fact that they conform to the shape of the wound and can be used to pack cavities. Disadvantages of foams include the opacity of the dressings and the fact that they may need to be changed each day. Foam dressings may not be appropriate on minimally exudative wounds, as they may cause desiccation.",
"   </p>",
"   <p>",
"    <br/>",
"    One small trial compared foams to films as dressings for skin tears in institutionalized adults and found that more complete healing occurred in the group using foams [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664393\">",
"    <span class=\"h3\">",
"     Alginates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural complex polysaccharides from various types of algae form the basis of alginate dressings. Their activity as dressings is unique because they are insoluble in water, but in the sodium-rich wound fluid environment these complexes exchange calcium ions for sodium ions and form an amorphous gel that packs and covers the wound. Alginates come in various forms including ribbons, beads, and pads. Their absorptive capacity ranges depending upon the type of polysaccharide used. In general, these dressings are more appropriate for moderately to heavily exudative wounds.",
"    <br/>",
"    <br/>",
"    Advantages of alginates include augmentation of hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], they can be used for wound packing, most can be washed away with normal saline in order to minimize pain during dressing changes, and they can stay in place for several days. Disadvantages of alginates are that they require a secondary dressing that must be removed in order to monitor the wound, they can be too drying on a minimally exudative wound, and they have an unpleasant odor.",
"   </p>",
"   <p>",
"    In a trial of 77 patients, patients with diabetic foot wounds were randomly assigned to alginate or petroleum gauze dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/74\">",
"     74",
"    </a>",
"    ]. Patients treated with alginates were found to have significantly superior granulation tissue coverage at four weeks of treatment, significantly less pain, and fewer dressing changes than the petroleum gauze group.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664386\">",
"    <span class=\"h3\">",
"     Hydrocolloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocolloid dressings usually consist of a gel or foam on a carrier of self-adhesive polyurethane film. The colloid composition of this dressing traps exudate and creates a moist environment. Bacteria and debris are also trapped, and washed away with dressing changes in a gentle, painless form of mechanical debridement. Another advantage of hydrocolloids is the ability to use them for packing wounds. Disadvantages include malodor and the potential need for daily dressing changes, and allergic contact dermatitis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/75\">",
"     75",
"    </a>",
"    ]. Hydrocolloid products include DuoDERM&reg;, Tegasorb&trade;, J and J Ulcer Dressing, and Comfeel&reg;.",
"    <br/>",
"    <br/>",
"    Cadexomer iodine is a type of hydrocolloid in which iodine is dispersed and slowly released after it comes in contact with wound fluid. The concentration of iodine released is low and does not cause tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/76\">",
"     76",
"    </a>",
"    ]. A multi-center trial found that over a 12-week period, Cadexomer iodine paste was more cost-effective than non-iodinated hydrocolloid dressing or paraffin gauze dressing in patients with exudating venous ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/77\">",
"     77",
"    </a>",
"    ]. A systematic review found some evidence that topical application of Cadexomer iodine enhanced venous ulcer healing rates compared with standard care (with and without compression) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/25\">",
"     25",
"    </a>",
"    ]. The treatment regimen was complex and it is unclear if the results are generalizable to most clinical settings. Iodine-induced hyperthyroidism has been documented with use of Cadexomer iodine for leg ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H369372661\">",
"     'Antiseptics and antimicrobials'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456664379\">",
"    <span class=\"h3\">",
"     Hydrogels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrogels are a matrix of various types of synthetic polymers with &gt;95 percent water formed into sheets, gels, or foams that are usually sandwiched between two sheets of removable film. The inner layer is placed against the wound, and the outer layer can be removed to make the dressing permeable to fluid. Sometimes a secondary adhesive dressing is needed. These unique matrices can absorb or donate water depending upon the hydration state of the tissue that surrounds them. Hydrogel products include Intrasite Gel&trade;, Vigilon&reg;, Carrington Gel, and Elastogel.",
"   </p>",
"   <p>",
"    <br/>",
"    Hydrogels are most useful for dry wounds. They initially lower the temperature of the wound environment they cover, which provides cooling pain relief for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/79\">",
"     79",
"    </a>",
"    ]. As a disadvantage, although there have been no reports of increased wound infection, hydrogels have been found to selectively permit gram-negative bacteria to proliferate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456665792\">",
"    <span class=\"h3\">",
"     Hydroactive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroactive, the most recently developed synthetic dressing, is a polyurethane matrix that combines the properties of a gel and a foam. Hydroactive selectively absorbs excess water while leaving growth factors and other proteins behind [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    A randomized trial compared hydroactive dressings with two different hydrocolloids and found the hydroactive dressing to be equally effective at promoting ulcer healing and alleviating ulcer-associated pain after 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/82\">",
"     82",
"    </a>",
"    ]. Another study found hydroactive dressings combined with enzymatic debridement to be more cost-efficient than gauze alone in dressing pressure ulcers and venous stasis ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456663840\">",
"    <span class=\"h1\">",
"     WOUND PACKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds with large soft-tissue defects may have an area of dead space between the surface of intact healthy skin and the wound base. These wounds are described as tunneled or undermined. Undermining is defined as extension of the wound under intact skin edges such that the wound measures larger at its base than is appreciated at the skin surface.",
"   </p>",
"   <p>",
"    When describing and documenting undermined wounds, it is important to accurately measure the depth of undermining in centimeters and location of undermining using clock formation as a guide (12:00, 6:00, etc.). The presence of necrotic tissue indicates the need for surgical debridement to decrease bacterial burden and prevent sequelae of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there have been no specific trials comparing packed versus unpacked wounds, wound packing is considered standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/84\">",
"     84",
"    </a>",
"    ]. Traditional gauze dressings are often used to pack wounds associated with significant dead space or undermining to aid in continuing debridement of devitalized tissue from the wound bed. The gauze is moistened with normal saline or tap water and placed into the wound and covered with dry layers of gauze. As the moistened gauze dries, it adheres to surface tissues, which are then removed when the dressing is changed. Dressing changes should be frequent enough that the gauze does not dry out completely, which can be two to three times daily. A disadvantage of gauze dressings is that they can also remove developing granulation tissue, resulting in reinjury. Thus, these dressings are discontinued when the necrotic tissue has been removed and granulation is occurring. An alternative to gauze dressing for managing wounds with significant dead space is negative pressure wound therapy. (See",
"    <a class=\"local\" href=\"#H55268832\">",
"     'Negative pressure wound therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many of the materials that are used as topical dressings for wounds (foams, alginates, hydrogels) can be molded into the shape of the wound and are useful for wound packing. As with their use in dressing wounds, there is little consensus over what constitutes the best material for wound packing. (See",
"    <a class=\"local\" href=\"#H55268776\">",
"     'Wound dressings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Wound dressing changes associated with large defects can be managed without repeated applications of tape to the skin by using Montgomery straps (",
"    <a class=\"graphic graphic_picture graphicRef69031 \" href=\"UTD.htm?9/32/9732\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268797\">",
"    <span class=\"h1\">",
"     WOUND CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure refers to the suture or staple closure of acute surgical or traumatic wounds after appropriate wound preparation (",
"    <a class=\"graphic graphic_figure graphicRef53921 \" href=\"UTD.htm?38/54/39785\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62583 \" href=\"UTD.htm?25/59/26554\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed primary closure achieves skin edge apposition following an interval of wound management. Delayed closure in abdominal wounds, chest wounds, and surgical wounds without evidence of infection is widely accepted (",
"    <a class=\"graphic graphic_figure graphicRef53921 \" href=\"UTD.htm?38/54/39785\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/85\">",
"     85",
"    </a>",
"    ]. However, a chronic wound should never be closed primarily. In contrast, delayed closure or coverage of chronic wounds is accepted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268832\">",
"    <span class=\"h2\">",
"     Negative pressure wound therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy enhances wound healing by reducing edema surrounding the wound, stimulating circulation, and increasing the rate of granulation tissue formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. The technique involves the application of a controlled subatmospheric pressure to a wound covered with a foam dressing. Negative pressure wound therapy is useful to manage large defects until closure can be performed. It has also been used with modest success in the treatment of pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/90-92\">",
"     90-92",
"    </a>",
"    ], and diabetic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/89,93\">",
"     89,93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452798128\">",
"    <span class=\"h1\">",
"     WOUND COVERAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268846\">",
"    <span class=\"h2\">",
"     Skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split-thickness and full-thickness skin grafts are the most basic biologic dressings and consist of skin taken from a donor site and grafted onto a wound on the same patient. Skin grafts are used for wound closure, to prevent fluid and electrolyte loss, and reduce bacterial burden and infection. Skin transplanted from one location to another on the same individual is termed an autogenous graft or autograft.",
"   </p>",
"   <p>",
"    Skin grafts are classified as either split-thickness or full-thickness, depending upon the amount of dermis included in the graft. A partial or split-thickness skin graft contains a variable thickness of dermis, while a full-thickness skin graft contains the entire dermis. The characteristics of normal skin are maintained with a thicker dermal component. However, thicker grafts require a more robust wound bed due to the greater amount of tissue that needs to be revascularized. The choice between full- and split-thickness skin grafting depends upon the condition of the wound, location, size, and need for cosmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/94\">",
"     94",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268853\">",
"    <span class=\"h3\">",
"     Full-thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full-thickness grafts contain the epidermis and dermis, and thus retain more of the characteristics of normal skin, including color, texture, and thickness, when compared with split-thickness grafts. Full-thickness skin grafts are limited to relatively small, uncontaminated, well-vascularized wounds. The skin used for full-thickness skin grafts is obtained from areas of redundant and pliable skin such as the groin, lateral thigh, lower abdomen, or lateral chest. Donor sites are usually closed primarily. The main disadvantages of full-thickness grafts include limited availability of donor skin and the potential for fluid accumulation beneath the graft.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268860\">",
"    <span class=\"h3\">",
"     Split-thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split-thickness skin grafts are commonly used tissue for wound coverage. A split-thickness skin graft includes the epidermis and a variable amount of dermis ranging between 0.008 to 0.012 inches (",
"    <a class=\"graphic graphic_picture graphicRef77019 \" href=\"UTD.htm?33/63/34802\">",
"     picture 3",
"    </a>",
"    ). Split-thickness skin grafts are further categorized as thin (0.005 to 0.012 inches), intermediate (0.012 to 0.018 inches), or thick (0.018 to 0.030 inches) based upon the thickness of graft harvested.",
"    <br/>",
"   </p>",
"   <p>",
"    Compared with full thickness skin grafts, split-thickness skin grafts tolerate a less-than-ideal wound bed and have a broader range of applications. They can be used to resurface large wounds, line cavities, resurface mucosal deficits, close donor sites of flaps, and resurface muscle flaps. They also are used to achieve temporary closure of wounds created by the removal of lesions that require pathologic examination prior to definitive reconstruction.",
"   </p>",
"   <p>",
"    Split thickness skin grafts can be meshed to provide coverage of a greater surface area at the recipient site, with expansion ratios generally ranging from 1:1 to 6:1. Split-thickness skin graft donor sites heal spontaneously with cells supplied by the remaining epidermal appendages. Donor sites can be re-harvested once healing is complete.",
"   </p>",
"   <p>",
"    Split-thickness grafts have disadvantages that need to be considered. Split-thickness grafts are more fragile, especially when placed over areas with little underlying soft tissue bulk for support. They contract more during healing, do not grow with the individual, and tend to be smoother and shinier than normal skin because of the absence of skin appendages in the graft. They also tend to be abnormally pigmented, either pale or white, or alternatively, hyperpigmented, particularly in darker-skinned individuals. For these reasons, split thickness skin grafts are more widely used for control of infection and prevention of",
"    <span class=\"nowrap\">",
"     fluid/electrolyte",
"    </span>",
"    loss rather than cosmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452797903\">",
"    <span class=\"h2\">",
"     Skin equivalents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human skin equivalent is",
"    <sup>",
"    </sup>",
"    a biologic dressing composed of a bilayered living-skin construct that contains an outer layer",
"    <sup>",
"    </sup>",
"    of live allogenic human keratinocytes and a second layer of",
"    <sup>",
"    </sup>",
"    live allogeneic fibroblasts on type 1 collagen dispersed in",
"    <sup>",
"    </sup>",
"    a dermal layer matrix. Both cell layers are grown from human",
"    <sup>",
"    </sup>",
"    infant foreskin. Human skin equivalent looks and feels like human skin and is a potent stimulator of wound healing.",
"   </p>",
"   <p>",
"    Skin equivalents can be used when traditional dressings have failed or are deemed inappropriate. One study has suggested that advanced biologics should be used when chronic wounds fail to heal at an appropriate rate of closure, (ie, 55 percent reduction in wound area within four weeks of treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/95\">",
"     95",
"    </a>",
"    ]. Human skin equivalent",
"    <sup>",
"    </sup>",
"    is ideal for the treatment for chronic ulcers because additional",
"    <sup>",
"    </sup>",
"    cells and growth factors are added to a deficient wound-healing environment.",
"    <sup>",
"    </sup>",
"    Accelerated wound healing reduces the risk of wound infection.",
"   </p>",
"   <p>",
"    These dressings are categorized based on the layer of skin from which they are derived:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermal skin equivalents are composed of dermal elements such as collagen and fibroblasts, which prevent wound contraction and provide greater stability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/96\">",
"       96",
"      </a>",
"      ]. Dermal skin substitutes include AlloDerm&reg;, which is made of decellularized allogenic dermal component, Integra&trade;, which is a bovine collagen-based dermal matrix, and Dermagraft-TC&trade;, which is a nylon mesh embedded with human fibroblast. Each of these has been used successfully for treating burn wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/97-99\">",
"       97-99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Composite skin equivalents use epidermal and dermal elements. Apligraf&reg; consists of bovine collagen and allogenic fibroblast and epidermal cells. Apligraf&reg; combined with compression therapy has been found to improve healing of venous stasis ulcers compared with compression therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/100\">",
"       100",
"      </a>",
"      ]. Clinical rejection has not been reported.",
"     </li>",
"     <li>",
"      Human skin equivalents have also been studied in patients with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/101-104\">",
"       101-104",
"      </a>",
"      ]. In one study of 208 patients with noninfected neuropathic ulcers, weekly application of Graftskin for four weeks improved the rate of complete wound healing compared with usual care (56 versus 38 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268902\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369375086\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy has been shown, in vitro, to have effects on wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/105\">",
"     105",
"    </a>",
"    ]. Endothelial progenitor cells play an important role in wound healing because they participate in the formation of new blood vessels in areas of hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/106\">",
"     106",
"    </a>",
"    ]. Although hyperoxia induced by hyperbaric oxygen effectively improves endothelial progenitor cells&rsquo; mobilization, therapy is not targeted to the wound site. Serious adverse events can be associated with hyperbaric oxygen therapy including seizures and pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link&amp;anchor=H2#H2\">",
"     \"Hyperbaric oxygen therapy\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When indicated, hyperbaric oxygen therapy is accomplished in a specialized chamber that allows for patient monitoring. Chamber pressure is typically maintained between 2.5 and 3.0 atmospheres of pressured oxygen or air. Therapy for nonhealing wounds generally consists of daily sessions of 1.5 to 2 hours for 20 to 40 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/105\">",
"     105",
"    </a>",
"    ]. The mechanisms and technique of hyperbaric oxygen therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyperbaric oxygen therapy\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperbaric oxygen has been used as an adjunct to wound care in the therapy of acute and chronic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/107-112\">",
"     107-112",
"    </a>",
"    ]. Most studies are observational and the few available trials are limited by small sample size and low quality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. A systematic review concluded that, although hyperbaric oxygen may benefit some types of wounds (eg, diabetic ulcers), there is insufficient evidence to support routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute injury &ndash; Hyperbaric oxygen therapy may be of value in patients with extensive soft tissue injury. A systematic review identified three trials evaluating the use of hyperbaric oxygen therapy in acute surgical and traumatic wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/117\">",
"       117",
"      </a>",
"      ]. Due to the small numbers of included patients and heterogeneity of patients treated, a metaanalysis could not be performed. The authors also noted a potential risk for bias. In one of the trials, 36 patients with crush injuries were randomly assigned to a 90 minute twice daily hyperbaric oxygen treatment or sham treatments for a total of six days postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/118\">",
"       118",
"      </a>",
"      ]. The group treated with hyperbaric oxygen had significantly more complete healing (17 versus 10 patients) and required fewer skin flaps, grafts, vascular surgery, or amputation (1 versus 6 patients). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19082?source=see_link&amp;anchor=H909588627#H909588627\">",
"       \"Surgical management of severe extremity injury\", section on 'Soft tissue debridement/coverage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fasciotomy wounds &ndash; Animal models of reperfusion following release of acute extremity compartment syndromes suggest that the hyperbaric oxygen therapy may be beneficial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=see_link&amp;anchor=H81875569#H81875569\">",
"       \"Patient management following extremity fasciotomy\", section on 'Hyperbaric oxygen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thermal injury &ndash; A systematic review of hyperbaric oxygen therapy in burn wounds found only two high quality trials and concluded that there was insufficient evidence to support the use of HBO following thermal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/119\">",
"       119",
"      </a>",
"      ]. The treatment of burn wounds is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic ulcers &ndash; Hyperbaric oxygen therapy has been used as an adjunct in the management of chronic, nonhealing wounds and ulcers due to venous insufficiency, diabetes, and peripheral artery disease. Support for hyperbaric oxygen therapy for venous or pressure ulcers, and wounds related to chronic ischemia (peripheral artery disease), is lacking. Although hyperbaric oxygen therapy has been associated with more rapid ulcer healing in patients with diabetes, the indications for hyperbaric oxygen in the treatment of nonhealing diabetic foot ulcers remains uncertain. Hyperbaric oxygen therapy for the management of diabetic foot ulceration is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link&amp;anchor=H26#H26\">",
"       \"Management of diabetic foot lesions\", section on 'Hyperbaric oxygen therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compromised skin grafts and flaps &ndash; Hyperbaric oxygen therapy may improve the survival of skin grafts and reconstructive flaps that have compromised blood flow, thereby preventing tissue breakdown and the development of wounds. Patients who require skin grafting or reconstructive flaps in areas with local vascular compromise, previous radiation therapy, or in sites of previous graft failure may benefit from prophylactic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=see_link&amp;anchor=H259477919#H259477919\">",
"       \"Principles of grafts and flaps for reconstructive surgery\", section on 'Vascular compromise'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link&amp;anchor=H14#H14\">",
"       \"Hyperbaric oxygen therapy\", section on 'Radiation injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369376015\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other therapies, such as low frequency ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/120,121\">",
"     120,121",
"    </a>",
"    ], electrical stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/122-125\">",
"     122-125",
"    </a>",
"    ], electromagnetic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/126\">",
"     126",
"    </a>",
"    ], and phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/127\">",
"     127",
"    </a>",
"    ], have been investigated primarily for the treatment of pressure ulcers or chronic venous wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/128-132\">",
"     128-132",
"    </a>",
"    ]. The treatment of pressure ulcers and chronic venous wounds are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link\">",
"     \"Treatment of pressure ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268937\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPECIFIC WOUNDS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple laceration &ndash; Simple traumatic lacerations may be cleaned and closed primarily with either staples or sutures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"       \"Closure of skin wounds with sutures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=see_link\">",
"       \"Closure of minor skin wounds with staples\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complicated laceration &ndash; Following cleansing of the wound and debridement, an attempt is often made to close more complicated lacerations. It is not uncommon for the irregular skin edges or skin at sites where lacerations meet to break down. Plastic surgery techniques may be needed to provide an acceptable cosmetic and functional result. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"       \"Z-plasty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large tissue defect &ndash; Large tissue defects can result from traumatic wounds or the need to remove devitalized tissue due to infection (eg, Fournier&rsquo;s gangrene). Once the debridement is completed, the wound can be packed open with wet to moist saline gauze dressings or using negative pressure wound therapy until the wound bed allows for skin graft or flap closure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/63/27642/abstract/89\">",
"       89",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"       \"Z-plasty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burns &ndash; Burn wound care depends on many factors including the depth of the burn and anatomic locations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H23#H23\">",
"       \"Emergency care of moderate and severe thermal burns in adults\", section on 'Wound management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"       \"Principles of burn reconstruction: Overview of surgical procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pressure ulcers &ndash; The treatment of pressure ulcers depends upon the stage of the ulcer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of pressure ulcers\", section on 'Ulcer treatment by stage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetic foot ulcer &ndash; The management of diabetic foot ulcers varies depending on the grade of ulcer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"       \"Management of diabetic foot lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous ulcer &ndash; The mainstay of treatment for venous ulcerations is compression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemic ulcerations and gangrene &ndash; The presence of ischemia influences the timing of debridement and definitive intervention. When faced with wet gangrene or abscess, the wound should be debrided immediately regardless of the need for revascularization. The dressing choice depends upon the level of anticipated drainage and size of the wound. Dead space is usually managed with gauze packing. If revascularization is required, the leg should be performed as soon as possible thereafter.",
"      <br/>",
"      <br/>",
"      However, if dry gangrene without cellulitis is present, the limb should be revascularized first. The primary goal for the dressing is to protect a wound, thereby reducing the risk for infection or trauma. To accomplish this, the wound is wrapped with a bulky dry gauze bandage, lightly wrapped so as not to aggravate the level ischemia. Following revascularization, the wound is monitored closely for signs of healing or instability that indicate a need for debridement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55268944\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For optimal wound healing, the wound bed needs to be well vascularized, free of devitalized tissue, clear of infection, and moist. (See",
"      <a class=\"local\" href=\"#H55268705\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound dressings should be chosen based upon their ability to manage dead space, control exudate, reduce pain during dressing changes (as applicable), prevent bacterial overgrowth, ensure proper fluid balance, be cost-efficient, and be manageable for the patient or nursing staff. (See",
"      <a class=\"local\" href=\"#H456663840\">",
"       'Wound packing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H55268776\">",
"       'Wound dressings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sharp surgical debridement over nonsurgical methods for the initial debridement of devitalized tissue associated with acute and chronic wounds or ulcers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H55268712\">",
"       'Wound debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical agents such as antiseptics and antimicrobial agents can be used to control locally heavy contamination. Significant improvements in rates of wound healing have not been found and tissue toxicity may be a significant disadvantage. (See",
"      <a class=\"local\" href=\"#H369372661\">",
"       'Antiseptics and antimicrobials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For deep wounds, negative pressure wound therapy may protect the wound and reduce the complexity and depth of the defect. Negative pressure wound therapy is frequently used to manage complex wounds prior to definitive closure. (See",
"      <a class=\"local\" href=\"#H55268832\">",
"       'Negative pressure wound therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following wound bed preparation, acute wounds can often be closed primarily. Chronic wounds that demonstrate progressive healing as evidenced by granulation tissue and epithelialization along the wound edges can undergo delayed closure or coverage with skin grafts or bioengineered tissues. (See",
"      <a class=\"local\" href=\"#H55268797\">",
"       'Wound closure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H452798128\">",
"       'Wound coverage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many other therapies have been used with the aim of enhancing wound healing and include hyperbaric oxygen therapy, and wound stimulation using ultrasound, electrical, and electromagnetic energy. Some of these therapies have shown a marginal benefit in randomized studies, and may be useful as adjuncts for wound healing. (See",
"      <a class=\"local\" href=\"#H55268902\">",
"       'Adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/1\">",
"      Atiyeh BS, Ioannovich J, Al-Amm CA, El-Musa KA. Management of acute and chronic open wounds: the importance of moist environment in optimal wound healing. Curr Pharm Biotechnol 2002; 3:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/2\">",
"      Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003; 11 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/3\">",
"      Golinko MS, Clark S, Rennert R, et al. Wound emergencies: the importance of assessment, documentation, and early treatment using a wound electronic medical record. Ostomy Wound Manage 2009; 55:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/4\">",
"      Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 2006; 117:212S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/5\">",
"      Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract 2006; 12 Suppl 3:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/6\">",
"      Ross R, Everett NB, Tyler R. Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J Cell Biol 1970; 44:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/7\">",
"      Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007; 257:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/8\">",
"      Stevenson TR, Thacker JG, Rodeheaver GT, et al. Cleansing the traumatic wound by high pressure syringe irrigation. JACEP 1976; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/9\">",
"      Rodeheaver G, Pettry D, Turnbull V, et al. Identification of the wound infection-potentiating factors in soil. Am J Surg 1974; 128:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/10\">",
"      Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/11\">",
"      Moscati RM, Reardon RF, Lerner EB, Mayrose J. Wound irrigation with tap water. Acad Emerg Med 1998; 5:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/12\">",
"      Loeb T, Loubert G, Templier F, Pasteyer J. [Iatrogenic gas embolism following surgical lavage of a wound with hydrogen peroxide]. Ann Fr Anesth Reanim 2000; 19:108.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ncbi.nlm.nih.gov/books/NBK12202/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/14\">",
"      Mote GA, Malay DS. Efficacy of power-pulsed lavage in lower extremity wound infections: a prospective observational study. J Foot Ankle Surg 2010; 49:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/15\">",
"      Wheeler CB, Rodeheaver GT, Thacker JG, et al. Side-effects of high pressure irrigation. Surg Gynecol Obstet 1976; 143:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/16\">",
"      Tabor OB Jr, Bosse MJ, Hudson MC, et al. Does bacteremia occur during high pressure lavage of contaminated wounds? Clin Orthop Relat Res 1998; :117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/17\">",
"      Brem H, Stojadinovic O, Diegelmann RF, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med 2007; 13:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/18\">",
"      Armstrong DG, Lavery LA, Nixon BP, Boulton AJ. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. Clin Infect Dis 2004; 39 Suppl 2:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/19\">",
"      Cardinal M, Eisenbud DE, Armstrong DG, et al. Serial surgical debridement: a retrospective study on clinical outcomes in chronic lower extremity wounds. Wound Repair Regen 2009; 17:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/20\">",
"      Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/21\">",
"      Schiffman J, Golinko MS, Yan A, et al. Operative debridement of pressure ulcers. World J Surg 2009; 33:1396.",
"     </a>",
"    </li>",
"    <li>",
"     Robson, MC. Treating bacterial infections in chronic wounds. Contemp Surg Suppl 2000; Sept:9.",
"    </li>",
"    <li>",
"     Sieggreen, MY, Maklebust, J. Debridement: choices and challenges. Adv Wound Care 1997; 10:32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/24\">",
"      Klasen HJ. A review on the nonoperative removal of necrotic tissue from burn wounds. Burns 2000; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     O'Meara, S, Al-Kurdi, D, Ovington, LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2008; :CD003557.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/26\">",
"      Demidova-Rice TN, Geevarghese A, Herman IM. Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing in vitro. Wound Repair Regen 2011; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/27\">",
"      Paul AG, Ahmad NW, Lee HL, et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J 2009; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/28\">",
"      Andersen AS, Sandvang D, Schnorr KM, et al. A novel approach to the antimicrobial activity of maggot debridement therapy. J Antimicrob Chemother 2010; 65:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/29\">",
"      Sherman RA, Wyle F, Vulpe M. Maggot therapy for treating pressure ulcers in spinal cord injury patients. J Spinal Cord Med 1995; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/30\">",
"      Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Repair Regen 2002; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/31\">",
"      Margolin L, Gialanella P. Assessment of the antimicrobial properties of maggots. Int Wound J 2010; 7:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/32\">",
"      Opletalov&aacute; K, Blaizot X, Mourgeon B, et al. Maggot therapy for wound debridement: a randomized multicenter trial. Arch Dermatol 2012; 148:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/33\">",
"      Sherman RA, Shapiro CE, Yang RM. Maggot therapy for problematic wounds: uncommon and off-label applications. Adv Skin Wound Care 2007; 20:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/34\">",
"      Steenvoorde P, Jukema GN. The antimicrobial activity of maggots: in-vivo results. J Tissue Viability 2004; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/35\">",
"      Dumville JC, Worthy G, Soares MO, et al. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers. Health Technol Assess 2009; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/36\">",
"      Soares MO, Iglesias CP, Bland JM, et al. Cost effectiveness analysis of larval therapy for leg ulcers. BMJ 2009; 338:b825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/37\">",
"      Wayman J, Nirojogi V, Walker A, et al. The cost effectiveness of larval therapy in venous ulcers. J Tissue Viability 2000; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/38\">",
"      Gottrup F, J&oslash;rgensen B. Maggot debridement: an alternative method for debridement. Eplasty 2011; 11:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/39\">",
"      Blake FA, Abromeit N, Bubenheim M, et al. The biosurgical wound debridement: experimental investigation of efficiency and practicability. Wound Repair Regen 2007; 15:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/40\">",
"      Grassberger M, Fleischmann W. The biobag - a new device for the application of medicinal maggots. Dermatology 2002; 204:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/41\">",
"      Steenvoorde P, Jacobi CE, Oskam J. Maggot debridement therapy: free-range or contained? An in-vivo study. Adv Skin Wound Care 2005; 18:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/42\">",
"      Spilsbury K, Cullum N, Dumville J, et al. Exploring patient perceptions of larval therapy as a potential treatment for venous leg ulceration. Health Expect 2008; 11:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/43\">",
"      Steenvoorde P, Budding T, Oskam J. Determining pain levels in patients treated with maggot debridement therapy. J Wound Care 2005; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/44\">",
"      Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/45\">",
"      Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/infopage/becaplermin/regranex_dhcp.pdf. Accessed March 5, 2009.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121631.htm (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     file://www.regranex.com/ (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/49\">",
"      Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/50\">",
"      Marques da Costa R, Jesus FM, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 1997; 173:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/51\">",
"      Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M. Randomized, double-blind, placebo-controlled, dose- ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/52\">",
"      Zhang L, Chen J, Han C. A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns. Wound Repair Regen 2009; 17:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/53\">",
"      Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009; 49:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/54\">",
"      Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev 2007; :CD005486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/55\">",
"      Woo KY, Ayello EA, Sibbald RG. SILVER versus other antimicrobial dressings: best practices! Surg Technol Int 2008; 17:50.",
"     </a>",
"    </li>",
"    <li>",
"     Brem H, Kirsner, R, Falanga, V. Protocol for the successful treatment of venous ulcers. Am J Surg 2004; 188:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/57\">",
"      Paddle-Ledinek JE, Nasa Z, Cleland HJ. Effect of different wound dressings on cell viability and proliferation. Plast Reconstr Surg 2006; 117:110S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/58\">",
"      Jeffcoate WJ, Price P, Harding KG, International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/59\">",
"      WINTER GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 1962; 193:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/60\">",
"      Eaglstein WH. Experiences with biosynthetic dressings. J Am Acad Dermatol 1985; 12:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/61\">",
"      Svensj&ouml; T, Pomahac B, Yao F, et al. Accelerated healing of full-thickness skin wounds in a wet environment. Plast Reconstr Surg 2000; 106:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/62\">",
"      Vogt PM, Andree C, Breuing K, et al. Dry, moist, and wet skin wound repair. Ann Plast Surg 1995; 34:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/63\">",
"      Ovington LG. Hanging wet-to-dry dressings out to dry. Home Healthc Nurse 2001; 19:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/64\">",
"      Chen WY, Rogers AA, Lydon MJ. Characterization of biologic properties of wound fluid collected during early stages of wound healing. J Invest Dermatol 1992; 99:559.",
"     </a>",
"    </li>",
"    <li>",
"     Trengrove, NJ, Bielefedlt-Ohmann, H, Stacey, MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Regen 2000; 8:13.",
"    </li>",
"    <li>",
"     Tranuzzer, RW, Schultz, G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Reg 1996; 4:321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/67\">",
"      Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen 1993; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/68\">",
"      HINMAN CD, MAIBACH H. EFFECT OF AIR EXPOSURE AND OCCLUSION ON EXPERIMENTAL HUMAN SKIN WOUNDS. Nature 1963; 200:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/69\">",
"      Dyson M, Young S, Pendle CL, et al. Comparison of the effects of moist and dry conditions on dermal repair. J Invest Dermatol 1988; 91:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/70\">",
"      Rakel BA, Bermel MA, Abbott LI, et al. Split-thickness skin graft donor site care: a quantitative synthesis of the research. Appl Nurs Res 1998; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     Thomas, DR, Goode, PS, LaMaster, K, et al. A comparison of an opaque foam dressing versus a transparent film dressing in the management of skin tears in institutionalized subjects. Ostomy Wound Manage 1999; 45:22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/72\">",
"      Blair SD, Jarvis P, Salmon M, McCollum C. Clinical trial of calcium alginate haemostatic swabs. Br J Surg 1990; 77:568.",
"     </a>",
"    </li>",
"    <li>",
"     Placquadio, D, Nelson, DB. Alginates: a \"new\" dressing alternative. J Dermatol Surg Oncol 1992; 18:90.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/74\">",
"      Lalau JD, Bresson R, Charpentier P, et al. Efficacy and tolerance of calcium alginate versus vaseline gauze dressings in the treatment of diabetic foot lesions. Diabetes Metab 2002; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/75\">",
"      Grange-Prunier A, Couilliet D, Grange F, Guillaume JC. [Allergic contact dermatitis to the Comfeel hydrocolloid dressing]. Ann Dermatol Venereol 2002; 129:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/76\">",
"      Zhou LH, Nahm WK, Badiavas E, et al. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol 2002; 146:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/77\">",
"      Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol 1998; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/78\">",
"      Michanek A, Hansson C, Berg G, M&aring;nesk&ouml;ld-Claes A. [Iodine-induced hyperthyroidism after cadexomer iodine treatment of leg ulcers]. Lakartidningen 1998; 95:5755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/79\">",
"      Coats TJ, Edwards C, Newton R, Staun E. The effect of gel burns dressings on skin temperature. Emerg Med J 2002; 19:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/80\">",
"      Menaker GM. Wound dressings for office-based surgery. Facial Plast Surg 2004; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/81\">",
"      Achterberg V, Meyer-Ingold W. Hydroactive dressings and serum proteins: an in vitro study. J Wound Care 1996; 5:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/82\">",
"      Charles H, Callicot C, Mathurin D, et al. Randomised, comparative study of three primary dressings for the treatment of venous ulcers. Br J Community Nurs 2002; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/83\">",
"      Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341:738.",
"     </a>",
"    </li>",
"    <li>",
"     Ovington, LG. Dressings and adjunctive therapies: ACHPR guidelines revisited. Ostomy Wound Manag 1999; 45(1A Suppl):94S.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/85\">",
"      Kimball EJ, Adams DM, Kinikini DV, et al. Delayed abdominal closure in the management of ruptured abdominal aortic aneurysm. Vascular 2009; 17:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/86\">",
"      Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997; 38:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/87\">",
"      Joseph, E, Hamori, CA, Bergman, S, et al. A prospective randomized trial of vacuum-assisted closure versus standard therapy of chronic nonhealing wounds. Wounds 2000; 12:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/88\">",
"      Mendez-Eastman S. Guidelines for using negative pressure wound therapy. Adv Skin Wound Care 2001; 14:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/89\">",
"      Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 366:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/90\">",
"      Bello YM, Phillips TJ. Recent advances in wound healing. JAMA 2000; 283:716.",
"     </a>",
"    </li>",
"    <li>",
"     Evans, D, Land, L. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2001; :CD001898.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/92\">",
"      Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg 2008; 95:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/93\">",
"      Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     Wood, B. Skin, Grafts. Retrieved 2010, from Emedicine plastic surgery: file://emedicine.medscape.com/article/1295109-overview",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/95\">",
"      Sheehan P, Jones P, Giurini JM, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg 2006; 117:239S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/96\">",
"      Bergemann R, Lauterbach KW, Vanscheidt W, et al. Economic evaluation of the treatment of chronic wounds: hydroactive wound dressings in combination with enzymatic ointment versus gauze dressings in patients with pressure ulcer and venous leg ulcer in Germany. Pharmacoeconomics 1999; 16:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/97\">",
"      Cuono C, Langdon R, McGuire J. Use of cultured epidermal autografts and dermal allografts as skin replacement after burn injury. Lancet 1986; 1:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/98\">",
"      Heimbach D, Luterman A, Burke J, et al. Artificial dermis for major burns. A multi-center randomized clinical trial. Ann Surg 1988; 208:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/99\">",
"      Purdue GF. Dermagraft-TC pivotal efficacy and safety study. J Burn Care Rehabil 1997; 18:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/100\">",
"      Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/101\">",
"      Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/102\">",
"      Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/103\">",
"      Edmonds M, Bates M, Doxford M, et al. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev 2000; 16 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/104\">",
"      Barber C, Watt A, Pham C, et al. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes. J Wound Care 2008; 17:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/105\">",
"      Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011; 127 Suppl 1:131S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/106\">",
"      Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/107\">",
"      Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/108\">",
"      Wattel F, Mathieu D, Nevi&egrave;re R, Bocquillon N. Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation. Anaesthesia 1998; 53 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/109\">",
"      Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998; 317:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/110\">",
"      Oriani, G, Meazza, D, Favales, F, et al. Hyperbaric therapy in diabetic gangrene. J Hyperb Med 1990; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/111\">",
"      Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plast Reconstr Surg 1994; 93:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/112\">",
"      L&ouml;ndahl M, Katzman P, Nilsson A, et al. A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers. J Wound Care 2006; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/113\">",
"      Kessler L, Bilbault P, Ort&eacute;ga F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003; 26:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/114\">",
"      Duzgun AP, Satir HZ, Ozozan O, et al. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg 2008; 47:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/115\">",
"      Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/116\">",
"      Wang C, Schwaitzberg S, Berliner E, et al. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003; 138:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/117\">",
"      Eskes A, Ubbink DT, Lubbers M, et al. Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds. Cochrane Database Syst Rev 2010; :CD008059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/118\">",
"      Bouachour G, Cronier P, Gouello JP, et al. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma 1996; 41:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/119\">",
"      Villanueva E, Bennett MH, Wasiak J, Lehm JP. Hyperbaric oxygen therapy for thermal burns. Cochrane Database Syst Rev 2004; :CD004727.",
"     </a>",
"    </li>",
"    <li>",
"     Flemming, K, Cullum, N. Therapeutic ultrasound for pressure sores. Cochrane Database Syst Rev 2000; :CD001275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/121\">",
"      Voigt J, Wendelken M, Driver V, Alvarez OM. Low-frequency ultrasound (20-40 kHz) as an adjunctive therapy for chronic wound healing: a systematic review of the literature and meta-analysis of eight randomized controlled trials. Int J Low Extrem Wounds 2011; 10:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/122\">",
"      Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: a meta-analysis. Wound Repair Regen 1999; 7:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/123\">",
"      Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997; 20:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/124\">",
"      Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil 2001; 82:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/125\">",
"      Sebastian A, Syed F, Perry D, et al. Acceleration of cutaneous healing by electrical stimulation: degenerate electrical waveform down-regulates inflammation, up-regulates angiogenesis and advances remodeling in temporal punch biopsies in a human volunteer study. Wound Repair Regen 2011; 19:693.",
"     </a>",
"    </li>",
"    <li>",
"     Flemming, K, Cullum, N. Electromagnetic therapy for the treatment of pressure sores. Cochrane Database Syst Rev 2001; :CD002930.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/127\">",
"      Fulop AM, Dhimmer S, Deluca JR, et al. A meta-analysis of the efficacy of phototherapy in tissue repair. Photomed Laser Surg 2009; 27:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/128\">",
"      Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/129\">",
"      Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/130\">",
"      Mustoe TA, Cutler NR, Allman RM, et al. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/131\">",
"      Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/63/27642/abstract/132\">",
"      Landi F, Aloe L, Russo A, et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med 2003; 139:635.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15912 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C3C4DA4C00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27642=[""].join("\n");
var outline_f26_63_27642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H55268944\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268705\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20794882\">",
"      MEDICAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20794890\">",
"      Role of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20794898\">",
"      Control of blood sugar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268712\">",
"      WOUND DEBRIDEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456665404\">",
"      Irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456663268\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55268733\">",
"      Enzymatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361001514\">",
"      Biologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268740\">",
"      TOPICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55268755\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369372661\">",
"      Antiseptics and antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268776\">",
"      WOUND DRESSINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456664428\">",
"      Importance of moisture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456665430\">",
"      Common dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456664407\">",
"      - Films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456664400\">",
"      - Foams",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456664393\">",
"      - Alginates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456664386\">",
"      - Hydrocolloids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456664379\">",
"      - Hydrogels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456665792\">",
"      - Hydroactive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H456663840\">",
"      WOUND PACKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268797\">",
"      WOUND CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55268832\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452798128\">",
"      WOUND COVERAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55268846\">",
"      Skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55268853\">",
"      - Full-thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55268860\">",
"      - Split-thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452797903\">",
"      Skin equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268902\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369375086\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369376015\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268937\">",
"      MANAGEMENT OF SPECIFIC WOUNDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55268944\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15912|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/54/39785\" title=\"figure 1\">",
"      Types of wound healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/59/26554\" title=\"figure 2\">",
"      Healing by primary and secondary intention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15912|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/32/9732\" title=\"picture 1\">",
"      Montgomery straps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/2/16423\" title=\"picture 2\">",
"      Treatment of necrotic tissue with maggots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34802\" title=\"picture 3\">",
"      Harvested STSG meshed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15912|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/26/36256\" title=\"movie 1\">",
"      Biologic debridement with larvae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15912|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/62/40940\" title=\"table 1\">",
"      Enzymatic debriding agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32070?source=related_link\">",
"      Overview and management strategies for the combined burn trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=related_link\">",
"      Patient management following extremity fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=related_link\">",
"      Principles of grafts and flaps for reconstructive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19082?source=related_link\">",
"      Surgical management of severe extremity injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=related_link\">",
"      Susceptibility to infections in persons with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_63_27643="CF risk after mutation analysis";
var content_f26_63_27643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of cystic fibrosis based upon mutation analysis for carrier status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Proportion of cystic fibrosis cases in the population caused by detectable mutations",
"      </td>",
"      <td class=\"subtitle1\">",
"       Carrier risk for person with negative test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       1 in 25.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       1 in 82.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       1 in 99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       1 in 126",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       85",
"      </td>",
"      <td>",
"       1 in 165",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       90",
"      </td>",
"      <td>",
"       1 in 246",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       1 in 491",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Carrier risk by detectable mutations in screening panel. The degree to which the risk of disease is reduced is determined by the number of mutations screened. For example, if a Caucasian patient of Northern European descent does not carry the &Delta;F508 mutation, her risk of being a CF carrier is reduced from about 1 in 25 (the a priori risk based solely on ethnic origin) to 1 in 99, since &Delta;F508 accounts for 75 percent of all CF cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elias, S, Annas, GJ, Simpson, JL. Carrier screening for cystic fibrosis: Implications for obstetric and gynecologic practice. Am J Obstet Gynecol 1991; 164:1077. Copyright &copy; 1991 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27643=[""].join("\n");
var outline_f26_63_27643=null;
var title_f26_63_27644="Abnormalities cirrhotic ascites";
var content_f26_63_27644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Circulatory, vascular, functional, and biochemical abnormalities in patients with cirrhosis and ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Circulatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduced systemic vascular resistance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduced arterial pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased heart rate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased cardiac index",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased plasma volume",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduced renal blood flow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased portal blood flow",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splanchnic vasodilation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal artery vasoconstriction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary vasodilation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Functional",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Activation of systemic vasodilator factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Activation of systemic vasoconstrictor factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Activation of renal vasodilator factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduced glomerular filtration rate",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Biochemical",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sodium retention",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water retention",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased systemic nitric oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased systemic prostaglandins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased renal nitric oxide and prostaglandins",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27644=[""].join("\n");
var outline_f26_63_27644=null;
var title_f26_63_27645="Ceftriaxone CSF concentrations in serum and cerebrospinal fluid of infants and children";
var content_f26_63_27645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ceftriaxone drug concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 308px; background-image: url(data:image/gif;base64,R0lGODlhwAE0AeYAAP///4CAgP8AAAAAAABmMwAz/0Bm/0CMZoCzmcDN/4CZ/8DAwP+AgP9AQP/AwMDZzUBAQP9gYP/w8GCA/7DQwP8wMKCz/+Dg4KDGs/+QkBBA/3CpjRBwQPDz/zAwMCB5Tf9wcODs5hAQEPDw8P/Q0P+wsJCQkKCgoGCggFCWc1Bz/zBZ//D28yAgIP8QENDZ/zCDWeDm/7CwsNDj2SBN/9DQ0HBwcFBQUJC8ppCm/3CN/7DA//+goK+//w8//5+y///g4P9QUP8gIGBgYL/M/8/Y/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADAATQBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/ssXFowYdMFEABkEDSIUNOJEgBMD/0mcSGqEDA8DFgi6IEIERhsAOHocABIARggDPFBcyZLTggEwNQKwMcAEABEDRtC0idPigBsAbgxY2LKoUUkoZSYFkHRp0gADAgCAKhXAggBYA8g8yrUr04yCnGYUezXqVLNWs0Ko6rVty6VB/4eaHFBDKEKMNUyQnFnTEFa3gCeOWIDRRA0AJ37KGNACsWLGIRkvaDHggl+2gTPrewlzAARBNnB6ODxTNOkTlFucOPRXs+vXrDHDnq25Ne3bgW3j3t1VN+/fLX0DHy5ROPHj+4wjX25POfPn8ZxDn85OOvXr56xj3y5OO/fv3byDH49NPPnz08yjX+9MPfv3ydzDn09MPv37v+zj369LP///tfgH4ICwCEjggasYiOCCpijI4IOhOAjhhJxISOGFl1iI4YaSaMjhh414COKIiIhI4omDmIjiiSquOGKLLn4IY4wbzkjjhdJJ0IAAAjQgwY1ApihbIRHwyGMEQQYpnf+RRiYJ5JJMCuDkjVAyOSWN0hVpJJJXupjjjgII0UCXXg6JiAQVcEkmieYB4QIPa7JpZiIkCEBCnCC6x4MLQODJoXwRVPCjnzjOuUgDEUigpQCJEoqgfRII4UKUYzpKoH51RimlpQP6p6kAcHL6n39gGlmBEEIwwACcIBgJgqjr+afolj/yoKqkUb4KK3ktflrCoLty16umOwoRQQZ3BkvdsFEKQkIGEQjRIwO/Krtci60yqSshEpTAQLHHJmstbzBmK8C2dEIrbQPUAgGmj+PWZqgr3X5LabyZ2XiJpmlm4AC+XulriaYOQFuBAP3+CzBLAldSao+FFBwowscqvHD/Pw1ToiOP8CYi8cEJX5xPxpb0CcnHFPsr8jwks4JyyCtXNy80L1ccc3YzU1OzyjeD07IuO/9rLro94zKYZRspNEhDD0VUyM++oJxr0bksIFRVIn0kyEkpxdbOpxEw4ACwVMfSWVU73ZTTYkDZddnXmhocZhBik112gmiRRdVZQ0IdzKeEOMADCMXSPfbdqez9lUZPmaX4VVit1Y65PBJNCAmD7+gCuyWYjHiEaLmNl14gpZ1W5DmLM/QjmBPuwubtfu7SEAMMoVFiNyzW2AWSUYY0IX5rA4S3DbzOLg/iyj5JZzCBZpogqDG22tteDf/tpA2AgLzyqgQ/DhAOMBDE/7raJ889KN6fI0H446c89qKNnm9J+uusL/7B98pfCf3vfGq45/pzBP/c8anMCQB22wugIgbYjodBbBDWa8C6bKZA4KXuNbM6kt24Fb6JVcBwG5QdAylSMMIdkHPmK9sIi0IC4mFPexbr2Qq7Yr/2palu0vAWtYYzw8BIrFicA2AGGRXCXKCpRwdjAHB6+BrMXW9z2nNgpXzBgHM5qwQAAEIEEHWn8GHOAeHrUxiBQK0ttjB7xbkgg6wXBMD9ggccY8Cd3FQBBrwOAFWclKoE8K8qgpFjB0QVqP7BxN98CmHs8lcRZWFHI/EgA4yyV/gEgEU88tGSf1TijgDgAAEo0f8fheSNFDnprSC8i24liOErBkWCVrErkqoi4yUxiclOalJKtiSkGic0xPgVYn0Z+NbBoCi2FJriWzxwQJHkiLBUgoAEfhQEJOsorUwCYJO5BOUunUSC8LkOkQxQZCkcAKZUCaIE+KuALBW2sQ/yMZfY9KQuF+aAUp6SWqrs1DY5BUxhnhAExRzVPq3VTQZ8swKJPNx7Qrmheorvnqnk1UCL1s8GDDN7AV3WRGVX0IMmdJG3YWiXHGpKjqEyn7ARqZ8qelGAOsCYbVEprDpaPHCKM2AbraAkSArRf/USpPSQ6cpY+qkpJienOu2EG/kh1LIt9ahJlcUoMYbUqGrip9r/tOp8mqpVllW1q7/hKljhIdaxuqOsZpVZWs+D1rWmo61uxVlcwQPXuZKjrnbtzlfzmq+98hUweP2rNwIrWG4QtrDaOCxiy+PXxR5FsY6tBmQjm57GUpZhlr0sRSar2WdwtrPN+CxolyHa0cYns6ZlKmpTq4/SsrYYrn3tMGIr22DQtrb5WS1ug6rb3crjtr7dBXCDm4vhErcUR1uaQyDitePuw2pomQtKVEI95+bjbIJgW1yIIiTrJgcte1OcBb3bWvA6Di2QC4DkyIsPxZGOLzY5nXp7i4wY5EABFuiAIF6gAPzq9wUJCHACYrCIF6jAABYohQ4MYIgFI8ICBniB/yNegGAaLYB2totMCyZTmeqawwIFCHEBGDyBAqzAACMGAIpFrIBF0EADCkgAikcx4wQUoMUAsACODaGAAiTAETbe8YqYNwDopWZ6T6NvMWJQAA38mL82XoEgOpADFRcgBwEm8CAgbAAV7CDHBaBBjGlw4x8n4MA60C9++UuIGChgBxOI8A4MoANB4NfOCZ5xiQ3QYh0DIAExVoEKJNzjH3dAAV3+MiE6EGcV3BgAHVjwBCQMgBc0OsExiPOkBZEDA9BZyzJSMjFyUIA6D4LJJtaBolE8gf6CGgAq0IECyBwDHTQZwRoYsQV2UIBY9xoATQ4xIWw84ibTgMwJTjGwGf884xWEmdkFAECP+awBDUjbxwBYAYydTWlBOFsHJW6xthWg7RgweQUKmIAKYqABdFcbACWW9Qp+nCdRD6PHQgbADsgc4glYWcT0FoSbDUDmHyt7xrC+8ayjbWJDBNnKf360slNc40dDvNAAsDWgffyCEafb4pUugL+D3PE68zoHHaeBDnJAZZEj2seOVkGM5YQOEDNY4PoFQAxAHG0UB/zU7bZAiQ1+c4SjuL/9XbbDH13xFk8c2hHH8YwxXuhC25jP/Q34w4O89UfPOdfodrmrGe3sAig61OkgM58PnAAaYJnU0P65IGysAhlj++BmfwGp6w5npRfi4U0HQK7BTfH/aNP9y1O/8g7ejfFqWyABOUjwlDVAgwTYusWUP3MBADyBHSSg2h1fged1YGks27rK9U5HDBwd5hysPtcamIB+fX6IErf77jdf/JWlzW8V+H3YTDf8oy1QbVtD3crWTjyZaUBobBs4xDQ4e45zffRKO5sGmC77CiS8A+27GfamTv1/MK4844qD/CKcKKNFLHv2vkM/BvDBD4jwAx/c3P1qnUQBejCIHkQb//knCfvXf/8HgOoAf/JXBPUnZQZ4gOpXYiHmaJL3DOvXbznXgI9gIFoGYhOYDB0gYPE3f/VnAAIWYN2Ggc2VCRy4CyV4X/11YJ7GbyHmaSjGf4LgfzQY/4MiJmI56GmthnQKgGUlmAAXmAgVKHJFOFcasoKb0AErZgBJuF8CpmP9tWCeVnYhdmI+iHSPZ4KHMIA3WICI8IFD6IJIF2c9uIPQ14MGsALyR3/291cewoSZMAE+0AM94AM0QIO5toaeJnNIV4KYEIIKGIekAGAlyGs2CAD+J4eZRYeQEAOQh2hl9wOC8AM+lmWocITttwpgyIhiqISoBWKdNoNR+IE6dmAz2GqeB2xFIAhEEIqq8GqrQIgj6IigAGJ3mIcTkAA7kG4GAHYy93hRCGyWCACY+A2cWIxr1SIFcIyYuIdBOGCOYId46AP+Fg60mFfO+IoAEIuU4ISmGP8OGIABiOWM0CiL9MACH8ABM1BYLWKNvFgJ5RgOD/AAG0AABAADLCBYLSKOI8aMjMCOH9CP1MAC94gBCIAAB3AAH6CPMAAD+qiPKeCP9lYJCECRFHCPDxACxoCQD4ADCLABDckBEHkAKbCQG/mOgnAAE6mPCICLuEABKPCSMNCQB2CS+sgBOHkAC6mSHOmRmVCPjhAC97iQKNCQE9mQKLCQ9yiUikABLzmRFMBXKzQDKMAB7fiSB3AIRnmPFPCTDImTOkkAPImTYrmRT4kI7OiOhDADDxCWCJACSmmWDbkBCIADa1kJFICXYrkBVcmNF8kIIYAAH/ABGzADUjmVgVn/CV8Zl2LZk2V5lg2ZAvr4AQcgkQSAmT6Zl/dokCgoCOnDAjgAAxyAAo3Zl3/ZmKXwmDhgkw8QmgI0mIaAAZaZAhgAmrbgki8Zk7LJCDNClIRAkxwAAzigm7ewmIz5m4sAIwRpkDOwAYe5AVC5C6q5msy5QL2VkQSwAaV5miyZndHQIiHAlawpnuO5WjOgmfrYlfUQAiKZm4IwAwspn3AZlIswA3RpjpKAAQcQnoVwABtgCAKKCAV6CDNwAPz5KDklnIJAmg85lQRwnu+AAVwJADV5kwTQlbwJk4vQjgjwAC4ZCQ+AANVJCAhgjg9AAL6ZooiwoYiwor7JoJXQlixJ/wG3SQHXuZCAOQ/lyQGxSZ8rCgMPigMA4JJ62ZGE4J8oWZUW+gEh+pAhCgAPQJcb0I8pSp+EUKIemaI4cAAogKXmWJM+CQAuGgJJKaD9CKOEwAJJaZkxyQIkiQI3SpcoEJtoCqYA+h3+wZ0wIJ0fcJz98JoDOgjluY89eqQE0JQmSggpgJcPGQL5yJMYYJIKKpWPSgAVaZb6iKIEEJsQ+ZAoAAAwKpGYSapdKaIIUJOjyqaDIJEbUJMxaZoIYJohYKEpmZIhUJwIwAEcwFYTdag7uaf7kJEzKggUEKGLqqgTGZuGypAPCaruOaIAAKeGSQCkSqSFkJHSCgAsAKMwKv+jgsCmGJCU4Oqe87msMjoD3QkAUokDrwkDLvqaTemSzkpXE9WhHvoPFoquIWCQt9qp9moIuwoD5fqpqNqS2KqoYpmw24qwbHquVMqi49qV+bgBK9qVrjqxMSmj4iquDKmPeLmoP3mi22EfyvmSFKoPD+mTdPkAgRqSMDqwhbCiKSCiEDutEzoDr3mzNOmwntqtCRuumlqVMzuh/Qq03qqV+EixTGuZPIuxuMquMLCRiSlRk7CjPLqy+RAClrmZOOC1Jnma/UizhVCTxZmzyGqSRnqtmqq0gsCtDiuxivqrMDoDlkq3g1CpG0qx67mZ5pisFNmPFKCZMGCy2GF+6Bn/IbS5uNKguI7rCZAbuRXSuJTbHpZ7ucwwuZqLCZzbufOTuaCLDJ87upNQuqYbCaibuhkouqw7W677urYVu7KbW7XbDqt7u4mQu7qbgr0rV7+LDrwbvN1FvOYwvMaLvMSrvMHLvL/rvL0LvZcbEE7jYcZLDRaBEVthvdcrDZwBFiVCu92LCnDhu+M7DeUrCOm1XudLDekrX+zbvtAwGIVBGtwrv8zwvZ4Rvvj7DdJ7u/9buwEsuwP8ugXMugecuglsuvOVFQ78wBAcwRI8wRRcwRZ8wRicwRq8wRzcwR78wSAcwiI8wiRcwlmxvb6QXhIMAWthwh7Mwi78wi0cwxsM/8M0rME2fMMZnMM6fME83MMW/MMPjMKnFQv0c8S0i8RGLL5TwcSnoMQFIr7pA8WvwD/DRcWugMWsoMVbzMTDtQBEvApgHAtjDAtl7ApnjMZhrApprMb9+8ZwHMdyPMd0XMd2fMfrwDTM1QoFEQAmUL2sAMaArAp9jGSrUMitUAPbKwN+/DumsAD2yzQB4MilAMmFoMiU7AxcQ12sgBIwwcmskBjgG8oDIAIQABSsUAMdcRKEfAI4MQg04QEdkcmgUANQ8Rmi2RkiQMufYMv7OwiqHF3PoF1uwwoyMAIjQBlrXAocERN8zBiDnDh70TzSTM0jUMoA8F6l4Mm4bBWWcf81psDNhIARwtwe50W7vtMKLPy+qKAXstwXqYwTQmHIqEDNL/EZ93wK+VwItEPPorDPUyECNOHEnxBe5awK2rwKJrDL7PzEtSMDOMHLpHABHtACODEErGDP+wvQpMDRAFADXaPPvwzSjHzQzPBepsMKNIHR6kxkyzwKeiEVDV0KQiEQyrwK1AzSKqFdj/zL0OMR0RwK+wwVzEPQncA7G5bOrCAULYAVLy0KikwYNRHUE80YEC0CVD0KGAbRHYYKARETlkEZMjDPppAXKSEQ2VzKNvAQZe3OAhEQF1Y7Ep0M0aMarkBksTvTplDX9qsKIyAUKcFdDVLUH40RAn0KnuwxzInt06Ow2FshXngc2ZI92ZRd2ZZ92Zid2Zq92Zzd2Z792aAd2qI92qRd2qZ92pUQCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean concentrations of ceftriaxone in serum and cerebrospinal fluid after IV infusion of 50 mg/kg in infants and children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27645=[""].join("\n");
var outline_f26_63_27645=null;
var title_f26_63_27646="Less com pathogens after BMT-I";
var content_f26_63_27646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78377%7EID%2F53314%7EID%2F76752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78377%7EID%2F53314%7EID%2F76752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Preengraftment (0 to 3 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Gram positive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Listeria spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Nocardia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Corynebacterium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. pseudodiphtheriticum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. striatum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. equi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Lactobacillus spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Leuconostoc spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Gram negative",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Aeromonas spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Capnocytophaga spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Yersinia enterocolitica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Salmonella spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Brucella spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Plesiomonas shigelloides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Campylobacter spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Vibrio spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Spirochetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Borrelia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Treponema spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Ehrlichia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Chlamydia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Mycoplasma spp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rickettsia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Anaerobes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bacteroides spp.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fungi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Candida spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            C. krusei",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            C. glabrata",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Zygomycetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Trichosporon spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Phaehyphomycoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Curvularia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Alternaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Exserohilum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bipolaris spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Hyalohyphomycoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Fusarium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Scedosporium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Scopulariopsis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Endemic fungi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Histoplasma spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Coccidioides immitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Paracoccidioides spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Respiratory viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rhinovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            BK virus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immediate postengraftment (3 weeks to 3 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Enteroviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Coxsackie A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Echovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rotavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BK virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leishmania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptosporidia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strongyloides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasmodium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardia intestinalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microsporidia spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        M. tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Atypical mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. avium complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. fortuitum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. chelonae",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late postengraftment (allogeneic BMT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parvovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BK/JC virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B, C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as immediate postengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as immediate postengraftment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27646=[""].join("\n");
var outline_f26_63_27646=null;
var title_f26_63_27647="Epileptic vis hallu";
var content_f26_63_27647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drawing by a patient with epileptic visual hallucinations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient had occipital seizures with this stereotyped hallucination for approximately 12 years without a diagnosis. He described a bright red circle that flickered with what looked like moving flames coming out of it. The hallucination typically lasted for seconds and was usually followed by subtle mental status changes, headache, and nausea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_63_27647=[""].join("\n");
var outline_f26_63_27647=null;
